user_input,reference_contexts,reference,synthesizer_name,answer,source_content,source_document_info
"Whats the neuro status of the pashent with systmic murmer at RUSB, especaily ther alertness and cranial nerve intactness?","['0070a23b-dc9f-483f-a66d-a8d84a4b995b\n\nCARDIOVASCULAR: Regular rate and rhythm with late ___ systolic\nmurmur at RUSB, no rubs or gallops\nLUNGS: clear to auscultation bilaterally without rhonchi,\nwheezes, or crackles\nGI: soft, nontender, without rebounding or guarding, \nnondistended\nwith normal active bowel sounds, no hepatomegaly\nEXTREMITIES: no clubbing, cyanosis, or edema\nGU: no foley\nSKIN: no rashes, petechia, lesions, or echymoses; warm to\npalpation\nNEURO: Alert and interactive to person, ___ (daughters\nstated that this is a hospital before pt named it), ___, but\nthinks that it is ___, cranial nerves II-XII intact, strength \nis\n___ in RUE, RLE, LLE, ___ in LUE elbow flexion/extension and\nhand grip. Gait is WNL, negative Romberg, negative pronator\ndrift.\nPSYCH: normal mood and affect\nDISCHARGE EXAM\nVS: 97.9 PO 151 / 65 64 18 99 RA \nGEN: Alert and interactive, comfortable, no acute distress\nHEENT: PERRL, anicteric, conjunctiva pink, oropharynx without\nlesion or exudate, moist mucus membranes, ears without lesions \nor', '688ac351-3658-4804-8bb2-2bd5b3e5aaac\n\nEXTREMITIES: 2+ pitting edema bilaterally in lower extremities.\nPulses 2+ bilaterally. \nNEURO: Alert & oriented x3. Non-focal neuro exam.\nDISCHARGE PHYSICAL EXAMINATION:  \n===============================\n24 HR Data (last updated ___ @ 809)\n    Temp: 98.1 (Tm 99.0), BP: 168/75 (142-168/69-79), HR: 88\n(87-95), RR: 18 (___), O2 sat: 97% (94-97)  \n___ Total Intake: 720ml PO Amt: 720ml \n___ Total Output: 1100ml Urine Amt: 1100ml \nFluid balance: -380\n___ Total Intake: 180ml PO Amt: 180ml \n___ Total Output: 900ml Urine Amt: 900ml \nFluid balance: -720\nGENERAL: Sitting up comfortably at edge of bed, in NAD\nHEENT: NC/AT\nNECK: Supple. unable to appreciate JVD at 90 degrees\nCARDIAC: RRR, no rubs/gallops\nLUNGS: Faint bibasilar crackles on auscultation\nABDOMEN: Soft, NTND\nEXTREMITIES: 2+ pitting edema bilaterally to knees in ___. Pulses\n2+ bilaterally. WARM']","The patient is Alert and interactive to person, with some memory or recognition issues (as indicated by the patient initially not naming the hospital correctly but later doing so). The patient thinks it is a different time/frame than actual (exact details not specified). Cranial nerves II-XII are intact. Strength is noted as being 5/5 in Right Upper Extremity (RUE), Right Lower Extremity (RLE), Left Lower Extremity (LLE), and 4/5 in Left Upper Extremity (LUE) for elbow flexion/extension and hand grip. Gait is Within Normal Limits (WNL), with a negative Romberg and negative pronator drift.",custom_multi_hop_query_synthesizer,"Based on the provided documents, here's the answer to the question about the neuro status of the patient, focusing on alertness and cranial nerve intactness, especially in relation to the systolic murmur mentioned (note: the murmur is described as ""systolic"" but the location ""RUSB"" is not mentioned in the documents; assuming the murmur's location is not crucial for the neuro status query):

**Answer:**

* **Patient/Subject ID:** 13180007 (consistent across all documents: Document 1, Document 2, Document 3, Document 4, and Document 5)
* **Neuro Status (Alertness and Cranial Nerve Intactness):**
	+ **Alertness:** A&O x3 (Alert and Oriented to person, place, and time) [Document 3, under ""Neuro""]
	+ **Cranial Nerve Intactness:** CN ___ intact (Unfortunately, the specific cranial nerves checked are not fully listed/specified in the provided documents, but it is noted that they are ""intact"") [Document 3, under ""Neuro""]
* **Systolic Murmur Context:** Mentioned in Document 3 as ""CV- RRR, systolic murmur, normal S1, S2"" without specifying the location as ""RUSB"" (which is not found in the documents).

**Additional Context for Clarity:**

- The systolic murmur is noted in the context of the cardiovascular examination in Document 3.
- The patient's neurological status, as described in Document 3, indicates alertness (A&O x3) and normal strength, sensation, speech, and gait, but the detailed cranial nerve examination is partially specified as ""intact"" without full details.

**Metadata Consistency:**
- Patient/Subject ID: Consistent across all documents (13180007)
- Note ID, Admission ID, Chart Time, and Store Time are also consistent but not directly relevant to the question asked.","['DISCHARGE PHYSICAL EXAM\n=======================\nGENERAL: NAD. Mood, affect appropriate.  \nHEENT: Normocephalic atraumatic. Sclera anicteric. EOMI.\nConjunctiva were pink. No pallor or cyanosis of the o', 'DISCHARGE PHYSICAL EXAM\n=======================\nGENERAL: NAD. Mood, affect appropriate.  \nHEENT: Normocephalic atraumatic. Sclera anicteric. EOMI.\nConjunctiva were pink. No pallor or cyanosis of the o', 'In the ED:  \nInitial VS: T 98.5, HR 102, BP 178/76, RR 22, SpO2 98% RA \n \nExam:\nGeneral- NAD\nHEENT- PERRL, EOMI, normal oropharynx\nLungs- Non-labored breathing, CTAB\nCV- RRR, systolic murmur, normal S', '# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\n', 'TRANSITIONAL ISSUES\n===================\n[ ] At discharge his symptoms associated with volume overload \nhad subsided, but he was still slightly volume up on exam with \n1+ edema to ankles bilaterally an']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
What were the initial presentation and immediate interventions for the patient with acute Heart Failure with preserved Ejection Fraction (HFpEF) exacerbation in the Emergency Department (ED)?,"['595bbed3-a542-444b-b48a-e6edf79ac096\n\nHistory of Present Illness:\n___ year old man with numerous cardiac risk factors, prior CVA\npresented with sudden onset worsening of subacute dyspnea found\nto have flash pulmonary edema admitted for acute HFpEF\nexacerbation. \n Per EMS and confirmed with family, patient was found on the\ncouch by his family was minimally responsive. Patient described\nsubacute shortness of breath over the last two weeks (e.g.,\nhaving to sit down multiple times when going to grocery store or\nup steps at home).  He has also had a cough, rhinorrhea but no\nfever, no sputum.  This worsened acutely this morning when he\nwoke-up struggling to breath.  EMS was called, SBP to 176 per ED\ndocumentation, patient was given nitro x2 and started on CPAP. \n In the ED, he was started on bipap diuresed with OV Lasix,\nstarted on home BP medications and then transferred to floor. \n - Initial vitals: HR 109 BP 176/67 RR 26 ___ 90, patient was\ntachypneic, unable to speak in full sentences, crackles L>R, no\nfocal deficits\n - EKG:  not commented upon\n - Labs/studies notable for: Patient was given: NG x2. Lasix IV\n40mg (at 4:30am), Zosyn/Vanc  \n Amlodipine 10mg, Carvedilol 25mg, Lisinopril 2.5mg,\nlevothyroxine, insulin 10U regular,  \n - Vitals on transfer:  ___ 1040 Temp: 98.4 PO BP: 115/45 R', ""a6e734ef-1c30-4cb6-ba6d-41227251d4d0\n\nWhen he came home to ___, he apparently thought that he was\nstill in ___, confused his wife for his daughter. On\n___ morning, he fell again. He was confused about the\nconfiguration of the bathroom (no tub in bathroom in PR), so he\ntripped and fell, called his daughter in tears (he often gets\nemotional since his CVA). She booked an appointment for same \nday,\nat which his FSBG>500, HbA1c (point of care, not in OMR) was\n15.0%. He declined to be transferred to the ED. Daughter ___\nwas on vacation from work, and so was able to check on him\nregularly. During these visits, she again established that he is\nnot taking prescribed medications. On the morning of\npresentation, pt's wife called daughter ___, concerned that \npt\nwas increasingly confused. FSBG was >500, and administered\nTresiba 50u at about 8 am. Pt called ___ about 15 minutes\nlater, at which time she again noted confusion and slurred\nspeech, which has intermittently been present since his CVA.\nDecision was made to bring him to the ED. \nOf note, during his last hospitalization ___, he had an\nepisode of dysarthria with confusion and mild expressive and\nreceptive aphasia for which code stroke was called. MRI/MRA \nbrain\nand EEG were unrevealing, with chronic changes and EEG slowing\nonly. He was continued on ASA and atorvastatin.""]","The patient, a man with numerous cardiac risk factors and a prior CVA, presented to the ED with sudden onset worsening of subacute dyspnea, leading to flash pulmonary edema. Initial vitals in the ED showed HR 109, BP 176/67, RR 26, with the patient being tachypneic. Immediate interventions included administration of nitro x2 by EMS, initiation of CPAP, which was later switched to BiPAP in the ED, diuresis with IV Lasix (40mg), and the continuation of home BP medications (Amlodipine 10mg, Carvedilol 25mg, Lisinopril 2.5mg).",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

**Patient Identification (from METADATA, consistent across all documents):**
* **Patient/Subject ID:** 13180007
* **Note ID:** 13180007-DS-19 (consistent across all documents, indicating these notes are part of the same medical record entry)
* **Admission ID:** 20774429 (consistent across all documents, confirming the same hospital admission)

**Initial Presentation in the Emergency Department (ED) (from Document 5 - CONTENT):**
* **Chief Complaints:** Dyspnea and chest pain
* **Initial Vital Signs (VS):** 
	+ Temperature (T): 98.5
	+ Heart Rate (HR): 102
	+ Blood Pressure (BP): 178/76
	+ Respiratory Rate (RR): 22
	+ Oxygen Saturation (SpO2): 98% on Room Air (RA)
* **Notable Exam Findings:**
	+ General: No Acute Distress (NAD)
	+ Lungs: Non-labored breathing, Clear To Auscultation Bilaterally (CTAB)
	+ Cardiovascular (CV): Regular Rate and Rhythm (RRR), systolic murmur
	+ Musculoskeletal (Msk): 2+ edema
* **Notable Initial Labs and Studies:**
	+ Hemoglobin (Hgb): 7.4
	+ Chemistry: Blood Urea Nitrogen (BUN) 39, Creatinine (Cr) 2.6
	+ pro-B-type Natriuretic Peptide (proBNP): 784
	+ Troponin T (TropT): 0.03
	+ Electrocardiogram (EKG): T-wave inversion (TWI) in lateral leads
	+ Chest X-Ray (CXR): Mild pulmonary vascular congestion with small bilateral pleural effusions (left greater than right)

**Immediate Interventions in the ED (from Document 5 - CONTENT):**
* **Medications:** Received IV Lasix (Furosemide) 80mg for diuresis, indicating treatment for fluid overload associated with the HFpEF exacerbation.
* **Vitals on Transfer (post-intervention):** 
	+ T: 97.3
	+ HR: 88
	+ BP: 120/54
	+ RR: 18
	+ SpO2: 98% RA, showing some stabilization of the patient's condition after the initial intervention.","['ACUTE PROBLEMS\n==============\n# Acute on chronic HFpEF: \nPatient presented with dyspnea and lower extremity edema and\nfound to be volume overloaded on exam. Warm and wet on exam.\nTrigger for HF exacer', 'ACUTE PROBLEMS\n==============\n# Acute on chronic HFpEF: \nPatient presented with dyspnea and lower extremity edema and\nfound to be volume overloaded on exam. Warm and wet on exam.\nTrigger for HF exacer', 'DISCHARGE LABS\n==============\n\n___ 06:35AM BLOOD WBC-5.4 RBC-2.92* Hgb-7.6* Hct-24.3* \nMCV-83 MCH-26.0 MCHC-31.3* RDW-15.9* RDWSD-47.8* Plt ___\n___ 06:35AM BLOOD Glucose-164* UreaN-51* Creat-2.9* Na-1', 'Name:  ___              Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   M\n \nService: MEDICINE\n \nAllergies: \nNo Known Allergies / Adver', 'In the ED:  \nInitial VS: T 98.5, HR 102, BP 178/76, RR 22, SpO2 98% RA \n \nExam:\nGeneral- NAD\nHEENT- PERRL, EOMI, normal oropharynx\nLungs- Non-labored breathing, CTAB\nCV- RRR, systolic murmur, normal S']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"Whats the relevent med list for DM managment in a pateint with Hx of CAD, ischemic CVA, CKD, and Hypothyroidism, with med speling dont mater?","['8c0badb1-fe3b-4585-8010-1ef4ba8fdd98\n\n================\n# Hx of CAD \n# Hx of ischemic CVA\nStress test in ___ with area of inducible ischemia in LCx \ndistribution. Trop peaked at 0.06 (iso CKD) and then \ndowntrended. No EKG changes seen. Continued home carvedilol, ASA \nand high dose atorvastatin. \n# CKD: Cr at presentation close to baseline. Underlying etiology \nlikely combination of HTN, DM. \n# Hypothyroidism: Continued home levothyroxine 100 mcg daily\n \nMedications on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Furosemide 40 mg PO 3X/WEEK (___) \n2. sevelamer CARBONATE 800 mg PO TID W/MEALS \n3. Minoxidil 2.5 mg PO DAILY \n4. Levothyroxine Sodium 100 mcg PO DAILY \n5. CARVedilol 37.5 mg PO BID \n6. amLODIPine 10 mg PO DAILY \n7. Albuterol Inhaler 2 PUFF IH Q6H \n8. Jardiance (empagliflozin) 10 mg oral DAILY \n9. Victoza 3-Pak (liraglutide) 1.2 mg subcutaneous DAILY', '8d31665e-700b-4b64-8af5-51456ad55ff5\n\n___ 06:35AM BLOOD WBC-5.4 RBC-2.92* Hgb-7.6* Hct-24.3* \nMCV-83 MCH-26.0 MCHC-31.3* RDW-15.9* RDWSD-47.8* Plt ___\n___ 06:35AM BLOOD Glucose-164* UreaN-51* Creat-2.9* Na-140 \nK-4.6 Cl-99 HCO3-25 AnGap-16\n___ 06:35AM BLOOD Calcium-8.4 Phos-6.0* Mg-2.1\n \nBrief Hospital Course:\nSUMMARY\n=======\n___ male with history of HFpEF (EF 55-60% in ___,\nprior CVA, CKD, DM, hypertension, and carotid artery disease\nwho presented with 1 day of dyspnea and discomfort, and was\nadmitted for HF exacerbation. The trigger was unclear, possible \nmedication non-compliance. He was diuresed with several doses of \nIV Lasix 80 and by time of discharge symptoms had improved. He \nwas still slightly volume up on exam, with JVP ~12 and 1+ edema \nto ankles.\nTRANSITIONAL ISSUES\n===================\n[ ] At discharge his symptoms associated with volume overload \nhad subsided, but he was still slightly volume up on exam with \n1+ edema to ankles bilaterally and JVP of 12cm. He is being \ndischarged on torsemide 100 daily for active diuresis, with \nabout 3lb of fluid still left to lose.']","Based on the provided context, for a patient with a history of CAD, ischemic CVA, CKD, Hypothyroidism, and specifically focusing on Diabetes Mellitus (DM) management, the relevant medications from the admission list are:  1. **Jardiance (empagliflozin) 10 mg oral DAILY** - an SGLT2 inhibitor used in the treatment of type 2 diabetes. 2. **Victoza 3-Pak (liraglutide) 1.2 mg subcutaneous DAILY** - a GLP-1 receptor agonist used for type 2 diabetes management. Additionally, medications indirectly beneficial for DM management due to their effects on related conditions include: - **CARVedilol 37.5 mg PO BID** and **amLODIPine 10 mg PO DAILY** for hypertension, a common comorbidity with DM. - **sevelamer CARBONATE 800 mg PO TID W/MEALS** for CKD, which can be influenced by DM management.",custom_multi_hop_query_synthesizer,"Based on the provided documents, I'll answer the question following the instructions:

**Question:** What's the relevant med list for DM management in a patient with Hx of CAD, ischemic CVA, CKD, and Hypothyroidism, with med spelling ignored?

**Relevant Patient IDs from Metadata (as per instruction 1 & 2):**
- **Patient/Subject ID:** 13180007 (consistent across all documents: Doc 1, Doc 2, Doc 3, Doc 4, Doc 5)
- **Note ID:** 13180007-DS-19 (consistent across all documents)
- **Admission ID:** 20774429 (consistent across all documents)

**Medical Conditions Relevant to the Question (extracted from document content):**
- **DM (Diabetes Mellitus):** Type 2 (Document 4)
- **Hx of CAD (Coronary Artery Disease):** Not explicitly confirmed; however, risk factors for ischemia mentioned (Document 3)
- **Ischemic CVA (Cerebrovascular Accident):** History of CVA (Documents 1, 2, 3, and mentioned as ""prior CVA"" in Document 5)
- **CKD (Chronic Kidney Disease):** Elevated Cr levels indicating renal dysfunction (Document 3)
- **Hypothyroidism:** Chronic problem (Documents 1 and 2)

**Relevant Medications for DM Management and Associated Conditions (ignoring spelling variations as per the question):**
- **For DM (Type 2):**
	1. **70/30 Insulin** (Dosage: 30 Units Breakfast, 10 Units Lunch) - (Documents 1 and 2)
	2. **Victoza (Liraglutide)** (Dosage: 0.6 mg/0.1 mL (18 mg/3 mL) subcutaneous DAILY) - (Documents 1 and 2)
- **For CKD (considering the patient's renal context):**
	1. **Sevelamer Carbonate** (Dosage: 800 mg PO TID W/MEALS) - (Documents 1 and 2, mentioned in the context of CKD in Document 3)
- **For Hypothyroidism:**
	1. **Levothyroxine Sodium** (Dosage: 100 mcg PO DAILY) - (Documents 1 and 2)
- **For Cardiovascular Conditions (including history of CVA and risk factors for ischemia):**
	1. **Aspirin** (Dosage: 81 mg PO DAILY) - (Documents 1, 2, and mentioned in the context of CVA in Document 3)
	2. **Atorvastatin** (Dosage: 80 mg PO QPM) - (Documents 1 and 2, continued for CVA in Document 3)

**Note:** The medications listed are those directly mentioned in the context of the patient's conditions relevant to the question. Other medications listed in the documents may also be part of the patient's overall treatment plan but are not highlighted here as they do not directly address the specified conditions (DM, CAD risk, ischemic CVA, CKD, Hypothyroidism) in the question's context.","['CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', 'CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', '# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\n', 'Studies notable for:  \n-CXR:  Mild pulmonary vascular congestion with small bilateral\npleural effusions, left greater than right. \n\nVitals on transfer: T 97.3, HR 88, BP 120/54, RR 18, SpO2 98% RA \n\n\n', 'Name:  ___              Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   M\n \nService: MEDICINE\n \nAllergies: \nNo Known Allergies / Adver']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
Whats the comon complictions of uncontrolld DM2 in patiants with exsisting CVA and HTN?,"['2574c42a-a6ef-418e-ac90-a21855611d18\n\npulmonary edema. No pneumonia, no pneumothorax.  The lateral \nradiograph shows mild flattening of the hemidiaphragms, \npotentially as a consequence of functional obstruction.\n___ CT HEAD -\n1. No evidence of acute intracranial abnormality.\n2. Unchanged appearance of chronic infarcts within the right \nfrontal lobe and left occipital lobe.\n3. Chronic lacunar infarcts within the right basal ganglia.\n4. Re-demonstration of few calcifications within the pons, \nfindings which are unchanged in appearance and likely sequela of \nprior ischemic or inflammatory process.\nMICRO:\n___ 3:38 pm URINE\n                            **FINAL REPORT ___\n   URINE CULTURE (Final ___:    < 10,000 CFU/mL. \n \nBrief Hospital Course:\nMr. ___ is a ___ ___ speaking male with a \nPMH of prior CVA ___, residual emotional lability, \ndysarthria), HFpEF, uncontrolled DM2, HTN, CAD, CKD, \n?hypothyroidism, asthma, mild cognitive impairment who presented', 'e2f22eea-f842-4b4c-8542-dfd4f8a519ce\n\n___ yo M with IDDM, HTN, CVA, asthma who presents to the ED after\nvomiting multiple times last night. He notes he ate taco bell at\n5, then at 6pm ate dinner and vomited all his rice at that time.\nContinued to vomit multiple times and decided to come to the ED.\nNon bilious non bloody. Doesn\'t have vomiting often. Denies any\nproblems with bowel movements. \nHe notes that he has been having problems with his BPs at home.\nNotes compliance and uses a pill box that his wife helps him\nfill. Notes that he tries to eat healthy (although he did have\ntacobell last night around 5pm). He also notes feeling ""off\nbalance"" when his BPs are raised but doesn\'t check them often at\nhome. Has been trying to check blood sugars more recently.\nDoesn\'t have a log here. \nNotes he sometimes has chest pain. Currently without chest pain.\nNotes that he doesn\'t get it with walking unless walking long\ndistance. Can walk up about 20 steps without stopping. \n \nPast Medical History:\n- DM2\n- Diabetic Retinopathy\n- Hypothyroidism\n- CKD Stage IIIa\n- HLD\n- HTN']","Based on the provided context, common complications or associated conditions with uncontrolled DM2 (Diabetes Mellitus Type 2) in patients with existing CVA (Cerebrovascular Accident) and HTN (Hypertension) include:               - **Chronic Infarcts**: As seen in the CT HEAD results, indicating potential previous brain tissue damage due to lack of blood supply.              - **Cognitive Impairment**: Mentioned in the brief hospital course, suggesting a decline in cognitive function.              - **Chronic Lacunar Infarcts**: Within the basal ganglia, indicative of small vessel disease, common in diabetes and hypertension.              - **CKD (Chronic Kidney Disease)**: Stage IIIa noted in the past medical history, a known complication of long-standing diabetes and hypertension.              - **Diabetic Retinopathy**: Listed in the past medical history, a common complication of diabetes affecting the eyes.              - **Emotional Lability and Dysarthria**: Residual effects from the CVA, potentially exacerbated by the metabolic and vascular stress of uncontrolled DM2 and HTN.",custom_multi_hop_query_synthesizer,"**Answering the Current Question**

Before diving into the common complications of uncontrolled DM2 in patients with existing CVA (Cerebrovascular Accident, commonly known as stroke) and HTN (Hypertension), let's establish the patient's profile based on the provided documents:

- **Patient/Subject ID**: 13180007 (consistent across all documents)
- **Relevant Conditions for the Question**:
  - **DM2 (Diabetes Mellitus Type 2)**: Mentioned in Document 5 under Past Medical History.
  - **CVA (Cerebrovascular Disease, status post CVA)**: Mentioned in Document 5 under Past Medical History.
  - **HTN (Hypertension)**: Mentioned in Document 5 under Past Medical History and implied through medication (e.g., amLODIPine, CARVedilol) in Document 4.

**Common Complications of Uncontrolled DM2 in Patients with Existing CVA and HTN:**

While the documents provide a comprehensive view of the patient's medical history and current conditions, they do not explicitly outline the complications of uncontrolled DM2 in the context of CVA and HTN. However, based on medical knowledge, here are common complications that could arise in such a patient profile:

1. **Increased Risk of Subsequent CVA**: Uncontrolled DM2 and HTN can exacerbate atherosclerosis, increasing the risk of another stroke.
2. **Cardiovascular Diseases**: Including but not limited to, myocardial infarction (heart attack), heart failure, and peripheral arterial disease, all of which can be worsened by the combination of DM2, CVA history, and HTN.
3. **Diabetic Nephropathy**: Uncontrolled DM2 can lead to kidney damage, a risk potentially compounded by HTN. (The patient is already on sevelamer, indicating some level of renal concern, possibly related to CKD mentioned in Documents 1 and 2.)
4. **Retinopathy and Potential Blindness**: DM2 can cause diabetic retinopathy, leading to blindness if not managed properly. HTN can also affect the eyes, leading to hypertensive retinopathy.
5. **Neuropathy**: Uncontrolled DM2 can cause nerve damage, leading to diabetic neuropathy, which might be further complicated by the vascular changes associated with CVA and HTN.
6. **Foot Ulcers and Amputations**: Poor circulation (common in CVA and HTN patients) combined with neuropathy from DM2 increases the risk of foot ulcers and, if not properly managed, amputations.
7. **Cognitive Decline**: There is evidence suggesting that uncontrolled DM2 and a history of CVA, alongside HTN, may increase the risk of cognitive decline or dementia.

**Important Note**: The patient's current level of DM2 control is not explicitly stated in the documents. The presence of complications would depend on the actual control of DM2, among other factors.

**Metadata IDs as Requested**:
- **Patient/Subject ID**: 13180007 (consistent across Documents 1 through 5)
- **Note ID**: 13180007-DS-19 (consistent across Documents 1 through 5)
- **Admission ID**: 20774429 (consistent across Documents 1 through 5)","['# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\n', '# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\n', 'ACUTE PROBLEMS\n==============\n# Acute on chronic HFpEF: \nPatient presented with dyspnea and lower extremity edema and\nfound to be volume overloaded on exam. Warm and wet on exam.\nTrigger for HF exacer', 'CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', 'Studies notable for:  \n-CXR:  Mild pulmonary vascular congestion with small bilateral\npleural effusions, left greater than right. \n\nVitals on transfer: T 97.3, HR 88, BP 120/54, RR 18, SpO2 98% RA \n\n\n']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"Whats the perscribd dose of Aspirin for a patiant with NSTEMI and hypertension, and whats its role in ther care plan?","['5afc91e0-6481-46b3-aa3c-473b2c2e6895\n\n#Community acquired pneumonia\nCough, worsened SOB, hypoxemia (although alternate explanation) \nbut no leukocytosis or fevers; influenza negative. Legionella \nand strep were negative. Patient was given a 5-day course of \nceftriaxone and azithromycin. \n#Hypertension\nGoal <130/80. As patient is on several anti-hypertensives with \nstill an elevated blood pressure, he underwent a secondary \nhypertension workup. His last renal ultrasound in ___ was \nwithin normal limits. He was placed on continuous O2 monitoring \novernight, and patient did not desaturate. His aldosterone to \nrenin ratio was 0.13, indicating no primary hyperaldosteronism. \n24 hour urine metanephrines and catecholamines were within \nnormal limits.\n#CAD w/ inducible ischemia\n#NSTEMI\nTroponin peaked at 0.02, thought to be type 2 due to volume \noverload. Continued aspirin, atorvastatin, carvedilol. The \ndecision was made to hold off on coronary angiogram due to \nkidney function and the suspicion that this was type 2.\n#H/o CVA\nPatient had an episode while in hospital with dysarthria,', '784a4f17-941d-40ee-a5aa-7471e6a5f600\n\n70/30 10 Units Lunch \n3.  Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath  \n4.  amLODIPine 10 mg PO DAILY  \n5.  Aspirin 81 mg PO DAILY  \n6.  Atorvastatin 80 mg PO QPM  \n7.  CARVedilol 50 mg PO BID  \n8.  Levothyroxine Sodium 100 mcg PO DAILY  \n9.  Minoxidil 10 mg PO DAILY  \n10.  Polyethylene Glycol 17 g PO DAILY:PRN Constipation - First \nLine  \n11.  sevelamer CARBONATE 800 mg PO TID W/MEALS  \n12.  Victoza 2-Pak (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) \nsubcutaneous DAILY  \n13.  Vitamin D 1000 UNIT PO DAILY  \n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nPrimary Diagnosis:\n-Acute on chronic diastolic heart failure exacerbation\nSecondary Diagnosis:']","For a patient with NSTEMI and hypertension, as observed in the provided medical context, the prescribed dose of Aspirin is 81 mg PO DAILY. The role of Aspirin in this care plan is consistent with managing Non-ST Elevation Myocardial Infarction (NSTEMI), where Aspirin is standard for its antiplatelet effects to reduce the risk of further cardiac events. Additionally, its anti-inflammatory properties may indirectly support the management of the patient's overall cardiovascular health, including hypertension, although its primary role in this context is related to the patient's CAD with inducible ischemia and NSTEMI rather than directly lowering blood pressure.",custom_multi_hop_query_synthesizer,"Based on the provided instructions and documents, I'll address the question to the best of my abilities. However, please note the following:

1. **Patient's Condition in Question (NSTEMI)**: The documents provided do not explicitly mention NSTEMI (Non-ST Elevation Myocardial Infarction) as part of the patient's current diagnoses or history. The primary and secondary diagnoses mentioned in Documents 1 and 2 include acute on chronic diastolic heart failure exacerbation, acute kidney injury, acute on chronic anemia, and type 2 diabetes mellitus, among others.

2. **Hypertension**: The patient is noted to have a history of hypertension, which is currently well controlled (Document 4).

3. **Aspirin Dosage for Patient with Hypertension (in the context of provided documents)**:
    - **Dosage**: According to Documents 1, 2, and 3, the prescribed dose of Aspirin for this patient is **81 mg PO DAILY**.
    - **Role in Care Plan**: While the documents do not explicitly outline the role of Aspirin in the patient's care plan for NSTEMI (since NSTEMI is not mentioned), Aspirin is commonly used for its antiplatelet effects in patients with cardiovascular diseases, including heart failure and hypertension, to reduce the risk of heart attacks and strokes. For this patient, with a history of hypertension and other cardiovascular conditions (e.g., history of CVA, carotid artery disease), Aspirin is likely prescribed for primary or secondary prevention of cardiovascular events.

**Answer Summary**:

- **Patient/Subject ID** (as per all documents' metadata): **13180007**
- **Note ID** (common across all documents): **13180007-DS-19**
- **Admission ID** (common across all documents): **20774429**
- **Aspirin Dosage for Patient with Hypertension**: **81 mg PO DAILY**
- **Role in Care Plan (inferred based on common practices for patients with similar conditions)**: Likely for the prevention of cardiovascular events given the patient's history of hypertension and other cardiovascular conditions. **Note**: The specific role in the context of NSTEMI cannot be accurately determined from the provided documents due to the absence of NSTEMI in the patient's listed conditions.","['Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', '# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o', 'Name:  ___              Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   M\n \nService: MEDICINE\n \nAllergies: \nNo Known Allergies / Adver']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What specific insulin regimen should a discharged patient, who was hospitalized for worsening shortness of breath and leg swelling, continue to follow as part of their post-discharge care, considering their pre-admission insulin schedule?","['cd30826d-ad9e-4a08-8b63-15e1e3bbfe0c\n\nYou were admitted to the hospital because:\n================================\n-You had worsening shortness of breath, with increased leg \nswelling and weight gain.\nDuring your stay:\n============\n-You had too much volume onboard so you were given IV diuretic \nmedications,. You improved significantly.\nAfter your discharge:\n================\n-Please continue taking all medications as prescribed (see \nbelow).\n-Please stop taking Lisinopril and metoprolol.\n-Please continue taking insulin according to the regimen you \nwere following before this admission.\n-New medications:\n  - Aspirin 81mg once daily\n  - Carvedilol 25mg twice daily\n  - Furosemide 40mg twice daily\n  - Hydralazine 100mg three times daily\n-Please attend any upcoming outpatient appointments you have \n(see below).\nWe wish you the very best!', ""fd49a2e0-9612-4cbf-91c3-bbfc765fb300\n\n[ ] Changed medications: Insulin (lantus 40 qam and 10 qpm w/ \nNovolog ___ w/ SSI with meals; discharged w/ insulin pens), \ncoreg was increased to 37.5 mg BID. Amlodipine was switched from \nqod to everyday.\n[ ] Please monitor BP as an outpatient and consider starting \nimdur.\n[ ] HFpEF - Consider initiation of spironolactone once Cr is \ndowntrending.\n[ ] ?COPD - Consider PFTs to see if patient has COPD. Started on \nadvair as an inpatient.\n[ ] DM: Please monitor his blood glucose as an outpatient as his \nblood glucoses ran elevated as an inpatient. He should follow-up \nwith ___ as an outpatient.\n[ ] Lung cancer screening - Given patient's smoking history, \nconsider outpatient CT Chest.\n[ ] Hyperlipidemia - Per prior cardiology note, patient approved \nfor PCSK9 inhibitor.\n[ ] Iron deficiency anemia: Will need a colonoscopy as an \noutpatient\n[ ] CKD - Anticipate he may need dialysis in the future. K on \ndischarge was 4.8 and Cr on discharge was 3.7.\n[ ] Labs: Please recheck a BMP at his next follow-up appointment \nto monitor K and Cr.\n[ ] Discharge weight: 72.7 kg\n==============""]","The patient should continue taking insulin according to the regimen they were following before this admission, which specifically includes: Insulin (Lantus 40 qam and 10 qpm with Novolog, with Sliding Scale Insulin (SSI) adjustments with meals), now discharged with insulin pens for administration.",custom_multi_hop_query_synthesizer,"Based on the provided documents, here's the answer to the question about the specific insulin regimen for the discharged patient:

**Answer:**
The patient should continue with the following insulin regimen as part of their post-discharge care:

* **70/30 Insulin:**
	+ 30 Units with Breakfast
	+ 10 Units with Lunch

* **Additional Context from Documents:**
	+ This regimen was specified in **Document 3** under ""Discharge Medications"".
	+ **Document 5** provides additional context, mentioning that the patient was transitioned to this home insulin regimen from Lantus 30u (administered on the night of admission) during their hospital stay.

**Metadata Relevance:**
The metadata (across all documents) consistently shows:
- **Patient/Subject ID:** 13180007 (consistent across all documents)
- **Note ID:** 13180007-DS-19 (consistent across all documents, reinforcing that the care instructions are relevant to this patient's discharge)
- **Admission ID:** 20774429 (consistent across all documents, linking the discharge instructions to this specific hospital admission)","['Discharge Condition:\nMental Status: Clear and coherent.\nLevel of Consciousness: Alert and interactive.\nActivity Status: Ambulatory - Independent.\n\n \nDischarge Instructions:\n Dear ___,  \n\n It was a ple', 'Discharge Condition:\nMental Status: Clear and coherent.\nLevel of Consciousness: Alert and interactive.\nActivity Status: Ambulatory - Independent.\n\n \nDischarge Instructions:\n Dear ___,  \n\n It was a ple', 'Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'TRANSITIONAL ISSUES\n===================\n[ ] At discharge his symptoms associated with volume overload \nhad subsided, but he was still slightly volume up on exam with \n1+ edema to ankles bilaterally an', '# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What ar the commen causis of Congestive Heart Failure (CHF) exaserbation in pashents with a history of hypertension and diabetis, and how do sympoms like shortness of breath and lower extremity edema relait to the condishun?","['6ca6759d-052d-4b9a-b47d-014a869a41be\n\nechocardiographic evidence of tamponade.\nIMPRESSION: Mild symmetric biventricular hypetrophy with \npreserved biventricular systolic function. No clinically \nsignificant valvular disease. Small, predominantly anterior \npericardial effusion\nwithout echocardiographic evidence of tamponade.\n \nBrief Hospital Course:\n___ M w/ PMH significant for HTN, HLD, T2DM, and CVA in ___ \nwho presents w/ increased SOB and volume retention, concerning \nfor CHF exacerbation. \nACTIVE ISSUES: \n==============\n#Acute HF exacerbation (preserved EF 65% on stress echo in ___, \nunknown current EF)\n#Hypertension\nPatient presented with worsening shortness of breath, lower \nextremity edema and was hypervolemic on exam w/ diffuse rhonchi \non lung auscultation, as well as elevated BNP, all concerning \nfor CHF exacerbation. Stress echo in ___ showed \npreserved EF. Etiology could be either uncontrolled hypertension \nvs ischemia (especially given history of positive stress echo). \nExacerbation could be due to medication/dietary non-compliance.', 'e0673342-03d7-4e47-9dd2-f1d0eaafa133\n\n___ (PORTABLE AP)\nIMPRESSION: \nIn comparison with the study of earlier in this date, the \nendotracheal tube\nhas been pulled back so that the tip now lies approximately 5 cm \nabove the\ncarina.  Cardiomediastinal silhouette is stable.  The vascular \ncongestion\nsuggested previously is no longer appreciated.\n \nBrief Hospital Course:\n___ year old male w history of diastolic CHF, diabetes type 2 \nrecent admission for CHF exacerbation, re-admitted ___ \nwith hyperglycemia and respiratory distress requiring \nintubation, status post treatment of acute diastolic CHF, \nsubsequently optimizing glucose control, able to be discharged \nhome with ___ for medication assistance.  \nTRANSITIONAL ISSUES:\n====================\n[ ] Will need repeat Cr at his ___ appointment on ___, \n___, to ensure stability.\n[ ] Repeat CMP within 1 week of discharge, to ensure stability \nin electrolytes \n[ ] Patient has now had multiple presentations the hospital with']","Based on the provided context, CHF exacerbation in patients with a history of hypertension and diabetes can be attributed to two main etiologies: **1. Uncontrolled Hypertension** and **2. Ischemia** (especially in patients with a history of positive stress echo). Symptoms such as **worsening shortness of breath (SOB)**, **lower extremity edema**, and being **hypervolemic on exam** along with **diffuse rhonchi on lung auscultation** and **elevated BNP**, are all concerning for CHF exacerbation. Additionally, **medication/dietary non-compliance** can also contribute to the exacerbation of CHF. In patients with diastolic CHF, optimizing glucose control (for those with diabetes) and managing the underlying causes are crucial for stabilization and discharge.",custom_multi_hop_query_synthesizer,"**Answering the Current Question with Analysis of Provided Documents**

**Common Causes of Congestive Heart Failure (CHF) Exacerbation in Patients with a History of Hypertension and Diabetes:**

While the provided documents do not explicitly list common causes of CHF exacerbation, we can infer some potential triggers based on the patient's presentation and history. For a patient with a history of hypertension and diabetes (as mentioned in Documents 3 and 4), common causes of CHF exacerbation might include:

1. **Medication Non-Compliance**: Suggested in Documents 1, 2, and 4 as a possible trigger for the current HF exacerbation.
2. **Dietary Indiscretion**: Although Document 1 mentions ""No evidence of dietary indiscretion,"" in general, consuming high-sodium foods can exacerbate CHF in susceptible individuals.
3. **Worsening of Underlying Conditions (Hypertension, Diabetes)**: Poor control of these conditions can lead to increased strain on the heart, potentially exacerbating CHF.
4. **Fluid Overload**: Directly observed in the patient's presentation (Documents 1, 2, and 3), which can be due to various factors including medication non-compliance or worsening heart function.

**Relationship of Symptoms (Shortness of Breath and Lower Extremity Edema) to CHF:**

1. **Shortness of Breath (Dyspnea)**: In CHF, especially in cases like the patient's with Heart Failure with preserved Ejection Fraction (HFpEF), dyspnea occurs due to fluid accumulation in the lungs (pulmonary congestion) or due to the heart's inability to meet the body's demands during exertion. (Observed in all documents as a presenting symptom.)
   
2. **Lower Extremity Edema**: This is a sign of fluid overload, a common manifestation of CHF exacerbation. The heart's reduced ability to pump blood efficiently leads to fluid buildup in the body's dependent parts, such as the legs and ankles. (Documented in Documents 1, 2, 3, and 4 as a presenting symptom or ongoing issue.)

**Metadata Analysis for IDs and Dates:**

- **Patient/Subject ID**: Consistently listed as **13180007** across all documents (Documents 1 through 5).
- **Note ID**: Uniformly identified as **13180007-DS-19** in all documents (Documents 1 through 5), indicating these notes are part of the same medical record entry.
- **Admission ID**: Always **20774429** (Documents 1 through 5), confirming these documents pertain to the same hospital admission.
- **Chart Time and Store Time**: Listed as **N/A** in all documents (Documents 1 through 5), indicating no specific charting or storage times were recorded or are available for these documents.
- **Dates (Admission, Discharge, Date of Birth)**: Not explicitly provided in the metadata of any document. However, Document 4 mentions an ""Admission Date"" and ""Discharge Date"" in its content section, but the actual dates are not filled in.","['ACUTE PROBLEMS\n==============\n# Acute on chronic HFpEF: \nPatient presented with dyspnea and lower extremity edema and\nfound to be volume overloaded on exam. Warm and wet on exam.\nTrigger for HF exacer', 'ACUTE PROBLEMS\n==============\n# Acute on chronic HFpEF: \nPatient presented with dyspnea and lower extremity edema and\nfound to be volume overloaded on exam. Warm and wet on exam.\nTrigger for HF exacer', 'DISCHARGE LABS\n==============\n\n___ 06:35AM BLOOD WBC-5.4 RBC-2.92* Hgb-7.6* Hct-24.3* \nMCV-83 MCH-26.0 MCHC-31.3* RDW-15.9* RDWSD-47.8* Plt ___\n___ 06:35AM BLOOD Glucose-164* UreaN-51* Creat-2.9* Na-1', 'Name:  ___              Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   M\n \nService: MEDICINE\n \nAllergies: \nNo Known Allergies / Adver', 'Discharge Condition:\nMental Status: Clear and coherent.\nLevel of Consciousness: Alert and interactive.\nActivity Status: Ambulatory - Independent.\n\n \nDischarge Instructions:\n Dear ___,  \n\n It was a ple']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
Whats the perscribed dose of CARVedilol for the patient with Hx of CAD and CKD stage III?,"['4b3d7a96-6534-434e-8295-b8356c5ca64d\n\nbasal/bolus four times daily regimen. However, this is not a \nsustainable regimen for patient on discharge. Discussed \npossibility of switching to 70/30 mix BID, however currently \npatient cannot be guaranteed to eat regular meal after each \ninsulin injection therefore currently not a tenable plan. In the \nfuture, if patient able to be placed in a day program, \npotentially could switch to this but for now will we continued \nhis prior home regimen (EXCEPT for Jardiance, which was \ndiscontinued due to contraindication with chronic kidney \ndisease) on discharge, with very close ___ follow-up and ___ \nservices to help increase compliance. With regards to his more \nsubacute mental status decompensation, would benefit from \nreferral for outpatient neurocognitive evaluation.\n# Hx of CAD: \n# Hx of ischemic CVA:\nStress test in ___ with area of inducible ischemia in LCx \ndistribution, in setting of multiple risk factors. Has been \nmedically optimized by prescribed medications, but as above it \nseems that pt has been taking these medications. TnT 0.04->0.02 \nin setting of CKD stage III-IV. Continued home aspirin, \natorvastatin, and carvedilol. Note that he was once on \nlisinopril (most recently filled in ___ for 2.5mg dose) \nhowever seems that this has since been discontinued.\n# CKD stage III:', 'dc9c33c0-6523-4835-a02f-162ecaa61776\n\n2. amLODIPine 10 mg PO DAILY \n3. Atorvastatin 80 mg PO QPM \n4. Minoxidil 10 mg PO DAILY \n5. CARVedilol 50 mg PO BID \n6. Levothyroxine Sodium 100 mcg PO DAILY \n7. Polyethylene Glycol 17 g PO DAILY:PRN Constipation - First \nLine \n8. sevelamer CARBONATE 800 mg PO TID W/MEALS \n9. Vitamin D 1000 UNIT PO DAILY \n10. Torsemide 100 mg PO DAILY \n11. Victoza 2-Pak (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) \nsubcutaneous DAILY \n12. 70/30 30 Units Breakfast\n70/30 10 Units Lunch\n13. Aspirin 81 mg PO DAILY \n \nDischarge Medications:\n1.  Acetaminophen 650 mg PO Q6H:PRN Pain - Mild/Fever  \n2.  70/30 30 Units Breakfast\n70/30 20 Units Dinner \n3.  Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath  \n4.  amLODIPine 10 mg PO DAILY  \n5.  Aspirin 81 mg PO DAILY  \n6.  Atorvastatin 80 mg PO QPM  \n7.  CARVedilol 50 mg PO BID']","The prescribed dose of CARVedilol for the patient is 50 mg PO BID (twice a day). This is part of the patient's medically optimized regimen for CAD, alongside other medications such as aspirin, atorvastatin, and with careful management due to CKD stage III-IV.",custom_multi_hop_query_synthesizer,"Based on the provided instructions and documents, here's the answer to the question:

**Question:** What's the prescribed dose of CARVedilol for the patient with Hx of CAD and CKD stage III?

**Answer Breakdown:**

1. **Patient ID Verification**:
	* The same **Patient/Subject ID** (`13180007`) is mentioned in all documents (Document 1 through Document 5), ensuring we're referring to the same patient across all analyses.
2. **Medical History**:
	* **CAD (Coronary Artery Disease) History**: While the question mentions ""Hx of CAD,"" the documents provided do not explicitly state a history of CAD for this patient. Instead, they discuss concerns for ischemia and a history of CVA (Cerebrovascular Accident), but no clear CAD history is noted.
	* **CKD (Chronic Kidney Disease) Stage III**: The documents imply CKD (e.g., Document 3 mentions ""CKD"" with a creatinine level of 2.6 on admission), but the specific stage (III) is not explicitly mentioned in the provided content.
3. **CARVedilol Dosage**:
	* Despite the uncertainty around the explicit mention of CAD and the stage of CKD, the dosage of CARVedilol can be directly answered from the medication lists provided.
	* **CARVedilol Dosage**: According to both **Document 1** and **Document 2** (which are identical in content), the prescribed dose of CARVedilol for this patient is:
		+ **50 mg PO BID** (50 milligrams, orally, twice a day).

**Answer**: 
- **Patient/Subject ID**: 13180007 (consistent across all documents)
- **CARVedilol Dosage for Patient with Referred Conditions**: 50 mg PO BID (Note: The patient's file does not explicitly confirm a history of CAD, and the CKD stage is not specified in the documents provided.)","['CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', 'CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', '# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\n', 'ACUTE PROBLEMS\n==============\n# Acute on chronic HFpEF: \nPatient presented with dyspnea and lower extremity edema and\nfound to be volume overloaded on exam. Warm and wet on exam.\nTrigger for HF exacer', 'Name:  ___              Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   M\n \nService: MEDICINE\n \nAllergies: \nNo Known Allergies / Adver']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What is the standard dosage of Levothyroxine for a patient with Hypothyroidism in the context of multiple comorbidities (e.g., Hypertension, IDDM, CKD) as observed in clinical care coordination?","['08e7114b-32bf-470b-a3c6-d919c6de4e69\n\n# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n# Acute on chronic anemia:\nHb on admission was 7.4. No evidence of bleeding per history or \nexam. Possibly related to worsening of his renal function vs \ndilutional iso heart failure. His Hb was 7.6 on discharge. He \nreceived 3 doses of ferric gluconate 250 mg IV on ___.\n#IDDM\nPoorly controlled. A1c 14.4 in ___ in ___ at ___. \nRepeat A1C ___ was 11.4%. He was given Lantus 30u night of \nadmission, then transitioned to home insulin ___ with 70/30 \n30u with breakfast and 20u with lunch. He was also on ISS while \ninpatient.\nCHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.', '8c0badb1-fe3b-4585-8010-1ef4ba8fdd98\n\n================\n# Hx of CAD \n# Hx of ischemic CVA\nStress test in ___ with area of inducible ischemia in LCx \ndistribution. Trop peaked at 0.06 (iso CKD) and then \ndowntrended. No EKG changes seen. Continued home carvedilol, ASA \nand high dose atorvastatin. \n# CKD: Cr at presentation close to baseline. Underlying etiology \nlikely combination of HTN, DM. \n# Hypothyroidism: Continued home levothyroxine 100 mcg daily\n \nMedications on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Furosemide 40 mg PO 3X/WEEK (___) \n2. sevelamer CARBONATE 800 mg PO TID W/MEALS \n3. Minoxidil 2.5 mg PO DAILY \n4. Levothyroxine Sodium 100 mcg PO DAILY \n5. CARVedilol 37.5 mg PO BID \n6. amLODIPine 10 mg PO DAILY \n7. Albuterol Inhaler 2 PUFF IH Q6H \n8. Jardiance (empagliflozin) 10 mg oral DAILY \n9. Victoza 3-Pak (liraglutide) 1.2 mg subcutaneous DAILY']","Based on the provided medical context, for patients with Hypothyroidism, alongside multiple comorbidities such as Hypertension, IDDM (Insulin-Dependent Diabetes Mellitus), and CKD (Chronic Kidney Disease), the continued home dosage of Levothyroxine is consistently noted as 100mcg daily. This dosage is mentioned across different patient scenarios, suggesting a standard approach for Hypothyroidism management in these complex cases, under the care coordination observed.",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

**Standard Dosage of Levothyroxine for Hypothyroidism with Multiple Comorbidities:**

In the context of clinical care coordination for a patient with hypothyroidism alongside multiple comorbidities (e.g., hypertension, IDDM, CKD), as observed in the provided documents, **the standard dosage of Levothyroxine is not explicitly defined in the metadata or content across all documents**. However, we can infer the patient's specific dosage from the content.

**Patient's Levothyroxine Dosage (as per Document Content):**
- **Dosage:** 100 mcg PO DAILY (as mentioned in Documents 1, 2, and 3 under ""CHRONIC PROBLEMS"" > ""#Hypothyroidism"")

**Important Note:** The standard or typical dosage of Levothyroxine for hypothyroidism can vary widely among patients, often ranging from 50 mcg to 200 mcg daily, depending on the patient's thyroid hormone levels, age, weight, and the presence of other health conditions. The dosage of 100 mcg daily for this patient (with ID: **13180007**) is likely tailored to their specific needs based on clinical evaluation, but this is not explicitly stated as a ""standard"" dosage for all similar cases in the provided documents.

**Metadata Observations (as per instructions):**

1. **Patient/Subject ID:** Consistently **13180007** across all documents (1, 2, 3, 4, 5).
2. **Note ID, Admission ID, Chart Time, and Store Time:** Remain constant across all documents, with **Note ID: 13180007-DS-19**, **Admission ID: 20774429**, and **Chart Time & Store Time: N/A**.

Given the instructions, for questions about IDs or dates, the metadata values are prioritized, but since the question pertains to medication dosage in the context of clinical care, the answer is derived from the document content with a note on the consistency of patient IDs across documents.","['CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', 'CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', '# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o', 'Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'ACUTE PROBLEMS\n==============\n# Acute on chronic HFpEF: \nPatient presented with dyspnea and lower extremity edema and\nfound to be volume overloaded on exam. Warm and wet on exam.\nTrigger for HF exacer']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What are the relevent medicashuns and ther underlaying efectivness for a pashent with a Hx of CAD, ischemic CVA, CKD (likely due to HTN, DM), and Hypothyroidism, consiederin the pashent is alredy on carvedilol, ASA, and high dose atorvastatin?","['8c0badb1-fe3b-4585-8010-1ef4ba8fdd98\n\n================\n# Hx of CAD \n# Hx of ischemic CVA\nStress test in ___ with area of inducible ischemia in LCx \ndistribution. Trop peaked at 0.06 (iso CKD) and then \ndowntrended. No EKG changes seen. Continued home carvedilol, ASA \nand high dose atorvastatin. \n# CKD: Cr at presentation close to baseline. Underlying etiology \nlikely combination of HTN, DM. \n# Hypothyroidism: Continued home levothyroxine 100 mcg daily\n \nMedications on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Furosemide 40 mg PO 3X/WEEK (___) \n2. sevelamer CARBONATE 800 mg PO TID W/MEALS \n3. Minoxidil 2.5 mg PO DAILY \n4. Levothyroxine Sodium 100 mcg PO DAILY \n5. CARVedilol 37.5 mg PO BID \n6. amLODIPine 10 mg PO DAILY \n7. Albuterol Inhaler 2 PUFF IH Q6H \n8. Jardiance (empagliflozin) 10 mg oral DAILY \n9. Victoza 3-Pak (liraglutide) 1.2 mg subcutaneous DAILY']","Based on the provided context, the patient's relevant medications and their underlying effectiveness for the mentioned conditions are as follows:  - **For CAD and Ischemic CVA Prevention:**   - **Carvedilol (CARVedilol 37.5 mg PO BID):** Continued for heart-related conditions, indicating its ongoing effectiveness.   - **ASA (Aspirin, dosage not specified in the context but mentioned as continued):** For antiplatelet effects to prevent further ischemic events.   - **Atorvastatin (dosage not specified, but mentioned as high dose):** For managing cholesterol, crucial in CAD management.  - **For CKD (with likely underlying etiology of HTN, DM):**   - **Furosemide 40 mg PO 3X/WEEK:** For fluid management in CKD.   - **Sevelamer CARBONATE 800 mg PO TID W/MEALS:** To control phosphorus levels in CKD patients.   - **Minoxidil 2.5 mg PO DAILY:** For blood pressure management (HTN).   - **AmLODIPine 10 mg PO DAILY:** Also for HTN management.   - **Jardiance (Empagliflozin) 10 mg oral DAILY:** Specifically for DM management, with the added benefit of renal protection in CKD.  - **For Hypothyroidism:**   - **Levothyroxine Sodium 100 mcg PO DAILY:** Continued for thyroid hormone replacement.  - **Additional for DM (as part of the themes):**   - **Victoza 3-Pak (Liraglutide) 1.2 mg subcutaneous DAILY:** For DM management, helping with glucose control and possibly aiding in weight management, which can be beneficial for overall cardiovascular health.",custom_multi_hop_query_synthesizer,"Based on the provided documents and the question, here's a structured answer:

**Patient Identification (from METADATA, as all documents have the same IDs):**

* **Patient/Subject ID:** 13180007 (consistent across all documents: 1, 2, 3, 4, 5)
* **Note ID:** 13180007-DS-19 (consistent across all documents: 1, 2, 3, 4, 5)
* **Admission ID:** 20774429 (consistent across all documents: 1, 2, 3, 4, 5)

**Relevant Medical History (from CONTENT across documents):**

* **History of CAD:** Not explicitly mentioned in the documents provided. The question posits a history of CAD, but documents mention ""No known history of CAD"" (Document 3).
* **Ischemic CVA (History of CVA):** Yes, mentioned in Documents 1, 2, and implied in Document 4 with ""Cerebrovascular disease, status post CVA in ___.""
* **CKD (likely due to HTN, DM):** Yes, mentioned in Documents 3 and 4, with CKD implied due to elevated Cr levels and a baseline of renal dysfunction, consistent with complications from HTN (Hypertension, Document 4) and DM (Diabetes Mellitus Type 2, Document 4).
* **Hypothyroidism:** Yes, mentioned in Documents 1 and 2.

**Current Medications and Underlying Effectiveness for the Stated Conditions:**

Given the patient's actual medical history as per the documents (focusing on ischemic CVA, CKD, Hypothyroidism, and assuming the presence of HTN and DM as per Document 4, but not CAD as it's not documented):

1. **Carvedilol (CARVedilol 50 mg PO BID, Documents 1 & 2):**
	* **Indication:** Primarily for Hypertension (HTN), Heart Failure (not explicitly mentioned but can be inferred from the context of other medications and conditions), and to some extent for ischemic heart disease prevention (though CAD is not confirmed in documents).
	* **Effectiveness for Stated Conditions:** Effective for HTN management, beneficial in the context of heart failure (if present), and would be beneficial for CAD prevention if CAD were confirmed.
2. **ASA (Aspirin 81 mg PO DAILY, Documents 1 & 2):**
	* **Indication:** Secondary prevention of ischemic events (given the history of CVA).
	* **Effectiveness for Stated Conditions:** Effective for reducing the risk of further ischemic CVAs and would be beneficial for CAD (if present, which is not documented).
3. **High Dose Atorvastatin (Atorvastatin 80 mg PO QPM, Documents 1 & 2):**
	* **Indication:** Management of Dyslipidemia (Document 4), and secondary prevention of cardiovascular events (given the history of CVA and assumed CAD, though the latter is not documented).
	* **Effectiveness for Stated Conditions:** Effective for managing Dyslipidemia, reducing the risk of further ischemic events (like CVA), and would be beneficial for CAD management (if CAD were confirmed).

**Additional Recommendations Based on Documented Conditions (not directly answering the medication effectiveness for unconfirmed CAD but addressing the overall clinical picture):**

* For **CKD**, the use of **Sevelamer** (sevelamer CARBONATE 800 mg PO TID W/MEALS, Documents 1 & 2) is appropriate for managing hyperphosphatemia, a common complication in CKD patients.
* For **Hypothyroidism**, **Levothyroxine** (Levothyroxine Sodium 100 mcg PO DAILY, Documents 1 & 2) is appropriately continued.
* Given the patient's **Diabetes Mellitus Type 2** (Document 4) and **Hypertension**, careful monitoring and management of these conditions are crucial to slow CKD progression. Medications like **Victoza (Liraglutide)** for Diabetes management are noted (Documents 1 & 2), but the overall efficacy would depend on blood glucose control, which is not detailed in the provided documents.

**Note:** The question's premise includes a history of CAD, which is not supported by the provided documents. Thus, the response focuses on the confirmed medical history from the documents.","['CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', 'CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', '# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\n', 'Studies notable for:  \n-CXR:  Mild pulmonary vascular congestion with small bilateral\npleural effusions, left greater than right. \n\nVitals on transfer: T 97.3, HR 88, BP 120/54, RR 18, SpO2 98% RA \n\n\n', 'ACUTE PROBLEMS\n==============\n# Acute on chronic HFpEF: \nPatient presented with dyspnea and lower extremity edema and\nfound to be volume overloaded on exam. Warm and wet on exam.\nTrigger for HF exacer']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What changes, if any, occurred in the patient's Furosemide dosage from admission to discharge, and what could be the clinical rationale behind such adjustments for a patient initially presenting with worsening shortness of breath, increased leg swelling, and weight gain?","['8c579626-76a5-4cd0-9f53-1feadb6904be\n\nMedications on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath \n2. amLODIPine 10 mg PO DAILY \n3. Atorvastatin 80 mg PO QPM \n4. CARVedilol 50 mg PO BID \n5. Furosemide 80 mg PO DAILY \n6. 70/30 30 Units Breakfast\n70/30 10 Units Lunch\n7. Levothyroxine Sodium 100 mcg PO DAILY \n8. Victoza 2-Pak (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) \nsubcutaneous DAILY \n9. Minoxidil 10 mg PO DAILY \n10. Polyethylene Glycol 17 g PO DAILY:PRN Constipation - First \nLine \n11. sevelamer CARBONATE 800 mg PO TID W/MEALS \n12. Aspirin 81 mg PO DAILY \n13. Vitamin D 1000 UNIT PO DAILY \n \nDischarge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast', 'cd30826d-ad9e-4a08-8b63-15e1e3bbfe0c\n\nYou were admitted to the hospital because:\n================================\n-You had worsening shortness of breath, with increased leg \nswelling and weight gain.\nDuring your stay:\n============\n-You had too much volume onboard so you were given IV diuretic \nmedications,. You improved significantly.\nAfter your discharge:\n================\n-Please continue taking all medications as prescribed (see \nbelow).\n-Please stop taking Lisinopril and metoprolol.\n-Please continue taking insulin according to the regimen you \nwere following before this admission.\n-New medications:\n  - Aspirin 81mg once daily\n  - Carvedilol 25mg twice daily\n  - Furosemide 40mg twice daily\n  - Hydralazine 100mg three times daily\n-Please attend any upcoming outpatient appointments you have \n(see below).\nWe wish you the very best!']","Upon admission, the patient was taking Furosemide 80 mg PO DAILY. At discharge, the medication regimen was adjusted to Furosemide 40mg twice daily. The initial presentation of worsening shortness of breath, increased leg swelling, and weight gain suggests fluid overload, for which IV diuretic medications were effectively administered during the hospital stay. The adjustment to a twice-daily regimen at a lower cumulative daily dose (40mg twice daily equals 80mg total daily) might reflect a clinical decision to maintain diuretic efficacy while minimizing potential side effects, considering the patient's improved condition following in-hospital diuretic treatment. This adjustment could also be tailored to manage outpatient fluid balance, given the patient's response to diuretics during the hospitalization.",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

**Patient/Subject ID:** 13180007 (consistent across all documents)

**Changes in Furosemide Dosage from Admission to Discharge:**

* **Admission Dosage:** IV Lasix (Furosemide) 80mg (mentioned in **Document 3** under ""ACUTE PROBLEMS"" and in **Document 4** under ""Brief Hospital Course"")
* **Discharge Dosage:** PO (oral) Torsemide 100mg daily (mentioned in **Documents 1**, **2**, and implied in **Document 3** as part of the transition from IV Lasix)

**Clinical Rationale for Adjustments:**

1. **Transition from IV to PO:** The switch from intravenous (IV) Lasix to oral (PO) Torsemide likely reflects the patient's improved condition, allowing for a transition from a more immediate-acting IV medication to a more manageable oral form for ongoing diuresis at home. This change is common in the management of heart failure exacerbations once the patient is stabilized.

2. **Change from Furosemide to Torsemide:** The substitution of Torsemide for Furosemide could be due to several reasons:
   - **Efficacy and Potency:** Torsemide is sometimes considered more potent than Furosemide, which might be beneficial for a patient still showing signs of volume overload (1+ edema, JVP of 12cm) at discharge.
   - **Pharmacokinetic Profile:** Torsemide has a longer half-life compared to Furosemide, which can lead to a more sustained diuretic effect. This might be advantageous for outpatient management to reduce the frequency of dosing and improve patient compliance.
   - **Side Effect Profile or Patient Tolerance:** Though not explicitly stated, the change could also be in response to side effects or tolerability issues with Furosemide, though this is speculative without further information.

3. **Dosage Adjustment (80mg Furosemide to 100mg Torsemide):** The increase in dosage (from 80mg of Furosemide to 100mg of Torsemide) might seem counterintuitive given the patient's improvement. However, considering Torsemide's different potency and pharmacokinetics, this adjustment could be intended to maintain or enhance the diuretic effect in an outpatient setting, especially since the patient was noted to still have about 3lb of fluid to lose at discharge.

**Metadata Consistency:**
- **Patient/Subject ID:** Consistently listed as 13180007 across all documents.
- **Note ID and Admission ID:** Also consistent across all documents (Note ID: 13180007-DS-19, Admission ID: 20774429), indicating these documents pertain to the same hospital admission and patient.","['TRANSITIONAL ISSUES\n===================\n[ ] At discharge his symptoms associated with volume overload \nhad subsided, but he was still slightly volume up on exam with \n1+ edema to ankles bilaterally an', 'TRANSITIONAL ISSUES\n===================\n[ ] At discharge his symptoms associated with volume overload \nhad subsided, but he was still slightly volume up on exam with \n1+ edema to ankles bilaterally an', 'ACUTE PROBLEMS\n==============\n# Acute on chronic HFpEF: \nPatient presented with dyspnea and lower extremity edema and\nfound to be volume overloaded on exam. Warm and wet on exam.\nTrigger for HF exacer', 'DISCHARGE LABS\n==============\n\n___ 06:35AM BLOOD WBC-5.4 RBC-2.92* Hgb-7.6* Hct-24.3* \nMCV-83 MCH-26.0 MCHC-31.3* RDW-15.9* RDWSD-47.8* Plt ___\n___ 06:35AM BLOOD Glucose-164* UreaN-51* Creat-2.9* Na-1', 'Name:  ___              Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   M\n \nService: MEDICINE\n \nAllergies: \nNo Known Allergies / Adver']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What is the role of Hydralazine in the treatment regimen for a patient discharged with a primary diagnosis of Acute on chronic heart failure with preserved ejection fraction, and how is its dosage administered?","['5d1619ab-197a-416d-b0af-616eff82199c\n\n#*60 Tablet Refills:*0 \n12.  HydrALAZINE 100 mg PO TID \nRX *hydralazine 100 mg 1 tablet(s) by mouth three times a day \nDisp #*90 Tablet Refills:*0 \n13.  Levothyroxine Sodium 100 mcg PO DAILY \nRX *levothyroxine 100 mcg 1 tablet(s) by mouth once a day Disp \n#*30 Tablet Refills:*0 \n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nPRIMARY DIAGNOSIS\n==================\nAcute on chronic heart failure with preserved ejection fraction\nSECONDARY DIAGNOSES\n====================\nAcute kidney injury\nCoronary artery disease\nType 2 Diabetes Mellitus\nHyperkalemia', 'ab26554b-50b4-4fe8-adc0-d18910279c6b\n\n=============== \n#Acute exacerbation of HFpEF (EF 57%)\nLikely ___s possible ischemia given his \npositive stress in ___. Also possibly triggered by \npneumonia. Did endorse occasional angina symptoms, but trop was \nflat with no EKG changes. TTE showed no regional wall motion \nabnormalities and no mitral regurgitation. He was actively \ndiuresed. His lisinopril was held due to ___. His heart failure \nregimen upon discharge:\nDIURESIS: Torsemide 40 mg QD\nAFTERLOAD: Hydralazine 100 mg TID\nClonidine 0.2 mg BID\nHeld lisinopril given ___\nAmlodipine 10 mg QD\nNHBK: Carvedilol 37.5 mg BID; \n- Discharge weight: 72.7 kg (160.27 lb) \n- Discharge Cr: 3.7\n___ on CKD:\n#Hyperkalemia:\nInitially due to venous congestion, then likely due to \noverdiuresis. He had underlying CKD and his creatinine did not \nreturn to his baseline upon discharge. We suspect that he will \nneed to initiate HD in the near future. His K rose to about 5.8 \nthe week prior to discharge, but this improved with Lasix IV, \nkayexelate, and low potassium diet.']","According to the patient's discharge information, Hydralazine plays a role in the 'AFTERLOAD' component of the heart failure treatment regimen. The dosage of Hydralazine is specifically 100 mg, administered three times a day (TID). This is part of a broader regimen that includes DIURESIS with Torsemide, additional blood pressure management with Clonidine and Amlodipine, and NHBK (likely referring to Neurohormonal Blockade) with Carvedilol. The use of Hydralazine in this context suggests its application in managing afterload reduction, crucial for heart failure management, especially in a patient with preserved ejection fraction and other complicating factors like coronary artery disease and hyperkalemia.",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

**Role of Hydralazine in the Treatment Regimen:**
* **Presence in Treatment Regimen:** Hydralazine is **NOT MENTIONED** in the provided documents (1, 2, 3, 4, 5) as part of the patient's treatment regimen upon discharge or during the hospital stay.

**Dosage Administration:**
* **Dosage Details:** Since Hydralazine is not mentioned in any of the documents as part of the patient's medications, **NO DOSAGE DETAILS ARE AVAILABLE**.

**Additional Observations Relevant to the Question Context:**

* **Primary Diagnosis:** As per Documents 1 and 2, the patient's primary diagnosis upon discharge is ""Acute on chronic diastolic heart failure exacerbation"" (not explicitly stated with preserved ejection fraction in these documents, but described in Document 5 as ""Acute on chronic HFpEF"").
* **Medications Listed:**
	+ Document 1, 2, and 3 list the patient's medications, which include:
		- Torsemide (for diuresis)
		- Albuterol Inhaler
		- Amlodipine (amLODIPine)
		- Aspirin
		- Atorvastatin
		- Carvedilol (CARVedilol)
		- Levothyroxine Sodium
		- Minoxidil
		- Polyethylene Glycol
		- Sevelamer Carbonate
		- Victoza (Liraglutide)
		- Vitamin D
	+ **Notably, Hydralazine is absent from these lists.**
* **Patient/Subject ID, Note ID, and Admission ID Consistency:**
	+ Across all documents (1, 2, 3, 4, 5), the **Patient/Subject ID** is consistently **13180007**.
	+ The **Note ID** is also consistent across all documents as **13180007-DS-19**.
	+ The **Admission ID** is consistently **20774429** across all documents.","['Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', 'TRANSITIONAL ISSUES\n===================\n[ ] At discharge his symptoms associated with volume overload \nhad subsided, but he was still slightly volume up on exam with \n1+ edema to ankles bilaterally an', 'ACUTE PROBLEMS\n==============\n# Acute on chronic HFpEF: \nPatient presented with dyspnea and lower extremity edema and\nfound to be volume overloaded on exam. Warm and wet on exam.\nTrigger for HF exacer']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
Whats the ushual dose of Vitimin D prescribd to pashents in thes hospitl recrds?,"['080dba33-29e9-4409-89cb-54a03af0e470\n\n8.  Levothyroxine Sodium 100 mcg PO DAILY  \n9.  Minoxidil 10 mg PO DAILY  \n10.  Polyethylene Glycol 17 g PO DAILY:PRN Constipation - First \nLine  \n11.  sevelamer CARBONATE 800 mg PO TID W/MEALS  \n12.  Torsemide 100 mg PO DAILY  \n13.  Victoza 2-Pak (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) \nsubcutaneous DAILY  \n14.  Vitamin D 1000 UNIT PO DAILY  \n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nPRIMARY DIAGNSOIS:\n==================\nAcute Hypoxemic Respiratory Failure\nAcute on Chronic Diastolic Heart Failure\nHyperglycemia, Type 2 Diabetes \n___ on CKD \nSECONDARY DIAGNOSIS:', '9c9ab9ab-4a9f-4e03-8ad8-d377af91b9d0\n\n11.  Tresiba U-100 Insulin (insulin degludec) 50 units \nsubcutaneous DAILY  \n12.  Victoza 2-Pak (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) \nsubcutaneous DAILY  \n13.  Vitamin D ___ UNIT PO 1X/WEEK (WE)  \n14. HELD- CloNIDine 0.4 mg PO BID  This medication was held. Do \nnot restart CloNIDine until see what BP is at PCP visit, to see \nif need more meds\n15. HELD- Gabapentin 400 mg PO TID  This medication was held. Do \nnot restart Gabapentin until you discuss with PCP the need for \nit, was not needed during this hospital stay\n16. HELD- HydrALAZINE 100 mg PO TID  This medication was held. \nDo not restart HydrALAZINE until discuss with primary care \ndoctor\n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nType II diabetes']","Based on the provided hospital records, two different dosages of Vitamin D are mentioned for patients:               1. **1000 UNIT PO DAILY** (Record: 080dba33-29e9-4409-89cb-54a03af0e470)              2. **___ UNIT PO 1X/WEEK (WE)** (Record: 9c9ab9ab-4a9f-4e03-8ad8-d377af91b9d0) - *Note: The exact unit dosage is not specified in this record.*",custom_multi_hop_query_synthesizer,"Based on the provided instructions, here's the answer to the question:

**Question:** What's the usual dose of Vitamin D prescribed to patients in these hospital records?

**Answer:**

* **Usual Dose of Vitamin D:** Based on the provided documents, there is only one mention of a specific Vitamin D dose, which appears to be a consistent prescription for the patient across multiple documents, rather than a range of usual doses for various patients.
* **Dose:** **1000 UNIT PO DAILY**
* **Source Documents:** This dose is mentioned in:
	1. **Document 1:** Content > Discharge Medications > #13
	2. **Document 2:** Content > Discharge Medications > #13 (Identical to Document 1, suggesting a duplicate document)
	3. **Document 3:** Content > Medications on Admission > #13 (Indicating this was also the admission dose)

**Metadata Relevance for this Question:** None directly, as the question pertains to medication dosage, which is found in the content of the documents, not in the metadata. However, it's noted that the same Patient/Subject ID (13180007) is consistent across all documents, indicating these observations pertain to the same individual.","['Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', 'TRANSITIONAL ISSUES\n===================\n[ ] At discharge his symptoms associated with volume overload \nhad subsided, but he was still slightly volume up on exam with \n1+ edema to ankles bilaterally an', 'In the ED:  \nInitial VS: T 98.5, HR 102, BP 178/76, RR 22, SpO2 98% RA \n \nExam:\nGeneral- NAD\nHEENT- PERRL, EOMI, normal oropharynx\nLungs- Non-labored breathing, CTAB\nCV- RRR, systolic murmur, normal S']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
Whats the perscribd dose of Asprin for the pashent in the givn clinikal kontext?,"['5a643f48-aebd-476f-bd5e-af9cd241686d\n\nCORE MEASURES\n==============\n#CODE: Full\n#CONTACT: ___ daughter HCP\n \n___ on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Lisinopril 2.5 mg PO DAILY \n2. CloNIDine 0.2 mg PO BID \n3. amLODIPine 10 mg PO EVERY OTHER DAY \n4. HydrALAZINE 100 mg PO TID \n5. Aspirin 81 mg PO DAILY \n6. CARVedilol 25 mg PO BID \n7. Atorvastatin 80 mg PO QPM \n8. liraglutide 1.2 mg subcutaneous DAILY \n9. Levothyroxine Sodium 100 mcg PO DAILY \n10. Glargine 55 Units Breakfast\n11. Furosemide 40 mg PO BID \n12. Albuterol Inhaler ___ PUFF IH Q6H:PRN wheezing, SOB \n \nDischarge Medications:\n1.  BD Ultra-Fine Short Pen Needle (pen needle, diabetic) 31 \ngauge x ___ miscellaneous ASDIR  \n2.  Fluticasone-Salmeterol Diskus (250/50)  1 INH IH BID \nRX *fluticasone-salmeterol [Advair Diskus] 250 mcg-50 mcg/dose 1', 'c91e9f73-a3db-4de7-b32b-2595064882de\n\ndose inhaled twice a day Disp #*1 Disk Refills:*0 \n3.  sevelamer CARBONATE 800 mg PO TID W/MEALS \nRX *sevelamer carbonate 800 mg 1 tablet(s) by mouth three times \na day with meals Disp #*90 Tablet Refills:*0 \n4.  Torsemide 40 mg PO DAILY \nRX *torsemide 20 mg 2 tablet(s) by mouth once a day Disp #*60 \nTablet Refills:*0 \n5.  amLODIPine 10 mg PO DAILY  \n6.  CARVedilol 37.5 mg PO BID \nRX *carvedilol 25 mg 1.5 tablet(s) by mouth twice a day Disp \n#*90 Tablet Refills:*0 \n7.  Glargine 30 Units Breakfast\nGlargine 10 Units Bedtime\nHumalog 5 Units Breakfast\nHumalog 5 Units Lunch\nHumalog 5 Units Dinner\nInsulin SC Sliding Scale using HUM Insulin \n8.  Albuterol Inhaler ___ PUFF IH Q6H:PRN wheezing, SOB  \n9.  Aspirin 81 mg PO DAILY \nRX *aspirin 81 mg 1 tablet(s) by mouth once a day Disp #*30 \nTablet Refills:*0 \n10.  Atorvastatin 80 mg PO QPM \nRX *atorvastatin 80 mg 1 tablet(s) by mouth once a day Disp #*30 \nTablet Refills:*0 \n11.  CloNIDine 0.2 mg PO BID \nRX *clonidine HCl 0.2 mg 1 tablet(s) by mouth twice a day Disp']","According to the provided clinical context, the prescribed dose of Aspirin is 81 mg PO (orally) DAILY. This is consistent across both the preadmission medication list (context node: 5a643f48-aebd-476f-bd5e-af9cd241686d, item 5) and the discharge medications (context node: c91e9f73-a3db-4de7-b32b-2595064882de, item 9), with the latter specifying a dispensing quantity of *30 tablets with 0 refills.",custom_multi_hop_query_synthesizer,"Based on the provided instructions and documents, here is the answer to the question:

**Question:** What's the prescribed dose of Aspirin for the patient in the given clinical context?

**Answer:**

* **Prescribed Dose of Aspirin:** 81 mg PO DAILY
* **Source:** CONTENT of multiple documents (to ensure consistency across documents)
	+ Document 1: CONTENT > Discharge Medications > 5. Aspirin 81 mg PO DAILY
	+ Document 2: CONTENT > Discharge Medications > 5. Aspirin 81 mg PO DAILY ( identical to Document 1, indicating consistency)
	+ Document 3: CONTENT > Medications on Admission > 12. Aspirin 81 mg PO DAILY (also consistent, but noted as part of admission meds, reinforcing the dose)
* **Patient/Subject ID (for context, as per instruction 3):** 13180007 (consistent across all documents: Document 1, Document 2, Document 3, Document 4, and Document 5)
* **Note ID (for additional context, as it matches across documents):** 13180007-DS-19 (consistent across all documents, reinforcing that these documents pertain to the same note/event for the patient)","['Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', 'TRANSITIONAL ISSUES\n===================\n[ ] At discharge his symptoms associated with volume overload \nhad subsided, but he was still slightly volume up on exam with \n1+ edema to ankles bilaterally an', 'In the ED:  \nInitial VS: T 98.5, HR 102, BP 178/76, RR 22, SpO2 98% RA \n \nExam:\nGeneral- NAD\nHEENT- PERRL, EOMI, normal oropharynx\nLungs- Non-labored breathing, CTAB\nCV- RRR, systolic murmur, normal S']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
What is the prescribed dosage and administration schedule for CloNIDine upon admission and at discharge?,"['44d8d766-27ad-43f8-9511-d17ad9f10f4d\n\nMedications on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. amLODIPine 10 mg PO DAILY \n2. Atorvastatin 80 mg PO QPM \n3. CloNIDine 0.2 mg PO BID \n4. Gabapentin 400 mg PO TID \n5. Lisinopril 40 mg PO DAILY \n6. MetFORMIN (Glucophage) 850 mg PO TID \n7. Metoprolol Tartrate 25 mg PO BID \n8. Basaglar (Glargine) 30 Units Breakfast\n9. Albuterol Inhaler 2 PUFF IH Q4H \n10. Levothyroxine Sodium 100 mcg PO DAILY \n11. Vitamin D ___ UNIT PO WEEKLY \n \nDischarge Medications:\n1.  Aspirin 81 mg PO DAILY \nRX *aspirin 81 mg 1 tablet(s) by mouth once daily Disp #*30 \nTablet Refills:*0 \n2.  Carvedilol 25 mg PO BID \nRX *carvedilol 25 mg 1 tablet(s) by mouth twice daily Disp #*60 \nTablet Refills:*0 \n3.  Furosemide 40 mg PO BID \nRX *furosemide 40 mg 1 tablet(s) by mouth twice daily Disp #*60 \nTablet Refills:*0', 'c91e9f73-a3db-4de7-b32b-2595064882de\n\ndose inhaled twice a day Disp #*1 Disk Refills:*0 \n3.  sevelamer CARBONATE 800 mg PO TID W/MEALS \nRX *sevelamer carbonate 800 mg 1 tablet(s) by mouth three times \na day with meals Disp #*90 Tablet Refills:*0 \n4.  Torsemide 40 mg PO DAILY \nRX *torsemide 20 mg 2 tablet(s) by mouth once a day Disp #*60 \nTablet Refills:*0 \n5.  amLODIPine 10 mg PO DAILY  \n6.  CARVedilol 37.5 mg PO BID \nRX *carvedilol 25 mg 1.5 tablet(s) by mouth twice a day Disp \n#*90 Tablet Refills:*0 \n7.  Glargine 30 Units Breakfast\nGlargine 10 Units Bedtime\nHumalog 5 Units Breakfast\nHumalog 5 Units Lunch\nHumalog 5 Units Dinner\nInsulin SC Sliding Scale using HUM Insulin \n8.  Albuterol Inhaler ___ PUFF IH Q6H:PRN wheezing, SOB  \n9.  Aspirin 81 mg PO DAILY \nRX *aspirin 81 mg 1 tablet(s) by mouth once a day Disp #*30 \nTablet Refills:*0 \n10.  Atorvastatin 80 mg PO QPM \nRX *atorvastatin 80 mg 1 tablet(s) by mouth once a day Disp #*30 \nTablet Refills:*0 \n11.  CloNIDine 0.2 mg PO BID \nRX *clonidine HCl 0.2 mg 1 tablet(s) by mouth twice a day Disp']","According to the provided medication lists, the prescribed dosage and administration schedule for CloNIDine are consistent across both admission and discharge: **CloNIDine 0.2 mg PO (orally) BID (twice a day)**. No changes in dosage or administration schedule are noted between admission and discharge medications.",custom_multi_hop_query_synthesizer,"Based on the provided instructions and documents, here is the answer to the question:

**Question:** What is the prescribed dosage and administration schedule for CloNIDine upon admission and at discharge?

**Answer:**

* **Upon Admission:** There is no mention of CloNIDine in the medications listed upon admission in **Document 4** (CHRONIC PROBLEMS and Medications on Admission). The medications listed include Albuterol, AmLODIPine, Atorvastatin, CARVedilol, Furosemide, 70/30 Insulin, Levothyroxine Sodium, Victoza, Minoxidil, Polyethylene Glycol, Sevelamer CARBONATE, Aspirin, and Vitamin D, but no CloNIDine.
* **At Discharge:** Similarly, there is no mention of CloNIDine in the discharge medications listed in **Documents 1** and **2** (Discharge Medications). These documents list the same medications as at admission, with the notable difference of Torsemide instead of Furosemide, but still no CloNIDine.

**Metadata Relevance to the Question:** None of the metadata fields (Patient/Subject ID, Note ID, Admission ID, Chart Time, Store Time) in any of the documents (**1**, **2**, **3**, **4**, **5**) provide information about CloNIDine or its dosage/administration schedule, as CloNIDine is not mentioned in the content of any document.

**IDs for Context (as per instruction 3):**
- The same **Patient/Subject ID (13180007)**, **Note ID (13180007-DS-19)**, and **Admission ID (20774429)** appear in all documents (**1**, **2**, **3**, **4**, **5**).","['Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'TRANSITIONAL ISSUES\n===================\n[ ] At discharge his symptoms associated with volume overload \nhad subsided, but he was still slightly volume up on exam with \n1+ edema to ankles bilaterally an', 'CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', '# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\n']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What is the role of Aspirin in the treatment of a patient with multiple conditions including hypertension, CAD with inducible ischemia, and NSTEMI, based on the provided medical context?","['5a643f48-aebd-476f-bd5e-af9cd241686d\n\nCORE MEASURES\n==============\n#CODE: Full\n#CONTACT: ___ daughter HCP\n \n___ on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Lisinopril 2.5 mg PO DAILY \n2. CloNIDine 0.2 mg PO BID \n3. amLODIPine 10 mg PO EVERY OTHER DAY \n4. HydrALAZINE 100 mg PO TID \n5. Aspirin 81 mg PO DAILY \n6. CARVedilol 25 mg PO BID \n7. Atorvastatin 80 mg PO QPM \n8. liraglutide 1.2 mg subcutaneous DAILY \n9. Levothyroxine Sodium 100 mcg PO DAILY \n10. Glargine 55 Units Breakfast\n11. Furosemide 40 mg PO BID \n12. Albuterol Inhaler ___ PUFF IH Q6H:PRN wheezing, SOB \n \nDischarge Medications:\n1.  BD Ultra-Fine Short Pen Needle (pen needle, diabetic) 31 \ngauge x ___ miscellaneous ASDIR  \n2.  Fluticasone-Salmeterol Diskus (250/50)  1 INH IH BID \nRX *fluticasone-salmeterol [Advair Diskus] 250 mcg-50 mcg/dose 1', '5afc91e0-6481-46b3-aa3c-473b2c2e6895\n\n#Community acquired pneumonia\nCough, worsened SOB, hypoxemia (although alternate explanation) \nbut no leukocytosis or fevers; influenza negative. Legionella \nand strep were negative. Patient was given a 5-day course of \nceftriaxone and azithromycin. \n#Hypertension\nGoal <130/80. As patient is on several anti-hypertensives with \nstill an elevated blood pressure, he underwent a secondary \nhypertension workup. His last renal ultrasound in ___ was \nwithin normal limits. He was placed on continuous O2 monitoring \novernight, and patient did not desaturate. His aldosterone to \nrenin ratio was 0.13, indicating no primary hyperaldosteronism. \n24 hour urine metanephrines and catecholamines were within \nnormal limits.\n#CAD w/ inducible ischemia\n#NSTEMI\nTroponin peaked at 0.02, thought to be type 2 due to volume \noverload. Continued aspirin, atorvastatin, carvedilol. The \ndecision was made to hold off on coronary angiogram due to \nkidney function and the suspicion that this was type 2.\n#H/o CVA\nPatient had an episode while in hospital with dysarthria,']","Based on the provided context, Aspirin (81 mg PO DAILY) is continued as part of the patient's treatment regimen for CAD with inducible ischemia and NSTEMI. Specifically, for NSTEMI, which was considered type 2 due to volume overload (with a troponin peak at 0.02), Aspirin is maintained alongside atorvastatin and carvedilol. This indicates its importance in managing cardiac conditions, likely for antiplatelet effects to prevent further cardiac events, although the context does not explicitly state its rationale beyond continuation in treatment.",custom_multi_hop_query_synthesizer,"Based on the provided medical context and following the instructions, here's the answer to the question:

**Question:** What is the role of Aspirin in the treatment of a patient with multiple conditions including hypertension, CAD with inducible ischemia, and NSTEMI, based on the provided medical context?

**Answer Analysis:**

1. **Patient Context**: The patient in question is identified by:
	* **Patient/Subject ID**: 13180007 (consistent across all documents: Document 1, Document 2, Document 3, Document 4, and Document 5)
2. **Conditions Mentioned in the Question**:
	* **Hypertension**: Confirmed in Document 5.
	* **CAD with Inducible Ischemia**: Not explicitly confirmed in the provided documents. Document 4 discusses chest pain and risk factors for ischemia but concludes that findings are ""not suggestive of ischemia.""
	* **NSTEMI**: Not mentioned in the provided documents. Document 4 mentions ""mild troponin elevation"" but interprets it as difficult to assess due to CKD and not indicative of ischemia based on the context.
3. **Role of Aspirin**:
	* **Hypertension (Confirmed)**: Aspirin is not primarily used for hypertension management. Its role here is not directly related to hypertension control.
	* **CAD with Inducible Ischemia (Not Confirmed)**: Typically, aspirin is used for its antiplatelet effects in patients with CAD or at risk of ischemic events. However, since CAD with inducible ischemia is not confirmed in the documents, this context does not directly apply.
	* **NSTEMI (Not Mentioned)**: Aspirin is a standard treatment for NSTEMI for its antiplatelet effects, but since NSTEMI is not mentioned, this context does not apply.
	* **Actual Context from Documents**: Aspirin (81 mg PO DAILY) is mentioned in the context of:
		+ **History of CVA (Cerebrovascular Accident)** in Document 1 and Document 2, indicating its use for secondary stroke prevention.
		+ **Chest Pain Evaluation** in Document 4, where the patient was ""continued on ASA (Aspirin) and atorvastatin,"" suggesting a cardiovascular protective role, but in the context provided, not specifically for CAD with inducible ischemia or NSTEMI.

**Conclusion**:
Given the provided medical context, the role of Aspirin for Patient/Subject ID 13180007 is primarily for:
- **Secondary stroke prevention** due to a history of CVA.
- **Cardiovascular protection** in a patient with risk factors for ischemia, though not specifically for confirmed CAD with inducible ischemia or NSTEMI, as these conditions are not established in the documents.

**IDs and Dates as per Instructions**:
- **Patient/Subject ID**: 13180007 (consistent across all documents)
- No specific dates were requested or relevant to the question's answer based on the provided instructions.","['CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', 'CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', 'Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', '# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\n', '# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What are the primary reasons for hospital admission and the corresponding in-hospital treatments for patients with conditions related to uncontrolled diabetes and heart failure, based on recent discharge summaries?","['462328c3-90c8-4169-90f0-27fed5e6b04f\n\nDischarge Instructions:\nDear ___, \nIt was a pleasure caring for you here at ___ \n___!\nWHY WAS I IN THE HOSPITAL?\n================================\n- You were admitted to the hospital due to uncontrolled diabetes \nwith blood glucose in a dangerous range. \nWHAT HAPPENED IN THE HOSPITAL?\n================================\n- You were given an insulin drip acutely to lower your glucose, \nfollowed by observation/stabilization on the medicine floor.\n- The ___ diabetes doctors came to help you with your insulin \nregimen; we gave you long acting insulin and insulin with your \ndaily meals. The ___ diabetes doctors talked with your \ndaughters and you to continue 2 medications at home with 2 \ninjections. We monitored your blood sugars here and made sure \nyou ate a healthy diet.\n- You were also given medication to lower your total volume in \nthe body.   \nWHAT SHOULD I DO WHEN I LEAVE THE HOSPITAL?', 'bc70aec9-8d49-462b-9afd-e5bb15b22e94\n\nDischarge Condition:\nMental Status: Clear and coherent.\nLevel of Consciousness: Alert and interactive.\nActivity Status: Ambulatory - Independent.\n \nDischarge Instructions:\nDear ___,  \nIt was a pleasure participating in your care. Please read \nthrough the following information.\nWHY WAS I ADMITTED TO THE HOSPITAL? \n- You were admitted to the hospital because you had been feeling \nshort of breath and you were found to have fluid on your lungs. \nThis was felt to be due to a condition called heart failure, \nwhere your heart does not pump hard enough and fluid backs up \ninto your lungs. \nWHAT HAPPENED WHILE I WAS IN THE HOSPITAL? \n- You were given a diuretic medication through the IV to help \nget the fluid out. You improved considerably and were ready to \nleave the hospital.  \n- You underwent an echocardiogram, which is an ultrasound of']","Based on recent discharge summaries, two primary reasons for hospital admission and their corresponding in-hospital treatments are as follows: nn1. **Uncontrolled Diabetes:**n   - **Reason for Admission:** Uncontrolled diabetes with blood glucose in a dangerous range.n   - **In-Hospital Treatment:** Patients were given an insulin drip to lower glucose levels, followed by observation and stabilization. Specialist diabetes doctors adjusted the patient's insulin regimen, including long-acting insulin and mealtime insulin, with educational support for patients and their families.nn2. **Heart Failure (leading to fluid on the lungs):**n   - **Reason for Admission:** Shortness of breath due to fluid buildup in the lungs, attributed to heart failure where the heart doesn't pump sufficiently.n   - **In-Hospital Treatment:** Administration of diuretic medication intravenously to reduce fluid, significantly improving the patient's condition. Additionally, an echocardiogram (ultrasound of the heart) was performed for further assessment.",custom_multi_hop_query_synthesizer,"**Analysis of Documents for Primary Reasons of Hospital Admission and Corresponding In-Hospital Treatments**

**Patient/Subject ID:** 13180007 (consistent across all documents, indicating all information pertains to the same patient)

**Admission ID:** 20774429 (consistent across all documents, confirming a single hospital admission event being referenced)

**Primary Reasons for Hospital Admission:**

1. **Heart Failure (HF):** Specifically, an exacerbation of acute on chronic diastolic heart failure, as indicated in **Document 4** under ""Discharge Diagnosis: Primary Diagnosis"".
2. **Symptoms Related to Heart Failure:**
	* Swelling in legs due to fluid accumulation (**Documents 1 & 2**, ""WHY WAS I ADMITTED TO THE HOSPITAL?"").
	* Dyspnea (shortness of breath) and chest pain on exertion, with worsening lower extremity edema and wheeze (**Document 5**, ""History of Present Illness"").
3. **Uncontrolled Diabetes (Type 2 Diabetes Mellitus):** Listed as a secondary diagnosis (**Document 4**, ""Discharge Diagnosis: Secondary Diagnosis"") with a history of poor control (A1c 14.4, later improved to 11.4%) (**Document 3**, ""#IDDM"").

**Corresponding In-Hospital Treatments:**

1. **For Heart Failure:**
	* Medications to help remove fluid (**Documents 1 & 2**, ""WHAT HAPPENED WHILE I WAS IN THE HOSPITAL?"").
	* Specifically, discharge medications include:
		+ Torsemide 100 mg PO DAILY (**Document 4**, a diuretic to reduce fluid buildup).
		+ CARVedilol 50 mg PO BID (**Document 4**, a beta-blocker for heart failure management).
2. **For Uncontrolled Diabetes:**
	* Insulin therapy:
		- Lantus 30u at night of admission (**Document 3**, ""#IDDM"").
		- Transitioned to home insulin with 70/30 30u with breakfast and 20u with lunch (**Document 3** and **Document 4**, for ongoing management).
	* Victoza (liraglutide) 0.6 mg/0.1 mL subcutaneous DAILY (**Document 4**, for type 2 diabetes management).

**Additional Context:**
- The patient also received treatments for other conditions, including hypertension, acute on chronic anemia, hypothyroidism, and was prescribed medications for potential constipation and to manage cholesterol levels.
- The patient was discharged ""Home With Service"" (**Document 4**), indicating the need for ongoing care and support post-discharge.","['Discharge Condition:\nMental Status: Clear and coherent.\nLevel of Consciousness: Alert and interactive.\nActivity Status: Ambulatory - Independent.\n\n \nDischarge Instructions:\n Dear ___,  \n\n It was a ple', 'Discharge Condition:\nMental Status: Clear and coherent.\nLevel of Consciousness: Alert and interactive.\nActivity Status: Ambulatory - Independent.\n\n \nDischarge Instructions:\n Dear ___,  \n\n It was a ple', '# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o', 'Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'Name:  ___              Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   M\n \nService: MEDICINE\n \nAllergies: \nNo Known Allergies / Adver']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
What are the notable trends and abnormalities in the patient's calcium levels based on the provided lab results?,"[""88b52764-61ad-4740-9004-35da4cf9a996\n\nAbsMono-0.42 AbsEos-0.09 AbsBaso-0.03\n___ 11:00AM BLOOD Glucose-98 UreaN-32* Creat-2.3* Na-139 \nK-4.1 Cl-100 HCO3-25 AnGap-14\n___ 11:00AM BLOOD ALT-8 AST-9 CK(CPK)-110 AlkPhos-144* \nTotBili-<0.2\n___ 11:00AM BLOOD Albumin-3.5 Calcium-9.2 Mg-2.3\nDISCHARGE LABS:\n___ 06:22AM BLOOD WBC-5.6 RBC-3.86* Hgb-10.1* Hct-32.1* \nMCV-83 MCH-26.2 MCHC-31.5* RDW-14.3 RDWSD-43.4 Plt ___\n___ 06:08AM BLOOD Glucose-157* UreaN-33* Creat-1.9* Na-138 \nK-4.5 Cl-100 HCO3-22 AnGap-16\nIMPORTANT RESULTS:\n___ 11:00AM BLOOD %HbA1c-14.4* eAG-367*\n___ 09:00PM BLOOD TSH-1.3\n___ 11:11AM BLOOD Lactate-1.6\n___ 11:00AM BLOOD CK-MB-4 proBNP-754*\nIMAGING:\nChest X-ray: \nComparison to ___.  On today's radiograph, a small\npleural left-sided calcification is seen.  There also is a small"", '9a673ed7-18d2-4d47-9b22-110fb9514b9b\n\nK-4.2 Cl-103 HCO3-22 AnGap-18\n___ 03:10PM BLOOD Glucose-236* UreaN-29* Creat-2.2* Na-135 \nK-4.1 Cl-96 HCO3-25 AnGap-14\n___ 07:27AM BLOOD Glucose-185* UreaN-27* Creat-2.1* Na-137 \nK-4.3 Cl-97 HCO3-27 AnGap-13\n___ 02:50PM BLOOD Glucose-248* UreaN-31* Creat-2.1* Na-137 \nK-4.6 Cl-97 HCO3-27 AnGap-13\n___ 06:45AM BLOOD Glucose-165* UreaN-27* Creat-2.0* Na-138 \nK-4.3 Cl-98 HCO3-26 AnGap-14\n___ 07:44AM BLOOD Calcium-9.0 Phos-4.4 Mg-1.7\n___ 05:00PM BLOOD Calcium-9.2 Phos-4.8* Mg-3.2*\n___ 07:00AM BLOOD Calcium-8.9 Phos-5.0* Mg-2.3\n___ 02:48PM BLOOD Calcium-9.0 Phos-5.3* Mg-2.2\n___ 07:35AM BLOOD Calcium-8.4 Phos-5.1* Mg-2.0\n___ 03:10PM BLOOD Calcium-8.8 Phos-5.0* Mg-2.1\n___ 07:27AM BLOOD Calcium-8.9 Phos-4.4 Mg-2.0\n___ 02:50PM BLOOD Calcium-8.5 Phos-4.4 Mg-2.1\n___ 06:45AM BLOOD Calcium-8.6 Phos-4.0 Mg-2.0\nLFTs\n___ 09:10AM BLOOD ALT-31 AST-25 AlkPhos-111 TotBili-<0.2\n___ 07:44AM BLOOD CK(CPK)-531*\n___ 07:00AM BLOOD CK(CPK)-509*\nCARDIAC ENZYMES:\n___ 09:10AM BLOOD proBNP-1140*']","Based on the lab results, here are the notable trends and abnormalities in the patient's calcium levels:      - **Variation in Calcium Levels:** Calcium levels fluctuated between 8.4 mg/dL (07:35 AM) and 9.2 mg/dL (05:00 PM and 11:00 AM in the first context node), indicating some variability throughout the day.     - **Abnormalities:** None of the calcium levels provided fall outside the typical normal range (approximately 8.6 to 10.2 mg/dL, though reference ranges may slightly vary). However, it's crucial to consider these in the context of the patient's overall health and other lab results.     - **Associated Abnormalities:** Notably, Phosphate (Phos) levels were occasionally elevated (* denotes abnormality), which can be related to calcium metabolism and may warrant further investigation. For example, a Phos level of 5.3* mg/dL at 02:48 PM is above the normal range (typically about 2.5 to 4.5 mg/dL for adults), which might suggest an imbalance in calcium-phosphate homeostasis.",custom_multi_hop_query_synthesizer,"Based on the provided instructions and documents, here's the response to the question about notable trends and abnormalities in the patient's calcium levels:

**Patient Identification (from METADATA, as per instruction 1):**
* Patient/Subject ID: **13180007** (consistent across all 5 documents)
* Note ID: **13180007-DS-19** (consistent across all 5 documents)
* Admission ID: **20774429** (consistent across all 5 documents)

**Calcium Levels Analysis (from CONTENT, focusing on Document 1 and Document 2 which explicitly mention lab results including Calcium):**

* **Document 1** and **Document 2** (identical content regarding lab results):
	+ Calcium Level: **8.4** (single measurement at 06:35 AM, no trend available)
	+ **Abnormality Assessment:** Based on standard reference ranges for adult blood calcium levels (typically approximately 8.6 to 10.2 mg/dL, though can slightly vary by lab), a level of **8.4** might be considered slightly below the normal range, depending on the specific laboratory's reference values. However, without more context (e.g., ionized calcium, albumin levels, or serial measurements) and given the proximity to the lower bound of normal, this might not be deemed significantly abnormal in this snapshot.

**Notable Trends:** 
* **None can be determined** from the provided documents, as only a single calcium level measurement is reported across the documents that mention lab results (Documents 1 and 2).

**Abnormalities:**
* **Potential mild hypocalcemia** (calcium level of 8.4), though this interpretation depends on the laboratory's specific reference range and is based on a single measurement.

**Additional Recommendations for Further Analysis:**
* Review laboratory reference ranges specific to the testing facility.
* Examine serial calcium measurements, if available, to assess trends.
* Consider albumin and ionized calcium levels for a more comprehensive evaluation of calcium status.","['DISCHARGE LABS\n==============\n\n___ 06:35AM BLOOD WBC-5.4 RBC-2.92* Hgb-7.6* Hct-24.3* \nMCV-83 MCH-26.0 MCHC-31.3* RDW-15.9* RDWSD-47.8* Plt ___\n___ 06:35AM BLOOD Glucose-164* UreaN-51* Creat-2.9* Na-1', 'DISCHARGE LABS\n==============\n\n___ 06:35AM BLOOD WBC-5.4 RBC-2.92* Hgb-7.6* Hct-24.3* \nMCV-83 MCH-26.0 MCHC-31.3* RDW-15.9* RDWSD-47.8* Plt ___\n___ 06:35AM BLOOD Glucose-164* UreaN-51* Creat-2.9* Na-1', 'ACUTE PROBLEMS\n==============\n# Acute on chronic HFpEF: \nPatient presented with dyspnea and lower extremity edema and\nfound to be volume overloaded on exam. Warm and wet on exam.\nTrigger for HF exacer', '# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o', '# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\n']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
Whats the perscribed dose of HydrALAZINE for this patient??,"['058d90f2-3d7b-4d29-bca6-e70e3cb19e4d\n\n4.  HydrALAZINE 100 mg PO TID \nRX *hydralazine 100 mg 1 tablet(s) by mouth three times daily \nDisp #*90 Tablet Refills:*0 \n5.  Glargine 30 Units Breakfast \n6.  Albuterol Inhaler 2 PUFF IH Q4H  \n7.  amLODIPine 10 mg PO DAILY  \n8.  Atorvastatin 80 mg PO QPM  \n9.  CloNIDine 0.2 mg PO BID  \n10.  Gabapentin 400 mg PO TID  \n11.  Levothyroxine Sodium 100 mcg PO DAILY  \n12.  MetFORMIN (Glucophage) 850 mg PO TID  \n13.  Vitamin D ___ UNIT PO WEEKLY  \n14. HELD- Lisinopril 40 mg PO DAILY  This medication was held. \nDo not restart Lisinopril until told to do so by your doctor\n15.Outpatient Lab Work\nChem-7 to be draw ___\nICD 10: I50.3: Diastolic (congestive) heart failure\nFax results to: ___ ATTN: ___\n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___', '5a643f48-aebd-476f-bd5e-af9cd241686d\n\nCORE MEASURES\n==============\n#CODE: Full\n#CONTACT: ___ daughter HCP\n \n___ on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Lisinopril 2.5 mg PO DAILY \n2. CloNIDine 0.2 mg PO BID \n3. amLODIPine 10 mg PO EVERY OTHER DAY \n4. HydrALAZINE 100 mg PO TID \n5. Aspirin 81 mg PO DAILY \n6. CARVedilol 25 mg PO BID \n7. Atorvastatin 80 mg PO QPM \n8. liraglutide 1.2 mg subcutaneous DAILY \n9. Levothyroxine Sodium 100 mcg PO DAILY \n10. Glargine 55 Units Breakfast\n11. Furosemide 40 mg PO BID \n12. Albuterol Inhaler ___ PUFF IH Q6H:PRN wheezing, SOB \n \nDischarge Medications:\n1.  BD Ultra-Fine Short Pen Needle (pen needle, diabetic) 31 \ngauge x ___ miscellaneous ASDIR  \n2.  Fluticasone-Salmeterol Diskus (250/50)  1 INH IH BID \nRX *fluticasone-salmeterol [Advair Diskus] 250 mcg-50 mcg/dose 1']","According to the medical records, the prescribed dose of HydrALAZINE for this patient is 100 mg, taken orally (PO) three times daily (TID). This is consistent across both the initial medication list (context ID: 058d90f2-3d7b-4d29-bca6-e70e3cb19e4d, item 4) and the CORE MEASURES list (context ID: 5a643f48-aebd-476f-bd5e-af9cd241686d, item 4).",custom_multi_hop_query_synthesizer,"Based on the provided instructions and documents, here is the answer to the current question:

**Question:** What's the prescribed dose of HydrALAZINE for this patient??

**Answer:** **NOT MENTIONED**

**Rationale:**

1. **Metadata Review**: The metadata across all documents (1 to 5) does not mention HydrALAZINE at all, focusing on patient, note, and admission IDs, which are consistent across documents (Patient/Subject ID: 13180007, Note ID: 13180007-DS-19, Admission ID: 20774429).
2. **Content Review**: A thorough review of the content in all documents reveals that HydrALAZINE is not prescribed or mentioned in the context of this patient's treatment, medications on admission, discharge medications, or any transitional issues and discharge labs.

**Consistency Note**: As per instruction 3, it's worth noting that the Patient/Subject ID, Note ID, and Admission ID are consistent across all five documents, reinforcing that these documents pertain to the same patient and admission event. However, this does not impact the answer to the question about HydrALAZINE, as it is simply not mentioned.","['CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', 'CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', 'Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'TRANSITIONAL ISSUES\n===================\n[ ] At discharge his symptoms associated with volume overload \nhad subsided, but he was still slightly volume up on exam with \n1+ edema to ankles bilaterally an', 'DISCHARGE LABS\n==============\n\n___ 06:35AM BLOOD WBC-5.4 RBC-2.92* Hgb-7.6* Hct-24.3* \nMCV-83 MCH-26.0 MCHC-31.3* RDW-15.9* RDWSD-47.8* Plt ___\n___ 06:35AM BLOOD Glucose-164* UreaN-51* Creat-2.9* Na-1']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What are the key findings and management strategies for a patient with a history of Coronary Artery Disease (CAD) and other comorbidities, as evident from recent hospital admissions and medication lists?","['2574c42a-a6ef-418e-ac90-a21855611d18\n\npulmonary edema. No pneumonia, no pneumothorax.  The lateral \nradiograph shows mild flattening of the hemidiaphragms, \npotentially as a consequence of functional obstruction.\n___ CT HEAD -\n1. No evidence of acute intracranial abnormality.\n2. Unchanged appearance of chronic infarcts within the right \nfrontal lobe and left occipital lobe.\n3. Chronic lacunar infarcts within the right basal ganglia.\n4. Re-demonstration of few calcifications within the pons, \nfindings which are unchanged in appearance and likely sequela of \nprior ischemic or inflammatory process.\nMICRO:\n___ 3:38 pm URINE\n                            **FINAL REPORT ___\n   URINE CULTURE (Final ___:    < 10,000 CFU/mL. \n \nBrief Hospital Course:\nMr. ___ is a ___ ___ speaking male with a \nPMH of prior CVA ___, residual emotional lability, \ndysarthria), HFpEF, uncontrolled DM2, HTN, CAD, CKD, \n?hypothyroidism, asthma, mild cognitive impairment who presented', '8c0badb1-fe3b-4585-8010-1ef4ba8fdd98\n\n================\n# Hx of CAD \n# Hx of ischemic CVA\nStress test in ___ with area of inducible ischemia in LCx \ndistribution. Trop peaked at 0.06 (iso CKD) and then \ndowntrended. No EKG changes seen. Continued home carvedilol, ASA \nand high dose atorvastatin. \n# CKD: Cr at presentation close to baseline. Underlying etiology \nlikely combination of HTN, DM. \n# Hypothyroidism: Continued home levothyroxine 100 mcg daily\n \nMedications on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Furosemide 40 mg PO 3X/WEEK (___) \n2. sevelamer CARBONATE 800 mg PO TID W/MEALS \n3. Minoxidil 2.5 mg PO DAILY \n4. Levothyroxine Sodium 100 mcg PO DAILY \n5. CARVedilol 37.5 mg PO BID \n6. amLODIPine 10 mg PO DAILY \n7. Albuterol Inhaler 2 PUFF IH Q6H \n8. Jardiance (empagliflozin) 10 mg oral DAILY \n9. Victoza 3-Pak (liraglutide) 1.2 mg subcutaneous DAILY']","Based on the provided context, key findings for the patient with a history of CAD include:    - **History of CAD** with a past stress test showing inducible ischemia in the LCx distribution, managed with carvedilol, ASA, and high-dose atorvastatin.   - **Comorbidities**: History of ischemic CVA, HFpEF, uncontrolled DM2, HTN, CKD, possible hypothyroidism, asthma, and mild cognitive impairment.   - **Recent Hospital Findings**: No acute intracranial abnormalities on CT HEAD, chronic infarcts in the right frontal and left occipital lobes, and unchanged calcifications within the pons.   - **Medication Management**: The patient is on a comprehensive medication regimen including diuretics (furosemide), sevelamer carbonate for CKD, minoxidil, levothyroxine for hypothyroidism, carvedilol and amlodipine for CAD and HTN, inhalers for asthma, and empagliflozin and liraglutide for DM2 management.   - **Urine Culture**: Showed < 10,000 CFU/mL, indicating no significant urinary tract infection.   Management strategies appear to focus on multifaceted pharmacological intervention to control the patients various comorbid conditions, alongside monitoring for any progression of CAD or other diseases.",custom_multi_hop_query_synthesizer,"**Response to Current Question**

**Patient Identification:**
* **Patient/Subject ID:** 13180007 (consistent across all documents: Document 1, Document 2, Document 3, Document 4, Document 5)
* **Note ID:** 13180007-DS-19 (consistent across all documents)
* **Admission ID:** 20774429 (consistent across all documents)

**Key Findings Related to CAD and Comorbidities:**

1. **Coronary Artery Disease (CAD):**
	* **History of CAD:** Not explicitly mentioned in any document as a known history. However, documents mention risk factors for ischemia and the management of potential CAD symptoms.
	* **Chest Pain and Troponin Elevation:** Presented with chest pain and mild troponin elevation, but interpreted with caution due to Chronic Kidney Disease (CKD). (Document 1 & Document 2)
	* **Management:** Continued on ASA (Aspirin) and atorvastatin. (Document 1 & Document 2)

2. **Other Comorbidities and Findings:**
	* **Chronic Kidney Disease (CKD):** Elevated Cr levels, concerns for renal congestion causing renal dysfunction. Managed with sevelamer. (Document 1, Document 2, & implied in others)
	* **Hypertension:** History, currently well controlled with amlodipine, Coreg, and minoxidil. (Document 5)
	* **Diabetes Mellitus Type 2 (IDDM):** Poorly controlled, with high A1c levels. Managed with insulin (Lantus and 70/30) and Victoza. (Document 4 & Document 5)
	* **Cerebrovascular Disease:** History of CVA, managed with aspirin and atorvastatin. (Document 4)
	* **Other Conditions:** Hypothyroidism (managed with levothyroxine), secundum ASD, mild AR, osteoarthritis, asthma, and others as listed in Document 3 (Past Medical History) and Document 4 (Chronic Problems and Medications).

**Management Strategies:**

1. **Cardiovascular:**
	* ASA and atorvastatin for potential CAD symptoms and risk factor management.
	* Blood pressure management with amlodipine, Coreg, and minoxidil for hypertension.
2. **Renal:**
	* Sevelamer for CKD management.
3. **Diabetes:**
	* Insulin therapy (Lantus and 70/30) and Victoza for glycemic control.
4. **Multidisciplinary Approach:**
	* Comprehensive management of multiple comorbidities through a broad range of medications (as listed in Document 4) and likely close monitoring in outpatient settings.

**Note:** The absence of explicit CAD history in the documents suggests a focus on managing risk factors and comorbid conditions that could impact cardiovascular health.","['# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\n', '# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\n', 'Studies notable for:  \n-CXR:  Mild pulmonary vascular congestion with small bilateral\npleural effusions, left greater than right. \n\nVitals on transfer: T 97.3, HR 88, BP 120/54, RR 18, SpO2 98% RA \n\n\n', 'CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', '# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What lab values indicate poor management of Diabetes Mellitus (DM) in the hospitalized male patient with HFpEF, and how might these relate to his discharge medication for diuresis?","['8d31665e-700b-4b64-8af5-51456ad55ff5\n\n___ 06:35AM BLOOD WBC-5.4 RBC-2.92* Hgb-7.6* Hct-24.3* \nMCV-83 MCH-26.0 MCHC-31.3* RDW-15.9* RDWSD-47.8* Plt ___\n___ 06:35AM BLOOD Glucose-164* UreaN-51* Creat-2.9* Na-140 \nK-4.6 Cl-99 HCO3-25 AnGap-16\n___ 06:35AM BLOOD Calcium-8.4 Phos-6.0* Mg-2.1\n \nBrief Hospital Course:\nSUMMARY\n=======\n___ male with history of HFpEF (EF 55-60% in ___,\nprior CVA, CKD, DM, hypertension, and carotid artery disease\nwho presented with 1 day of dyspnea and discomfort, and was\nadmitted for HF exacerbation. The trigger was unclear, possible \nmedication non-compliance. He was diuresed with several doses of \nIV Lasix 80 and by time of discharge symptoms had improved. He \nwas still slightly volume up on exam, with JVP ~12 and 1+ edema \nto ankles.\nTRANSITIONAL ISSUES\n===================\n[ ] At discharge his symptoms associated with volume overload \nhad subsided, but he was still slightly volume up on exam with \n1+ edema to ankles bilaterally and JVP of 12cm. He is being \ndischarged on torsemide 100 daily for active diuresis, with \nabout 3lb of fluid still left to lose.']","Based on the provided context, lab values indicating poor management of Diabetes Mellitus (DM) include: Glucose-164* (elevated, suggesting hyperglycemia), Hgb-7.6* and Hct-24.3* (indicating anemia, which can be a complication of poorly managed DM), and Phos-6.0* (elevated phosphate, which can be seen in diabetic patients due to kidney impairment, as hinted at by CKD in the patient's history). The discharge medication, torsemide 100 daily for active diuresis, aims to reduce volume overload (noted by 1+ edema to ankles and JVP of 12cm at discharge). While torsemide does not directly manage DM, effective diuresis can help in managing fluid overload associated with diabetic nephropathy, indirectly benefiting DM management by reducing the body's fluid volume and, consequently, the workload on the kidneys.",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

**Patient Identification (from METADATA, as per instruction 1):**
* **Patient/Subject ID:** 13180007 (consistent across all documents: Doc 1, Doc 2, Doc 3, Doc 4, Doc 5)
* **Note ID:** 13180007-DS-19 (consistent across all documents)
* **Admission ID:** 20774429 (consistent across all documents)

**Lab Values Indicative of Poor Management of Diabetes Mellitus (DM):**
* **Glucose Level:** 164* (indicated in Doc 1 and Doc 2, under ""06:35AM BLOOD"" results)
* **A1C Levels:**
	+ 14.4% (mentioned in Doc 5, from a previous test)
	+ 11.4% (repeat A1C, mentioned in Doc 5, indicating though an improvement, still poorly controlled)

**Relation to Discharge Medication for Diuresis:**
* **Discharge Medication for Diuresis:** Transitioned to PO torsemide 100 (mentioned in Doc 4)
* **Relation to DM Management:**
	+ Elevated glucose levels (164*) may indicate the need for careful monitoring of fluid and electrolyte balance, especially when diuresing with medications like torsemide.
	+ Poorly controlled diabetes (as evidenced by high A1C levels) can exacerbate fluid overload and worsen heart failure symptoms. Effective management of diabetes is crucial in the context of HFpEF to minimize the risk of complications that could necessitate adjustments in diuretic therapy.
	+ The choice of torsemide, which is known for its efficacy in patients with heart failure and can have a more favorable metabolic profile compared to some other diuretics (e.g., less potassium loss), might be considered in the context of managing a patient with both HFpEF and poorly controlled diabetes. However, the direct relation between the choice of torsemide and the patient's diabetes management lab values is not explicitly stated in the documents provided.","['DISCHARGE LABS\n==============\n\n___ 06:35AM BLOOD WBC-5.4 RBC-2.92* Hgb-7.6* Hct-24.3* \nMCV-83 MCH-26.0 MCHC-31.3* RDW-15.9* RDWSD-47.8* Plt ___\n___ 06:35AM BLOOD Glucose-164* UreaN-51* Creat-2.9* Na-1', 'DISCHARGE LABS\n==============\n\n___ 06:35AM BLOOD WBC-5.4 RBC-2.92* Hgb-7.6* Hct-24.3* \nMCV-83 MCH-26.0 MCHC-31.3* RDW-15.9* RDWSD-47.8* Plt ___\n___ 06:35AM BLOOD Glucose-164* UreaN-51* Creat-2.9* Na-1', 'Name:  ___              Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   M\n \nService: MEDICINE\n \nAllergies: \nNo Known Allergies / Adver', 'ACUTE PROBLEMS\n==============\n# Acute on chronic HFpEF: \nPatient presented with dyspnea and lower extremity edema and\nfound to be volume overloaded on exam. Warm and wet on exam.\nTrigger for HF exacer', '# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What is the current management and recommendation for the patient's hypertension, specifically regarding the use of hydralazine, given its prior discontinuation by the primary care physician before admission?","['71b11357-64d1-43f3-b5b3-9e2b962adaf4\n\n# Volume overload\n# HFpEF, LVEF 55-60% in ___\nVolume overload on exam. Diuresis began while in ICU, net \nnegative 1.8L prior to transfer. Dry weight appears to be \n154-157. s/p Lasix 80mg x 2 so far. 163.4 lb on ___ A-Strict \nI/Os, daily weights. Continued home carvedilol at increased dose \nas below. He was sent home with PO 60 mg Lasix daily and was net \neven in the hospital. \n# HTN\nBlood pressure medications initially held when he was started on \npropofol. Anti-HTN meds started on day of transfer. Persistently \nhypertensive. Increased carvedilol to 50 mg BID and increased \nminoxidil to 5 mg and continued amlodipine 10 mg QD. Of note, he \nhad been on clonidine and hydralazine but these were stopped by \nPCP just prior to admission. He remained mostly normotensive \nalthough goal SBP <130 and should continue to be goal as an \noutpatient. \n# Normocytic Anemia\nBaseline of ___, secondary to CKD and possible AoCD. Required \n1u pRBC on arrival. Hb stable. \nCHRONIC ISSUES:', '9c9ab9ab-4a9f-4e03-8ad8-d377af91b9d0\n\n11.  Tresiba U-100 Insulin (insulin degludec) 50 units \nsubcutaneous DAILY  \n12.  Victoza 2-Pak (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) \nsubcutaneous DAILY  \n13.  Vitamin D ___ UNIT PO 1X/WEEK (WE)  \n14. HELD- CloNIDine 0.4 mg PO BID  This medication was held. Do \nnot restart CloNIDine until see what BP is at PCP visit, to see \nif need more meds\n15. HELD- Gabapentin 400 mg PO TID  This medication was held. Do \nnot restart Gabapentin until you discuss with PCP the need for \nit, was not needed during this hospital stay\n16. HELD- HydrALAZINE 100 mg PO TID  This medication was held. \nDo not restart HydrALAZINE until discuss with primary care \ndoctor\n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nType II diabetes']","According to the provided context, hydralazine (100 mg PO TID) was held during the hospital stay. The patient's hypertension management was adjusted by increasing carvedilol to 50 mg BID and minoxidil to 5 mg, continuing amlodipine 10 mg QD, which resulted in mostly normotensive readings, though aiming for SBP <130. The recommendation is not to restart hydralazine until discussed with the primary care doctor, implying that outpatient follow-up will determine the necessity of its reinitiation or alternative adjustments to achieve the desired blood pressure goal.",custom_multi_hop_query_synthesizer,"Based on the provided instructions and documents, here is the response to the current question:

**Question:** What is the current management and recommendation for the patient's hypertension, specifically regarding the use of hydralazine, given its prior discontinuation by the primary care physician before admission?

**Answer:**

* **Hypertension Management:** According to **Document 3**, the patient's hypertension is ""currently well controlled."" The medications used for managing hypertension, as mentioned in **Document 3** and consistently across other documents (especially in medication lists), are:
	1. **Amlodipine 10 mg PO DAILY** (mentioned in all documents with medication lists)
	2. **Carvedilol (Coreg) 50 mg PO BID** (mentioned in all documents with medication lists)
	3. **Minoxidil 10 mg PO DAILY** (mentioned in all documents with medication lists)
* **Hydralazine:** There is **no mention** of hydralazine in any of the provided documents (**Document 1** through **Document 5**), including both the metadata and the content. This suggests that:
	+ Hydralazine is not currently part of the patient's management plan as per the provided documents.
	+ There is no direct information available within the provided documents regarding the prior discontinuation of hydralazine by the primary care physician before admission, as this event is not documented in the content of any of the documents.

**Metadata ID Values (for context, as per instruction 2):**
- **Patient/Subject ID:** 13180007 (consistent across all documents)
- **Note ID:** 13180007-DS-19 (consistent across all documents)
- **Admission ID:** 20774429 (consistent across all documents)

**Note:** To accurately address the question about hydralazine's prior discontinuation and its current recommendation, additional information from outside these documents (e.g., primary care physician's notes, earlier admission records) would be necessary, as the provided documents do not mention hydralazine at all.","['CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', 'CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', '# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o', 'ACUTE PROBLEMS\n==============\n# Acute on chronic HFpEF: \nPatient presented with dyspnea and lower extremity edema and\nfound to be volume overloaded on exam. Warm and wet on exam.\nTrigger for HF exacer', 'Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What are the key considerations and potential complications for a patient with asthma, presenting with no current respiratory distress, but having a complex past medical history including cardiac risk factors and cerebrovascular disease, in a long-term healthcare management context?","['281ec1ee-1c32-43a3-8667-6c9eaa2f4734\n\nEKG:  SR, NL axis, NIs, TWIs laterally (c/w prior) \nLabs/studies notable for:  proBNP: 1140, Cr 1.9\nPatient was given:  IV Furosemide 10mg\nOn the floor...  \n---------------\nStates that he feels better than he did when he came to the\nhospital. No SOB, CP, or palpitations. Only complaint is the\nburning/itching in his lower extremities. \n \nPast Medical History:\n1. CARDIAC RISK FACTORS  \n- Type 2 Diabetes Mellitus\n- Hypertension  \n- Dyslipidemia  \n- Coronary artery disease\n2. CARDIAC HISTORY  \n- Secondum ASD\n- Mild AR\n3. OTHER PAST MEDICAL HISTORY  \n- Extensive intracranial atherosclerosis, worse in the right\nMCA territory.\n- Cerebrovascular disease, status post CVA in ___\n- Asthma\n- OSteoarthritis', '3a943d1f-0e52-4cc8-939c-42f2386be179\n\n- Cerebrovascular disease, status post CVA in ___\n- Asthma\n- OSteoarthritis\n \nSocial History:\n___\nFamily History:\nBoth parents have heart disease. Mother-___ w/ heart problems and\ndiabetes & father is ___ w/ diabetes. 16 brothers and sisters. No\nknown hx of early coronary artery disease or sudden cardiac \ndeath.\n \nPhysical Exam:\nADMISSION EXAM:\nVS: ___ Temp: 97.3 PO BP: 168/78 HR: 85 RR: 18 O2 sat:\n97% O2 delivery: RA Dyspnea: 0 RASS: 0 Pain Score: ___ \nGEN: alert and interactive, comfortable, no acute distress\nHEENT: PERRL, anicteric, conjunctiva pink, oropharynx without\nlesion or exudate, moist mucus membranes, ears without lesions \nor\napparent trauma\nLYMPH: no anterior/posterior cervical, supraclavicular \nadenopathy']","Based on the provided context, key considerations for managing a patient with asthma, like the one described, include monitoring for potential exacerbations, especially given the patient's complex past medical history. Notably, the patient's current presentation without SOB (shortness of breath), CP (chest pain), or palpitations, but with a complaint of burning/itching in lower extremities, suggests that asthma is not currently the primary acute concern. However, the patient's history of cardiac risk factors (Type 2 Diabetes Mellitus, Hypertension, Dyslipidemia, Coronary artery disease), cardiac history (Secondum ASD, Mild AR), and cerebrovascular disease (status post CVA), alongside extensive intracranial atherosclerosis, necessitates a holistic approach. This includes careful management of medications (e.g., the IV Furosemide given for an unspecified but likely cardiac-related issue, given the proBNP and Cr levels), regular monitoring for signs of cardiac decompensation or stroke, and adjusting asthma management to prevent triggering other conditions. The patient's family history of heart disease and diabetes also warrants close long-term monitoring for early signs of these conditions. Physical exams, like the one documented, are crucial for ongoing assessment, particularly focusing on the patient's comfort, distress levels, and specific systemic evaluations (e.g., HEENT, Lymphatic).",custom_multi_hop_query_synthesizer,"**Key Considerations and Potential Complications for Long-term Healthcare Management**

**Patient Identification:**
* **Patient/Subject ID:** 13180007 (consistent across all documents: Document 1, Document 2, Document 3, Document 4, Document 5)
* **Note ID:** 13180007-DS-19 (consistent across all documents)
* **Admission ID:** 20774429 (consistent across all documents)

**Clinical Summary:**

1. **Asthma:** Currently, no respiratory distress is noted (Document 1, Document 2, and implied in Document 3's Physical Exam section). However, asthma's chronic nature requires ongoing management to prevent exacerbations, especially in a patient with a complex medical history.

2. **Cardiac Risk Factors and Conditions:**
   - **Hypertension** (Document 1, Document 2)
   - **Dyslipidemia** (Document 1, Document 2)
   - **Secundum ASD** (Document 1, Document 2)
   - **Mild AR** (Document 1, Document 2)
   - **Carotid Artery Disease** (Document 1, Document 2)
   - **History of Cerebrovascular Disease with CVA** (Document 1, Document 2)
   - **Extensive Intracranial Atherosclerosis** (Document 1, Document 2)
   - **Family History of Heart Disease** (Document 3)

3. **Other Relevant Conditions:**
   - **Diabetes Mellitus Type 2** (Document 1, Document 2, and implied family history in Document 3)
   - **Chronic Kidney Disease (CKD)** with elevated Cr levels (Document 4)
   - **Osteoarthritis** (Document 1, Document 2)

**Key Considerations for Long-term Management:**

- **Multidisciplinary Care:** Given the complexity of the patient's medical history, a team approach including cardiology, neurology, nephrology, endocrinology, and pulmonology (for asthma) is crucial.
- **Regular Monitoring:**
  - **Cardiac Function:** Regular echocardiograms to monitor ASD and AR, and to assess for any signs of heart failure.
  - **Renal Function:** Close monitoring of Cr levels to manage CKD.
  - **Diabetic Control:** Regular HbA1c checks to ensure optimal diabetes management.
  - **Asthma Control:** Regular peak flow monitoring and symptom assessment to adjust asthma management as needed.
- **Preventive Measures:**
  - **Antiplatelet Therapy:** Continuation of ASA (as mentioned in Document 4) for cardiovascular protection.
  - **Lipid Management:** Atorvastatin (mentioned in Document 4) for dyslipidemia, with regular lipid profile checks.
  - **Blood Pressure Control:** Tight BP management to reduce cardiovascular and renal risk.
  - **Vaccinations:** Ensuring the patient is up-to-date on all recommended vaccinations, especially the influenza and pneumococcal vaccines, given the asthma and CKD.
- **Lifestyle Modifications:**
  - **Dietary Counseling:** For management of diabetes, dyslipidemia, and CKD.
  - **Exercise Plan:** A tailored exercise plan considering the patient's osteoarthritis and cardiac conditions.
  - **Smoking Cessation:** If applicable, given the absence of smoking status in the documents.

**Potential Complications to Watch For:**

- **Cardiovascular Events:** Myocardial infarction, stroke, given the extensive cardiac risk factors.
- **Heart Failure Exacerbation:** Especially with the history of HFpEF (Document 5).
- **Renal Decline:** Progression of CKD to end-stage renal disease.
- **Asthma Exacerbations:** Potentially triggered by respiratory infections or poor environmental conditions.
- **Diabetic Complications:** Nephropathy (beyond current CKD), retinopathy, neuropathy, or foot ulcers.
- **Cerebrovascular Accidents:** Given the history of CVA and extensive intracranial atherosclerosis.","['Studies notable for:  \n-CXR:  Mild pulmonary vascular congestion with small bilateral\npleural effusions, left greater than right. \n\nVitals on transfer: T 97.3, HR 88, BP 120/54, RR 18, SpO2 98% RA \n\n\n', 'Studies notable for:  \n-CXR:  Mild pulmonary vascular congestion with small bilateral\npleural effusions, left greater than right. \n\nVitals on transfer: T 97.3, HR 88, BP 120/54, RR 18, SpO2 98% RA \n\n\n', 'Social History:\n___\nFamily History:\nHis parents have heart disease.  Mother is ___ with heart \nproblems\nand diabetes.  Father, ___, with diabetes.  He has 16 brothers \nand\nsisters.  There is no known ', '# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\n', 'Name:  ___              Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   M\n \nService: MEDICINE\n \nAllergies: \nNo Known Allergies / Adver']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
What is the prescribed dosage of Hydralazine for a patient post-hospital discharge for managing hypertension alongside other conditions?,"['71b11357-64d1-43f3-b5b3-9e2b962adaf4\n\n# Volume overload\n# HFpEF, LVEF 55-60% in ___\nVolume overload on exam. Diuresis began while in ICU, net \nnegative 1.8L prior to transfer. Dry weight appears to be \n154-157. s/p Lasix 80mg x 2 so far. 163.4 lb on ___ A-Strict \nI/Os, daily weights. Continued home carvedilol at increased dose \nas below. He was sent home with PO 60 mg Lasix daily and was net \neven in the hospital. \n# HTN\nBlood pressure medications initially held when he was started on \npropofol. Anti-HTN meds started on day of transfer. Persistently \nhypertensive. Increased carvedilol to 50 mg BID and increased \nminoxidil to 5 mg and continued amlodipine 10 mg QD. Of note, he \nhad been on clonidine and hydralazine but these were stopped by \nPCP just prior to admission. He remained mostly normotensive \nalthough goal SBP <130 and should continue to be goal as an \noutpatient. \n# Normocytic Anemia\nBaseline of ___, secondary to CKD and possible AoCD. Required \n1u pRBC on arrival. Hb stable. \nCHRONIC ISSUES:', 'cd30826d-ad9e-4a08-8b63-15e1e3bbfe0c\n\nYou were admitted to the hospital because:\n================================\n-You had worsening shortness of breath, with increased leg \nswelling and weight gain.\nDuring your stay:\n============\n-You had too much volume onboard so you were given IV diuretic \nmedications,. You improved significantly.\nAfter your discharge:\n================\n-Please continue taking all medications as prescribed (see \nbelow).\n-Please stop taking Lisinopril and metoprolol.\n-Please continue taking insulin according to the regimen you \nwere following before this admission.\n-New medications:\n  - Aspirin 81mg once daily\n  - Carvedilol 25mg twice daily\n  - Furosemide 40mg twice daily\n  - Hydralazine 100mg three times daily\n-Please attend any upcoming outpatient appointments you have \n(see below).\nWe wish you the very best!']","According to the discharge instructions, the patient is prescribed Hydralazine 100mg three times daily, in addition to other medications such as Carvedilol and Furosemide, for managing conditions that include hypertension, indicating a return to this medication after it was stopped by the PCP just prior to the hospital admission.",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

* **Prescribed Dosage of Hydralazine:** Not specified in any of the provided documents (1 through 5). 
* **Reason:** Hydralazine is not mentioned at all in the content of the documents provided for patient **13180007**. The documents list various medications for managing conditions such as heart failure, diabetes, and hypertension, but Hydralazine is not among them. For hypertension, medications like **amLODIPine (10 mg PO DAILY)** and **CARVedilol (50 mg PO BID)** are mentioned.

**Additional Observations Based on Instructions**

1. **IDs and Dates:**
	* **Patient/Subject ID:** Consistently **13180007** across all documents (1 through 5).
	* **Note ID:** Consistently **13180007-DS-19** across all documents (1 through 5).
	* **Admission ID:** Consistently **20774429** across all documents (1 through 5).
	* **Chart Time & Store Time:** Both are **N/A** across all documents (1 through 5).
2. **Reporting Exact ID Values:**
	* As instructed, exact ID values are reported above.
3. **Same ID in Multiple Documents:**
	* **Patient/Subject ID, Note ID, and Admission ID** are the same across all five documents, as noted above.
4. **Prioritizing Metadata over Content for ID Values:**
	* Since the question about Hydralazine dosage doesn't involve ID values but rather medication dosage (which is not present in the metadata for such specific clinical information), the content of the documents was consulted, revealing no mention of Hydralazine.","['Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'DISCHARGE LABS\n==============\n\n___ 06:35AM BLOOD WBC-5.4 RBC-2.92* Hgb-7.6* Hct-24.3* \nMCV-83 MCH-26.0 MCHC-31.3* RDW-15.9* RDWSD-47.8* Plt ___\n___ 06:35AM BLOOD Glucose-164* UreaN-51* Creat-2.9* Na-1', 'WHAT HAPPENED WHILE I WAS IN THE HOSPITAL?  \n You were given medications to help get the fluid out. Your \nsymptoms got better and were ready to leave the hospital.  \n\n WHAT DO YOU NEED TO DO WHEN YOU ', 'TRANSITIONAL ISSUES\n===================\n[ ] At discharge his symptoms associated with volume overload \nhad subsided, but he was still slightly volume up on exam with \n1+ edema to ankles bilaterally an']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What treatment approach was taken for patient with CAD w/ inducible ischemia & NSTEMI, considering kidney function?","['5afc91e0-6481-46b3-aa3c-473b2c2e6895\n\n#Community acquired pneumonia\nCough, worsened SOB, hypoxemia (although alternate explanation) \nbut no leukocytosis or fevers; influenza negative. Legionella \nand strep were negative. Patient was given a 5-day course of \nceftriaxone and azithromycin. \n#Hypertension\nGoal <130/80. As patient is on several anti-hypertensives with \nstill an elevated blood pressure, he underwent a secondary \nhypertension workup. His last renal ultrasound in ___ was \nwithin normal limits. He was placed on continuous O2 monitoring \novernight, and patient did not desaturate. His aldosterone to \nrenin ratio was 0.13, indicating no primary hyperaldosteronism. \n24 hour urine metanephrines and catecholamines were within \nnormal limits.\n#CAD w/ inducible ischemia\n#NSTEMI\nTroponin peaked at 0.02, thought to be type 2 due to volume \noverload. Continued aspirin, atorvastatin, carvedilol. The \ndecision was made to hold off on coronary angiogram due to \nkidney function and the suspicion that this was type 2.\n#H/o CVA\nPatient had an episode while in hospital with dysarthria,', 'd2113a66-fe4f-4869-b3c0-73646862b32b\n\ngluconate (received 3 doses ___. Upon review of recent \noutpatient visit notes, it appears his volume exam is similar to \nbaseline, and patient was asymptomatic during hospital course. \nHe was diuresed effectively with IV Lasix 80. He was \ntransitioned to PO torsemide 100. His BP was well controlled \nwith regimen as described below.\n# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\nat or lower than levels earlier this year. He has denied chest\npain during admission. He does have risk factors for ischemia \nand\nhas not had stress since ___. However, findings and history \nto\ndate are not suggestive of ischemia and he has an ___. TTE did \nnot show evidence of focal wall motion abnormalities or other \nfindings suggestive of ischemia, so further workup was not \npursued. He was continued on ASA and atorvastatin.\n# ___ on CKD:\nCr elevated to 2.6 on admission from baseline of 1.8-2.2. Given\nevidence of congestion elsewhere, concerns for renal congestion\ncausing renal dysfunction. Cr remained stable and was 2.9 on day \nof discharge. He was continued on home sevelamer.']","For the patient with CAD w/ inducible ischemia & NSTEMI, the decision was made to hold off on coronary angiogram due to kidney function concerns and the suspicion that the NSTEMI was type 2 (likely due to volume overload, as troponin peaked at 0.02). The patient was continued on aspirin, atorvastatin, and carvedilol.",custom_multi_hop_query_synthesizer,"Based on the provided instructions and documents, here's the response to the current question:

**Question:** What treatment approach was taken for patient with CAD w/ inducible ischemia & NSTEMI, considering kidney function?

**Response:**

* **Patient/Subject ID:** 13180007 (consistent across all documents: Document 1, Document 2, Document 3, Document 4, Document 5)
* **Relevance to CAD w/ Inducible Ischemia & NSTEMI:**
	+ The documents do not explicitly mention ""CAD with inducible ischemia & NSTEMI"" as the patient's condition. Instead, they discuss:
		- Chest pain with mild troponin elevation, but in the context of Chronic Kidney Disease (CKD), making troponin elevation difficult to interpret (Document 1, Document 2).
		- No evidence of focal wall motion abnormalities or findings suggestive of ischemia on TTE (Transthoracic Echocardiogram), leading to no further ischemia workup (Document 1, Document 2, mentioned in context in Document 3).
		- The primary focus is on managing Acute on Chronic Heart Failure with preserved Ejection Fraction (HFpEF), CKD, anemia, hypertension, hypothyroidism, and poorly controlled IDDM.
* **Treatment Approach Considering Kidney Function:**
	+ For **CKD and potential renal congestion causing renal dysfunction:**
		- Continued on home sevelamer (Document 1, Document 2).
		- Monitoring of Cr (Creatinine) levels, which remained stable but elevated (2.9 on discharge, baseline 1.8-2.2) (Document 1, Document 2, Document 4).
	+ For **Anemia in the context of CKD and possibly heart failure:**
		- Received ferric gluconate 250 mg IV (with a consideration for completing the 4-day course post-discharge) (Document 3, Document 4, Document 5).
	+ **No specific treatment for CAD with inducible ischemia & NSTEMI is mentioned** because the documents do not confirm this as the patient's diagnosis. Instead, they focus on managing other conditions while noting the absence of clear evidence for ischemia.

**Metadata Values Relevant to the Question:**

* **Patient/Subject ID:** 13180007 (consistent across all documents)
* **Note ID:** 13180007-DS-19 (consistent across all documents)
* **Admission ID:** 20774429 (consistent across all documents)
* **Chart Time & Store Time:** N/A (consistent across all documents)","['# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\n', '# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\n', 'ACUTE PROBLEMS\n==============\n# Acute on chronic HFpEF: \nPatient presented with dyspnea and lower extremity edema and\nfound to be volume overloaded on exam. Warm and wet on exam.\nTrigger for HF exacer', 'TRANSITIONAL ISSUES\n===================\n[ ] At discharge his symptoms associated with volume overload \nhad subsided, but he was still slightly volume up on exam with \n1+ edema to ankles bilaterally an', '# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What are the key findigns from the CT scans (head, abd/pelvis, C spine) for a patient with edema, and how do these relait to possibl aspiration or pneumonia, based on the providd medikal imagig reports?","['a0523bf3-a15e-4abc-bd78-1c98b6c5dc7e\n\nedema.  No\nevidence of displaced fracture.\nCT head ___:\nThere is no evidence of infarction, hemorrhage, edema,or midline \nshift.  There\nis prominence of the ventricles and sulci suggestive of \ninvolutional changes.\n \nThere is no evidence of fracture.  Opacification of the mastoid \nair cells. \nThe visualized portion of the paranasal sinuses, mastoid air \ncells, and middle\near cavities are clear.  The visualized portion of the orbits \nare\nunremarkable.\nCT abd/pelvis ___:\n1. Bilateral lower lobe opacities, concerning for aspiration or \npneumonia.\n2. No acute finding in the abdomen or pelvis.\nCT C spine ___:\nNG tube and endotracheal tube are noted.  Alignment is normal. \nNo fractures\nare identified. There is no evidence of high-grade spinal canal', 'dd2587c0-7ebc-4cd2-878e-f8cd5d8d0c1b\n\nBMP - Na 135, K 5, Cr 2.0 (baseline ___, HCO3 20, BG 625, AG 16\nCa 8, phos 6.6\nUA - neg leuk, neg nitr, 7 WBC, neg ketone, 1000 glucose\nUrine tox negative\nTSH pending\nBCx, UCx\nTrop 0.03 -> 0.06\nEKG with T-wave inversion in lateral leads, unchanged from prior\nImaging:  \n- CT head w/o contrast:\n1. No evidence of intracranial bleed. No evidence of acute\nintracranial abnormality.\n2. Opacification of the mastoid air cells.\n- CT C-spine w/o contrast\nNo evidence of acute fracture or malalignment\n- CT A/P w/o contrast\n1. No evidence of acute abdominal or pelvic abnormality. \n2. Extensive bibasilar atelectasis. \n3. Small left pleural effusion. \n- CXR\nSmall left pleural effusion. Opacities likely represent\natelectasis however pneumonia cannot be excluded in the correct\nclinical setting. \nConsults: none']","Based on the provided medical imaging reports, here are the key findings from the CT scans and their relation to possible aspiration or pneumonia:       1. **CT Head**: No evidence of infarction, hemorrhage, edema, or midline shift. Prominence of ventricles and sulci suggests involutional changes. No fracture, but opacification of mastoid air cells is noted.       2. **CT Abd/Pelvis**: **Key Finding Relevant to Aspiration/Pneumonia**: Bilateral lower lobe opacities, concerning for **aspiration or pneumonia**. No acute findings in the abdomen or pelvis.       3. **CT C Spine**: Normal alignment, no fractures, and no evidence of high-grade spinal canal stenosis. NG and endotracheal tubes are noted, which might relate to the patient's condition leading to or resulting from aspiration or pneumonia, but the CT C Spine itself does not directly indicate aspiration or pneumonia.       **Relation to Aspiration/Pneumonia**: The primary indicator from the CT scans for aspiration or pneumonia comes from the **CT Abd/Pelvis**, highlighting bilateral lower lobe opacities. This finding, coupled with the clinical context (e.g., edema, the presence of endotracheal tubes suggesting respiratory support), supports the concern for aspiration or pneumonia. The **CXR** from the second report further supports this with small left pleural effusion and opacities likely representing atelectasis, though it also cannot exclude pneumonia without the correct clinical setting.",custom_multi_hop_query_synthesizer,"Based on the provided instructions and documents, here is the response to the current question:

**Answer:**

* **Key Findings from CT Scans (Head, Abd/Pelvis, C Spine):** 
	+ **None Reported**: The provided documents (1 through 5) do not mention CT scans for the head, abdomen/pelvis, or C spine. The imaging studies mentioned are:
		- **CXR (Chest X-Ray)** in Document 1 and implied in Document 5 (though not explicitly listed as CXR in Doc 5, it discusses findings related to heart structure and function, and a small pericardial effusion, which aligns with chest imaging).
		- **TTE (Transthoracic Echocardiogram)** in Document 4, discussing heart valve and chamber findings.
* **Relation to Possible Aspiration or Pneumonia:**
	+ **Limited Relevance**: Given the absence of CT scan reports for the specified areas (head, abd/pelvis, C spine) and the focus of the provided imaging reports (CXR and TTE), there's limited direct relevance to assessing aspiration or pneumonia from the documents. However:
		- **CXR Findings** in Document 1 (Mild pulmonary vascular congestion with small bilateral pleural effusions) could be indirectly related to pneumonia or fluid overload but are more suggestive of congestive heart failure or fluid overload issues, as discussed in the context of the patient's overall condition.

**Metadata Observations (as per instruction 3):**

* The **Patient/Subject ID**, **Note ID**, and **Admission ID** are identical across all five documents:
	+ **Patient/Subject ID:** 13180007
	+ **Note ID:** 13180007-DS-19
	+ **Admission ID:** 20774429
* **Chart Time** and **Store Time** are listed as **N/A** in all documents.","['In the ED:  \nInitial VS: T 98.5, HR 102, BP 178/76, RR 22, SpO2 98% RA \n \nExam:\nGeneral- NAD\nHEENT- PERRL, EOMI, normal oropharynx\nLungs- Non-labored breathing, CTAB\nCV- RRR, systolic murmur, normal S', 'In the ED:  \nInitial VS: T 98.5, HR 102, BP 178/76, RR 22, SpO2 98% RA \n \nExam:\nGeneral- NAD\nHEENT- PERRL, EOMI, normal oropharynx\nLungs- Non-labored breathing, CTAB\nCV- RRR, systolic murmur, normal S', 'DISCHARGE PHYSICAL EXAM\n=======================\nGENERAL: NAD. Mood, affect appropriate.  \nHEENT: Normocephalic atraumatic. Sclera anicteric. EOMI.\nConjunctiva were pink. No pallor or cyanosis of the o', '# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\n', 'leaflets (3) are mildly thickened. There is no\naortic valve stenosis. There is no aortic regurgitation. The \nmitral valve leaflets are mildly thickened with\nno mitral valve prolapse. There is trivial ']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What is the current treatment plan for a patient with Hypothyroidism, and how does it relate to their other chronic conditions like Hypertension and IDDM, considering their recent discharge diagnosis and condition?","['08e7114b-32bf-470b-a3c6-d919c6de4e69\n\n# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n# Acute on chronic anemia:\nHb on admission was 7.4. No evidence of bleeding per history or \nexam. Possibly related to worsening of his renal function vs \ndilutional iso heart failure. His Hb was 7.6 on discharge. He \nreceived 3 doses of ferric gluconate 250 mg IV on ___.\n#IDDM\nPoorly controlled. A1c 14.4 in ___ in ___ at ___. \nRepeat A1C ___ was 11.4%. He was given Lantus 30u night of \nadmission, then transitioned to home insulin ___ with 70/30 \n30u with breakfast and 20u with lunch. He was also on ISS while \ninpatient.\nCHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.', '8ffe5463-ba8e-4c92-be15-e075478499d9\n\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nPRIMARY:\n=======================================\nHyperglycemic hyperosmolar syndrome \nType 2 diabetes mellitus\nSECONDARY: \n=======================================\nCoronary artery disease\nChronic kidney disease\nHypertension\nHeart failure preserved ejection fraction\nNormocytic Anemia\nHypothyroidism\n \nDischarge Condition:\nMental Status: Clear and coherent.\nLevel of Consciousness: Alert and interactive.\nActivity Status: Ambulatory - Independent.']","According to the patient's records, for Hypothyroidism, the patient is continued on home levothyroxine 100mcg daily. This treatment plan is managed alongside other chronic conditions. For Hypertension, the patient is on home amlodipine 10, Coreg 50 BID, and minoxidil 10 daily, with the condition currently well controlled. For IDDM (Poorly controlled with an A1c of 14.4, later improved to 11.4%), the patient was transitioned from Lantus 30u at night of admission to home insulin with 70/30 30u with breakfast and 20u with lunch, also utilizing ISS while inpatient. At discharge, the patient's mental status was clear and coherent, alert, interactive, and ambulatory-independent, with Hypothyroidism listed among the secondary discharge diagnoses, indicating its ongoing management as part of the patient's overall care plan.",custom_multi_hop_query_synthesizer,"**Answer:**

**Patient Identifier:**
* **Patient/Subject ID:** 13180007 (consistent across all documents: Document 1, Document 2, Document 3, Document 4, and Document 5)
* **Note ID:** 13180007-DS-19 (consistent across all documents)
* **Admission ID:** 20774429 (consistent across all documents)

**Current Treatment Plan for Hypothyroidism and Relation to Other Conditions:**

1. **Hypothyroidism Treatment:**
	* **Medication:** Levothyroxine Sodium 100 mcg PO DAILY (Document 1, Document 2, Document 3, and Document 4)
	* **Note:** The treatment for hypothyroidism remains consistent across all documents, indicating no changes to this regimen upon discharge.

2. **Relation to Hypertension:**
	* **Hypertension Status:** History of hypertension, currently well controlled (Document 3)
	* **Hypertension Medications:**
		+ Amlodipine 10 mg PO DAILY (Documents 1, 2, and 4)
		+ Carvedilol 50 mg PO BID (Documents 1, 2, and 4)
		+ Minoxidil 10 mg PO DAILY (Documents 1, 2, and 4)
	* **Relation to Hypothyroidism Treatment:** There is no direct interaction mentioned between the hypothyroidism treatment (Levothyroxine) and the hypertension medications. The patient's hypertension is noted as well controlled, suggesting the current regimen (including the unchanged hypothyroidism treatment) is effective for managing both conditions.

3. **Relation to IDDM (Insulin-Dependent Diabetes Mellitus):**
	* **IDDM Status:** Poorly controlled with an A1c of 14.4 (later improved to 11.4%) (Document 3)
	* **IDDM Medications upon Discharge:**
		+ 70/30 Insulin 30 Units with Breakfast, 10 Units with Lunch (Documents 3 and 4)
	* **Relation to Hypothyroidism Treatment:** There's no direct interaction mentioned between the IDDM treatment and Levothyroxine. However, it's clinically relevant to monitor the patient's thyroid status, as changes in thyroid function can impact glucose metabolism and thus the management of diabetes. No changes to the hypothyroidism treatment were noted, suggesting it is not currently impacting the IDDM management.

**Recent Discharge Diagnosis and Condition:**
* **Primary Diagnosis:** Acute on chronic diastolic heart failure exacerbation
* **Secondary Diagnoses:** Acute kidney injury, Acute on chronic anemia, Type 2 Diabetes Mellitus
* **Relevance to Hypothyroidism Treatment:** The discharge diagnoses do not directly impact the treatment plan for hypothyroidism as per the provided documents. However, the patient's overall health status, including the recent exacerbation of heart failure and presence of acute kidney injury, necessitates careful monitoring of all medications, including Levothyroxine, for potential interactions or the need for dosage adjustments, though none are mentioned in the provided documents.

**Additional Recommendations Based on Provided Documents:**
* Follow-up labs for monitoring kidney function (eGFR with Creatinine levels) and possibly adjusting medications as necessary.
* Consideration for completing the course of ferric gluconate for anemia treatment.
* Monitoring of the patient's volume status and edema, managed with torsemide upon discharge.","['CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', 'CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', '# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o', 'Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'TRANSITIONAL ISSUES\n===================\n[ ] At discharge his symptoms associated with volume overload \nhad subsided, but he was still slightly volume up on exam with \n1+ edema to ankles bilaterally an']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What specific adjustments were made to the patient's medication regimen during the recent hospitalization to manage poorly-controlled Type 2 Diabetes Mellitus (T2DM) with Hyperosmolar Hyperglycemic State (HHS), and what follow-up actions are recommended for the Clinical Care Coordinator to ensure the patient's continued care?","['386e4975-89d1-411a-99a3-9d225138df6c\n\n[] Ensure that patient was able to adhere to a diabetic diet\nPCP:\n[] Had elevated SBP in 130s-150s. Increased minoxidil to 5mg and \ncarvedilol to 50 mg BID. Please follow-up on blood pressures. \n[] Follow up on diuretics and volume status. Please get \nfollow-up labs BUN/Cr at follow-up appointment.\nNew meds: 70-30 novolog (30 units in AM, 20 units at dinner)\nStopped meds: none\nChanged meds: Carvedilol 50 mg twice a day, increased minoxidil \n5 mg daily \nACUTE ISSUES: \n=============== \n# HHS\n# T2DM\nPatient has history of poorly-controlled DM w/ A1c ~14. Based on \nlabs, determined to be in HHS likely precipitated by med \nnon-adherence or difficulty understanding multi-step process. No \nclear infection was identified. Of note, he tends to have high \ninsulin requirements. Pt was continued on insulin basal/bolus \nwhile inpatient. There was significant efforts to have him bring \nin home Victoza but he only had a half dose so he was continued \non basal/bolus course and made a plan for close outpatient \nfollow up and home 2 injections (Victoza and pre-mixed insulin).']","During the hospitalization, adjustments to the patient's medication regimen included increasing carvedilol to 50 mg twice a day and minoxidil to 5 mg daily. The patient was also continued on insulin basal/bolus. For discharge, a plan was made for close outpatient follow-up with the patient administering two injections at home: Victoza and pre-mixed insulin (70-30 novolog, with 30 units in the AM and 20 units at dinner). As the Clinical Care Coordinator, recommended follow-up actions include: (1) ensuring the patient adheres to the diabetic diet, (2) following up on blood pressures given the recent medication changes, (3) monitoring diuretics and volume status, and (4) obtaining follow-up labs (BUN/Cr) at the next appointment to assess the effectiveness of the current regimen and make any necessary adjustments.",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

**Specific Adjustments to Medication Regimen for T2DM during Hospitalization:**

Based on the provided documents, the specific adjustments made to the patient's medication regimen to manage poorly-controlled Type 2 Diabetes Mellitus (T2DM) during the recent hospitalization are:

1. **Initial Adjustment:** Administration of **Lantus 30u** on the night of admission (Document 1).
2. **Transition to Home Insulin Regimen:** Transitioned from inpatient insulin (details not specified in the transition process, but mentioned as being on ""ISS"" while inpatient) to a **home insulin regimen** with:
	* **70/30 Insulin:** 30 units with breakfast and 20 units with lunch (Document 1 and reiterated in Discharge Medications, Document 4).
3. **Additional Medication for T2DM Management (not an adjustment but a continuation):** 
	* **Victoza (Liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) subcutaneous DAILY** (listed in Discharge Medications, Document 4, indicating continuation of this medication).

**Note on Hyperosmolar Hyperglycemic State (HHS):** There is no explicit mention of HHS in the provided documents. The management adjustments mentioned above are based on the patient's poorly controlled T2DM.

**Follow-up Actions for the Clinical Care Coordinator:**

To ensure the patient's continued care for poorly-controlled T2DM:

1. **Verify Medication Adherence:**
	* Schedule a follow-up call/appointment to confirm the patient is taking the prescribed medications (Lantus, 70/30 Insulin, Victoza, and other discharge medications) as directed.
2. **Blood Glucose Monitoring:**
	* Ensure the patient has a glucometer and is monitoring blood glucose levels regularly.
	* Discuss the importance of logging readings to track control and adjust medications as needed.
3. **A1C Recheck:**
	* Schedule an appointment for an A1C check within the next 3 months to assess the effectiveness of the current regimen.
4. **Dietary and Lifestyle Counseling:**
	* Arrange for the patient to receive dietary counseling focused on T2DM management.
	* Encourage regular physical activity, as feasible, given the patient's other conditions (e.g., HFpEF, CKD).
5. **Multidisciplinary Care Team Coordination:**
	* Inform and coordinate with the patients primary care physician, endocrinologist (if applicable), and other relevant healthcare providers about the hospitalization, medication adjustments, and follow-up plan.
6. **Patient Education:**
	* Provide the patient with educational resources on T2DM management, recognizing the signs of hyperglycemia and hypoglycemia, and when to seek emergency care.

**Metadata Consistency Note:**
- **Patient/Subject ID:** Consistently listed as **13180007** across all documents.
- **Note ID and Admission ID:** Also consistent across all documents (**13180007-DS-19** and **20774429**, respectively), indicating these documents pertain to the same hospital admission.","['# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o', '# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o', 'ACUTE PROBLEMS\n==============\n# Acute on chronic HFpEF: \nPatient presented with dyspnea and lower extremity edema and\nfound to be volume overloaded on exam. Warm and wet on exam.\nTrigger for HF exacer', 'Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'DISCHARGE LABS\n==============\n\n___ 06:35AM BLOOD WBC-5.4 RBC-2.92* Hgb-7.6* Hct-24.3* \nMCV-83 MCH-26.0 MCHC-31.3* RDW-15.9* RDWSD-47.8* Plt ___\n___ 06:35AM BLOOD Glucose-164* UreaN-51* Creat-2.9* Na-1']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What is the ussage of Minoxidil in a patient with Hypertension (HTN) and other comorbidities, and what dose ajustments were made?","['08e7114b-32bf-470b-a3c6-d919c6de4e69\n\n# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n# Acute on chronic anemia:\nHb on admission was 7.4. No evidence of bleeding per history or \nexam. Possibly related to worsening of his renal function vs \ndilutional iso heart failure. His Hb was 7.6 on discharge. He \nreceived 3 doses of ferric gluconate 250 mg IV on ___.\n#IDDM\nPoorly controlled. A1c 14.4 in ___ in ___ at ___. \nRepeat A1C ___ was 11.4%. He was given Lantus 30u night of \nadmission, then transitioned to home insulin ___ with 70/30 \n30u with breakfast and 20u with lunch. He was also on ISS while \ninpatient.\nCHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.', '71b11357-64d1-43f3-b5b3-9e2b962adaf4\n\n# Volume overload\n# HFpEF, LVEF 55-60% in ___\nVolume overload on exam. Diuresis began while in ICU, net \nnegative 1.8L prior to transfer. Dry weight appears to be \n154-157. s/p Lasix 80mg x 2 so far. 163.4 lb on ___ A-Strict \nI/Os, daily weights. Continued home carvedilol at increased dose \nas below. He was sent home with PO 60 mg Lasix daily and was net \neven in the hospital. \n# HTN\nBlood pressure medications initially held when he was started on \npropofol. Anti-HTN meds started on day of transfer. Persistently \nhypertensive. Increased carvedilol to 50 mg BID and increased \nminoxidil to 5 mg and continued amlodipine 10 mg QD. Of note, he \nhad been on clonidine and hydralazine but these were stopped by \nPCP just prior to admission. He remained mostly normotensive \nalthough goal SBP <130 and should continue to be goal as an \noutpatient. \n# Normocytic Anemia\nBaseline of ___, secondary to CKD and possible AoCD. Required \n1u pRBC on arrival. Hb stable. \nCHRONIC ISSUES:']","Minoxidil was prescribed for a patient with a history of hypertension, among other conditions (Acute on chronic anemia, IDDM, Hypothyroidism, History of CVA, and later mentioned Volume overload, HFpEF, and Normocytic Anemia). Initially, the patient was on minoxidil 10mg daily. However, during the hospital stay, due to persistently hypertensive readings, the dose of minoxidil was adjusted to 5mg, alongside increases in carvedilol to 50mg BID and continuation of amlodipine 10mg QD, aiming for a goal SBP <130 as an outpatient.",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

**Patient Context:**
* **Patient/Subject ID:** 13180007 (consistent across all documents)
* **Relevant Conditions:** Hypertension (HTN), Acute on chronic anemia, IDDM (Insulin-Dependent Diabetes Mellitus), Hypothyroidism, and others as listed in the documents.

**Usage of Minoxidil in a patient with Hypertension (HTN) and other comorbidities:**

* **Indication for Minoxidil:** While the primary indication for Minoxidil is often for alopecia (hair loss) when used topically, in the context of hypertension and the provided medical documents, Minoxidil is being used orally for its potent antihypertensive effects. Oral Minoxidil is typically reserved for severe, symptomatic hypertension that is not manageable with maximal therapeutic doses of a diuretic plus two other antihypertensive drugs.
* **Dosage:** The dosage of Minoxidil mentioned in the documents is **10 mg PO DAILY**. This dosage is consistent across the documents where Minoxidil is mentioned (Documents 1, 3, and 5).

**Dose Adjustments:**
* **Observed in Documents:** There is **no mention of dose adjustments** for Minoxidil in any of the provided documents. The patient was continued on home Minoxidil 10 mg daily, indicating no change in dosage during the hospital stay as per the documents.

**Additional Observations:**

* **Consistency Across Documents:** The patient's ID (13180007), Note ID (13180007-DS-19), and Admission ID (20774429) are consistent across all documents, suggesting these documents pertain to the same hospital admission.
* **Medication Consistency:** The inclusion of Minoxidil in both the admission medications (Document 3) and discharge medications (Document 5) at the same dosage (10 mg PO DAILY) highlights the ongoing need for this medication in managing the patient's hypertension.","['# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o', '# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o', 'CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', 'ACUTE PROBLEMS\n==============\n# Acute on chronic HFpEF: \nPatient presented with dyspnea and lower extremity edema and\nfound to be volume overloaded on exam. Warm and wet on exam.\nTrigger for HF exacer', 'Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What is the prescribed dosage and administration schedule for Polyethylene Glycol in the provided patient discharge information, and what is the indicated use for this medication?","['784a4f17-941d-40ee-a5aa-7471e6a5f600\n\n70/30 10 Units Lunch \n3.  Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath  \n4.  amLODIPine 10 mg PO DAILY  \n5.  Aspirin 81 mg PO DAILY  \n6.  Atorvastatin 80 mg PO QPM  \n7.  CARVedilol 50 mg PO BID  \n8.  Levothyroxine Sodium 100 mcg PO DAILY  \n9.  Minoxidil 10 mg PO DAILY  \n10.  Polyethylene Glycol 17 g PO DAILY:PRN Constipation - First \nLine  \n11.  sevelamer CARBONATE 800 mg PO TID W/MEALS  \n12.  Victoza 2-Pak (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) \nsubcutaneous DAILY  \n13.  Vitamin D 1000 UNIT PO DAILY  \n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nPrimary Diagnosis:\n-Acute on chronic diastolic heart failure exacerbation\nSecondary Diagnosis:', '8c579626-76a5-4cd0-9f53-1feadb6904be\n\nMedications on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath \n2. amLODIPine 10 mg PO DAILY \n3. Atorvastatin 80 mg PO QPM \n4. CARVedilol 50 mg PO BID \n5. Furosemide 80 mg PO DAILY \n6. 70/30 30 Units Breakfast\n70/30 10 Units Lunch\n7. Levothyroxine Sodium 100 mcg PO DAILY \n8. Victoza 2-Pak (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) \nsubcutaneous DAILY \n9. Minoxidil 10 mg PO DAILY \n10. Polyethylene Glycol 17 g PO DAILY:PRN Constipation - First \nLine \n11. sevelamer CARBONATE 800 mg PO TID W/MEALS \n12. Aspirin 81 mg PO DAILY \n13. Vitamin D 1000 UNIT PO DAILY \n \nDischarge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast']","According to the discharge medications list (not explicitly mentioned but inferred from the context of medications) and the medications on admission list, Polyethylene Glycol is prescribed as follows: **Dosage:** 17 g **Administration Schedule:** PO (orally) DAILY:PRN (as needed) **Indicated Use:** Constipation - First Line treatment.",custom_multi_hop_query_synthesizer,"Based on the provided documents, here is the answer to the question:

**Question:** What is the prescribed dosage and administration schedule for Polyethylene Glycol in the provided patient discharge information, and what is the indicated use for this medication?

**Answer:**

* **Prescribed Dosage:** 17 g
* **Administration Schedule:** PO (orally) DAILY, **PRN (as needed)**
* **Indicated Use:** **Constipation - First Line**

**Source Document(s):** 
This information is consistently found in:
* **Document 1:** CONTENT > Discharge Medications > 10. Polyethylene Glycol...
* **Document 2:** CONTENT > Discharge Medications > 10. Polyethylene Glycol... (Note: Document 2 is identical to Document 1 in the relevant section)

**Metadata Relevance for Context:**
* **Patient/Subject ID:** 13180007 (consistent across all documents, including the ones relevant to this question)
* **Note ID:** 13180007-DS-19 (consistent across all documents, indicating these are all part of the same discharge summary) 
* **Admission ID:** 20774429 (consistent across all documents, linking to the same hospital admission)","['Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'TRANSITIONAL ISSUES\n===================\n[ ] At discharge his symptoms associated with volume overload \nhad subsided, but he was still slightly volume up on exam with \n1+ edema to ankles bilaterally an', 'DISCHARGE LABS\n==============\n\n___ 06:35AM BLOOD WBC-5.4 RBC-2.92* Hgb-7.6* Hct-24.3* \nMCV-83 MCH-26.0 MCHC-31.3* RDW-15.9* RDWSD-47.8* Plt ___\n___ 06:35AM BLOOD Glucose-164* UreaN-51* Creat-2.9* Na-1', 'Name:  ___              Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   M\n \nService: MEDICINE\n \nAllergies: \nNo Known Allergies / Adver']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What is the role of Aspirin in the medication regimen of patients with chronic conditions, as observed in the provided medical records, and what are the associated health conditions?","['499f5ec0-b3d8-4161-93fa-07c1b6a6de75\n\ncolonoscopy report in our system previously. Iron studies from \n___ with low normal ferritin (53), low iron, low normal \nTIBC - possibly consistent with anemia of chronic disease or \ninflammation, however hard to rule out concomitant iron \ndeficiency.\n# Hypothyroidism: TSH wnl. Continued home levothyroxine.\n# Asthma: Albuterol inhaler prn continued.\nTRANSITIONAL ISSUES:\n- consideration of outpatient colonoscopy referral if not up to \ndate with screening, particularly iso chronic anemia\n- re-check BP at next PCP appointment, decision on further med \ntitration as above (?increase BB, resuming another home agent\n- ?resume Veltassa if K elevated\n- PCP: consider referral to ___ clinic\n \nMedications on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Aspirin 81 mg PO DAILY \n2. Atorvastatin 80 mg PO QPM \n3. CloNIDine 0.4 mg PO BID \n4. HydrALAZINE 100 mg PO TID \n5. Levothyroxine Sodium 100 mcg PO DAILY', '784a4f17-941d-40ee-a5aa-7471e6a5f600\n\n70/30 10 Units Lunch \n3.  Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath  \n4.  amLODIPine 10 mg PO DAILY  \n5.  Aspirin 81 mg PO DAILY  \n6.  Atorvastatin 80 mg PO QPM  \n7.  CARVedilol 50 mg PO BID  \n8.  Levothyroxine Sodium 100 mcg PO DAILY  \n9.  Minoxidil 10 mg PO DAILY  \n10.  Polyethylene Glycol 17 g PO DAILY:PRN Constipation - First \nLine  \n11.  sevelamer CARBONATE 800 mg PO TID W/MEALS  \n12.  Victoza 2-Pak (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) \nsubcutaneous DAILY  \n13.  Vitamin D 1000 UNIT PO DAILY  \n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nPrimary Diagnosis:\n-Acute on chronic diastolic heart failure exacerbation\nSecondary Diagnosis:']","Based on the provided medical context, Aspirin (81 mg PO DAILY) is consistently present in the medication lists. Associated health conditions and considerations include:  - **Chronic Anemia**: Aspirin is mentioned alongside considerations for outpatient colonoscopy referral for screening, particularly in the context of chronic anemia. - **Cardiovascular Health**: The presence of Aspirin, alongside medications like Atorvastatin (for cholesterol), CARVedilol and HydrALAZINE (for blood pressure), and amLODIPine (for hypertension), suggests its role in managing cardiovascular risk. - **Diastolic Heart Failure Exacerbation**: Aspirin is part of the discharge medication list for a patient with a primary diagnosis of acute on chronic diastolic heart failure exacerbation, indicating its continued use in heart failure management. - **General Health Maintenance**: Aspirin's antiplatelet properties are beneficial for overall cardiovascular health, which is a common theme across the observed medical conditions.",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

**Role of Aspirin in the Medication Regimen:**
Based on the provided medical records, Aspirin (specifically, Aspirin 81 mg PO DAILY) appears to be prescribed for its antiplatelet properties, likely for the prevention of further cardiovascular events.

**Associated Health Conditions:**
The associated health conditions, as observed in the medical records, are:

1. **History of CVA (Cerebrovascular Accident)**: Document 1, Document 2, and implied in Document 5 under ""Cerebrovascular disease, status post CVA"".
2. **Hypertension**: Mentioned in all documents, either as a chronic problem or within the patient's past medical history.
3. **Dyslipidemia**: Listed in Document 5 under Past Medical History, and managed with Atorvastatin in all documents.
4. **Acute on Chronic Diastolic Heart Failure Exacerbation**: Primary Discharge Diagnosis in Document 3, suggesting Aspirin's role in managing cardiovascular health.
5. **Carotid Artery Disease** and **Extensive Intracranial Atherosclerosis**: Mentioned in Document 5 under Past Medical History, further indicating Aspirin's use for antiplatelet therapy to prevent stroke or further vascular events.

**Metadata Observations (as per instruction 3):**
- The **Patient/Subject ID (13180007)**, **Note ID (13180007-DS-19)**, and **Admission ID (20774429)** are consistent across all five documents, indicating they pertain to the same patient's single admission and care process. 
- **Chart Time** and **Store Time** are listed as **N/A** in all documents.","['CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', 'CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', 'Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', '# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o', 'Studies notable for:  \n-CXR:  Mild pulmonary vascular congestion with small bilateral\npleural effusions, left greater than right. \n\nVitals on transfer: T 97.3, HR 88, BP 120/54, RR 18, SpO2 98% RA \n\n\n']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What are the trends and implications of CK-MB levels in the provided patient data, considering the fluctuations observed across different time points, and how do these levels correlate with other diagnostic findings such as cardiac silhouette size and pulmonary vascular congestion?","[""2b2ce4e1-1e51-4483-8a53-32a58ee918d2\n\nleft pleural effusion. Borderline size of the cardiac silhouette\nwithout pulmonary edema. No pneumonia, no pneumothorax.  The\nlateral radiograph shows mild flattening of the hemidiaphragms,\npotentially as a consequence of functional obstruction.\nHead CT: 1. No evidence of acute intracranial abnormality.\n2. Unchanged appearance of chronic infarcts within the right\nfrontal lobe and left occipital lobe.\n3. Chronic lacunar infarcts within the right basal ganglia.\n4. Redemonstration of few calcifications within the pons,\nfindings which are unchanged in appearance and likely sequela of\nprior ischemic or inflammatory process.\n___ 11:00AM BLOOD cTropnT-0.04*\n___ 09:00PM BLOOD cTropnT-0.02*\n___ 11:00AM BLOOD %HbA1c-14.4* eAG-367*\n___ 11:00AM BLOOD Lipase-73*\n___ 11:00AM BLOOD CK-MB-4 proBNP-754*\nIMAGING:\n___ CXR -\nComparison to ___.  On today's radiograph, a small \npleural\nleft-sided calcification is seen.  There also is a small left \npleural\neffusion.  Borderline size of the cardiac silhouette without"", 'db1f4cbf-c584-4ec8-b5c0-1cf04afe2fb4\n\n___ 07:44AM BLOOD CK-MB-7 cTropnT-0.03*\n___ 05:00PM BLOOD CK-MB-7 cTropnT-0.03*\n___ 07:00AM BLOOD CK-MB-6 cTropnT-0.02*\nTFTs:\n___ 09:10AM BLOOD TSH-9.6*\n___ 07:44AM BLOOD T4-6.5 T3-118 Free T4-1.0\nIMAGING:\n========\nCXR (___):\nFINDINGS:  \nThe lung volumes are low-normal.  There is no focal \nconsolidation.  There is mild prominence of the bilateral \npulmonary vessels suggestive of volume \noverload.  The heart is top-normal in size.  There is no large \neffusion or a pneumothorax.  There is no acute osseous \nabnormality, chronic left rib \nfractures are noted. \n  \nIMPRESSION:  \nStable top-normal heart size with mild pulmonary vascular \ncongestion. \nTTE (___):\nThe left atrial volume index is normal. There is no evidence for']","Based on the provided context, here are the observations and implications of CK-MB levels in relation to other diagnostic findings:           **CK-MB Levels Over Time:**      - **11:00 AM (initial context node):** CK-MB = 4, indicating a relatively low level of cardiac muscle damage.      - **07:44 AM, 05:00 PM, and 07:00 AM (subsequent context node):** CK-MB levels were consistently higher, at 7 (07:44 AM and 05:00 PM) and slightly lower at 6 (07:00 AM), suggesting an increase in cardiac muscle damage or stress over the initial measurement.           **Correlation with Cardiac Silhouette Size:**      - **Initial Context Node:** Describes a 'borderline size of the cardiac silhouette without pulmonary edema,' which, coupled with a CK-MB of 4, might suggest minimal to no acute cardiac injury at the time of the initial assessment.      - **Subsequent Context Node:** Mentions a 'top-normal heart size' with 'mild pulmonary vascular congestion.' The increased CK-MB levels (6 and 7) here could imply worsening cardiac function or additional cardiac stress, though the heart size is described as only top-normal.           **Implications and Considerations:**      - The fluctuations in CK-MB levels, particularly the increase observed in the subsequent measurements, warrant close monitoring of cardiac function.      - The correlation between CK-MB levels and cardiac silhouette size/pulmonary vascular congestion suggests that as CK-MB increases, there is a noticeable, though mild, impact on cardiac function and pulmonary vascular status.      - Further diagnostic workup, including but not limited to serial CK-MB measurements, detailed cardiac imaging (e.g., more frequent TTE), and clinical assessment, is crucial for accurately determining the prognosis and guiding management.",custom_multi_hop_query_synthesizer,"**CK-MB Trends and Implications Analysis**

**Patient Identification:**
* **Patient/Subject ID:** 13180007 (consistent across all documents)
* **Note ID:** 13180007-DS-19 (consistent across all documents)
* **Admission ID:** 20774429 (consistent across all documents)

**CK-MB Levels Analysis:**

| **Time Point** | **CK-MB Level** | **Source Document** |
| --- | --- | --- |
| 09:01 AM | 4 | Document 5 |
| 07:35 PM | 4 | Document 5 |
| (No specific time mentioned, but in context of admission) | Flat CK-MB | Documents 1 & 2 |

**Observations and Trends:**

1. **Stable CK-MB Levels:** The CK-MB levels remain constant at 4 across two time points (09:01 AM and 07:35 PM) in Document 5. This stability suggests that there is no significant acute cardiac muscle damage progression during the observed period.
2. **Comparison with Troponin (cTropnT) Levels:**
	* The cTropnT levels are consistently elevated at 0.03* across multiple time points in Document 5, indicating some level of cardiac stress or damage.
	* The combination of elevated troponin with stable, low CK-MB levels might suggest a condition where troponin elevation is not solely due to acute myocardial infarction (e.g., chronic cardiac disease, renal dysfunction affecting troponin clearance).
3. **Correlation with Other Diagnostic Findings:**
	* **Cardiac Silhouette Size:** Not explicitly mentioned in the provided documents, making direct correlation with CK-MB levels impossible.
	* **Pulmonary Vascular Congestion:** Noted in Documents 3 and 4 with ""Mild pulmonary vascular congestion with small bilateral pleural effusions"" on CXR. This finding, in conjunction with stable CK-MB and elevated troponin, might indicate cardiac dysfunction leading to congestive symptoms rather than an acute coronary event.

**Implications:**

1. **Cardiac Condition:** The patient's cardiac issue appears more chronic or functional rather than an acute myocardial infarction, given the stable CK-MB levels and the clinical context.
2. **Further Investigation:** Needed to clarify the cause of troponin elevation in the context of chronic kidney disease (CKD) and its implications for cardiac health.
3. **Management:** Focus might be on managing congestive symptoms (e.g., with diuretics like IV Lasix, as mentioned) and addressing the underlying cardiac and renal conditions.

**Limitations of Analysis:**
- Lack of direct information on cardiac silhouette size.
- Limited time points for CK-MB analysis.
- Dependence on the interpretation of troponin elevation in the context of CKD.","['# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\n', '# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\n', 'In the ED:  \nInitial VS: T 98.5, HR 102, BP 178/76, RR 22, SpO2 98% RA \n \nExam:\nGeneral- NAD\nHEENT- PERRL, EOMI, normal oropharynx\nLungs- Non-labored breathing, CTAB\nCV- RRR, systolic murmur, normal S', 'Studies notable for:  \n-CXR:  Mild pulmonary vascular congestion with small bilateral\npleural effusions, left greater than right. \n\nVitals on transfer: T 97.3, HR 88, BP 120/54, RR 18, SpO2 98% RA \n\n\n', '___ 09:01AM BLOOD WBC-4.8 RBC-2.88* Hgb-7.4* Hct-24.0* \nMCV-83 MCH-25.7* MCHC-30.8* RDW-16.1* RDWSD-48.5* Plt ___\n___ 09:01AM BLOOD Neuts-78.5* Lymphs-12.1* Monos-7.5 \nEos-1.3 Baso-0.4 Im ___ AbsNeut-']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"Whats the plan for Asthma management for this patient, espeshally with Albuterol inhaler?","['499f5ec0-b3d8-4161-93fa-07c1b6a6de75\n\ncolonoscopy report in our system previously. Iron studies from \n___ with low normal ferritin (53), low iron, low normal \nTIBC - possibly consistent with anemia of chronic disease or \ninflammation, however hard to rule out concomitant iron \ndeficiency.\n# Hypothyroidism: TSH wnl. Continued home levothyroxine.\n# Asthma: Albuterol inhaler prn continued.\nTRANSITIONAL ISSUES:\n- consideration of outpatient colonoscopy referral if not up to \ndate with screening, particularly iso chronic anemia\n- re-check BP at next PCP appointment, decision on further med \ntitration as above (?increase BB, resuming another home agent\n- ?resume Veltassa if K elevated\n- PCP: consider referral to ___ clinic\n \nMedications on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Aspirin 81 mg PO DAILY \n2. Atorvastatin 80 mg PO QPM \n3. CloNIDine 0.4 mg PO BID \n4. HydrALAZINE 100 mg PO TID \n5. Levothyroxine Sodium 100 mcg PO DAILY']","According to the patient's record, for Asthma management, the Albuterol inhaler is to be continued on an as-needed basis (prn). No changes or additional instructions are noted in the provided context beyond this continuation.",custom_multi_hop_query_synthesizer,"**Answer to Current Question**

**Asthma Management Plan with Albuterol Inhaler:**

Based on the provided documents, here is the information related to the plan for Asthma management, specifically with the Albuterol inhaler for Patient **13180007** (common across all documents, as per metadata):

* **Medication Details:**
	+ **Albuterol Inhaler**:
		- **Dosage:** 2 PUFF IH (inhalation) Q8H (every 8 hours) 
		- **Administration:** As Needed (PRN) for **shortness of breath**
* **Consistency Across Documents:**
	+ The Albuterol Inhaler prescription details are **identical** in:
		- **Document 1:** Medications on Admission
		- **Document 2:** (Duplicate of Document 1, including medication list)
		- **Document 3:** Discharge Medications (indicating continuation)
* **No Specific Asthma Management Plan Beyond Medication:**
	+ None of the documents (1 through 5) provide additional details on a comprehensive asthma management plan beyond the prescription of Albuterol Inhaler for PRN use.

**Metadata Relevance:**
- The question doesn't directly require date or admission/discharge specifics, but for context:
	- **Patient/Subject ID:** Consistently **13180007** across all documents.
	- **Note ID, Admission ID** are also consistent but not directly relevant to the asthma management query.

**Recommendation for Further Information:**
- For a more comprehensive understanding of the patient's asthma management plan, reviewing additional documents or the patient's full medical record, especially those focused on pulmonary or allergy services, might be necessary.","['CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', 'CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', 'Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', '# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o', 'Name:  ___              Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   M\n \nService: MEDICINE\n \nAllergies: \nNo Known Allergies / Adver']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What are the patient's vital signs (VS) upon discharge, and are there any notable findings in the cardiovascular examination?","['0070a23b-dc9f-483f-a66d-a8d84a4b995b\n\nCARDIOVASCULAR: Regular rate and rhythm with late ___ systolic\nmurmur at RUSB, no rubs or gallops\nLUNGS: clear to auscultation bilaterally without rhonchi,\nwheezes, or crackles\nGI: soft, nontender, without rebounding or guarding, \nnondistended\nwith normal active bowel sounds, no hepatomegaly\nEXTREMITIES: no clubbing, cyanosis, or edema\nGU: no foley\nSKIN: no rashes, petechia, lesions, or echymoses; warm to\npalpation\nNEURO: Alert and interactive to person, ___ (daughters\nstated that this is a hospital before pt named it), ___, but\nthinks that it is ___, cranial nerves II-XII intact, strength \nis\n___ in RUE, RLE, LLE, ___ in LUE elbow flexion/extension and\nhand grip. Gait is WNL, negative Romberg, negative pronator\ndrift.\nPSYCH: normal mood and affect\nDISCHARGE EXAM\nVS: 97.9 PO 151 / 65 64 18 99 RA \nGEN: Alert and interactive, comfortable, no acute distress\nHEENT: PERRL, anicteric, conjunctiva pink, oropharynx without\nlesion or exudate, moist mucus membranes, ears without lesions \nor', '29d118b8-9203-4616-bc9a-07f5566771d6\n\nVS: \n24 HR Data (last updated ___ @ 817)\n    Temp: 98.3 (Tm 98.4), BP: 136/56 (135-164/56-69), HR: 78\n(57-84), RR: 20 (___), O2 sat: 97% (95-97), O2 delivery: RA  \n24 HR Data (last updated ___ @ 817)\n    Temp: 98.3 (Tm 98.4), BP: 136/56 (135-164/56-69), HR: 78\n(57-84), RR: 20 (___), O2 sat: 97% (95-97), O2 delivery: RA  \nFluid Balance (last updated ___ @ 600) \n  Last 8 hours  Total cumulative -405ml\n    IN: Total 120ml, PO Amt 120ml\n    OUT:  Total 525ml, Urine Amt 525ml\n  Last 24 hours  Total cumulative -725ml\n    IN: Total 1000ml, PO Amt 900ml, IV Amt Infused 100ml\n    OUT:  Total 1725ml, Urine Amt 1725ml     \nWEIGHT: 74.3 kg (75.6 kg)\n \nGENERAL: Sitting up in a chair next to bed. NAD.\nNECK: JVP 7-8 cm. \nCARDIAC: Regular rate and rhythm. Normal S1, S2. Right upper\nborder systolic murmur III/VI. \nLUNGS: Respiration is unlabored with no accessory muscle use.\nCTAB. No wheezes/rales/rhonchi. \nABDOMEN: +BS. Distended but soft. Non-tender to palpation.\nEXTREMITIES: Warm. 1+ edema L > RLE.']","Upon discharge, the patient's vital signs (VS) were: Temperature (Temp) = 97.9, Pulse (PO) = 151, Blood Pressure (BP) = 65/64, Respiratory Rate (RR) = 18, Oxygen Saturation (O2 sat) = 99% on Room Air (RA). Notably, the cardiovascular examination revealed a regular rate and rhythm with a late systolic murmur at the Right Upper Sternal Border (RUSB), but no rubs or gallops were detected.",custom_multi_hop_query_synthesizer,"Based on the provided documents, here is the answer to the question:

**Question:** What are the patient's vital signs (VS) upon discharge, and are there any notable findings in the cardiovascular examination?

**Answer:**

1. **Vital Signs (VS) upon Discharge:**
	* The **exact vital signs upon discharge** are not consistently reported across all documents. However, we can find some information:
		+ **Document 1 & 2** (which appear to be duplicates): Provide ""Vitals on transfer"" (not explicitly stated as discharge vitals, but closest match): T 97.3, HR 88, BP 120/54, RR 18, SpO2 98% RA
		+ **Document 3 (DISCHARGE LABS)** and **Document 4 (TRANSITIONAL ISSUES)** do not provide a full set of vital signs upon discharge. **Document 4** mentions a discharge weight (166.6lb) and discharge Cr (2.9), but not the full vital signs.
	* **Best available answer for VS upon discharge (assuming ""Vitals on transfer"" might be closest to discharge in Documents 1 & 2, but this is an assumption):** T 97.3, HR 88, BP 120/54, RR 18, SpO2 98% RA

2. **Notable Findings in the Cardiovascular Examination:**
	* **Location in Documents:** Document 1, Document 2 (identical content), and briefly mentioned in the context of the patient's condition in other documents.
	* **Findings:**
		- **CV Examination:** RRR (Regular Rate and Rhythm), **systolic murmur**, normal S1, S2
		- **Additional Relevant Information (not part of the direct CV exam but related to cardiovascular health):**
			- **EKG:** TWI (T-wave inversion) in lateral leads (Document 1 & 2)
			- **Past Medical History (Document 5):** Includes hypertension, carotid artery disease, secundum ASD, mild AR, among others, which are relevant to cardiovascular health.","['In the ED:  \nInitial VS: T 98.5, HR 102, BP 178/76, RR 22, SpO2 98% RA \n \nExam:\nGeneral- NAD\nHEENT- PERRL, EOMI, normal oropharynx\nLungs- Non-labored breathing, CTAB\nCV- RRR, systolic murmur, normal S', 'In the ED:  \nInitial VS: T 98.5, HR 102, BP 178/76, RR 22, SpO2 98% RA \n \nExam:\nGeneral- NAD\nHEENT- PERRL, EOMI, normal oropharynx\nLungs- Non-labored breathing, CTAB\nCV- RRR, systolic murmur, normal S', 'DISCHARGE LABS\n==============\n\n___ 06:35AM BLOOD WBC-5.4 RBC-2.92* Hgb-7.6* Hct-24.3* \nMCV-83 MCH-26.0 MCHC-31.3* RDW-15.9* RDWSD-47.8* Plt ___\n___ 06:35AM BLOOD Glucose-164* UreaN-51* Creat-2.9* Na-1', 'TRANSITIONAL ISSUES\n===================\n[ ] At discharge his symptoms associated with volume overload \nhad subsided, but he was still slightly volume up on exam with \n1+ edema to ankles bilaterally an', 'Studies notable for:  \n-CXR:  Mild pulmonary vascular congestion with small bilateral\npleural effusions, left greater than right. \n\nVitals on transfer: T 97.3, HR 88, BP 120/54, RR 18, SpO2 98% RA \n\n\n']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What happen to patient come to ED for asthma but family say no asthma, have weight loss, chills, hand and leg cramping, and history of CVA, what all test and meds patient have in ED?","['33441964-a7d6-441d-ac8e-c600d6bf9f69\n\nED Course:\nExam: no focal neuro deficits. \nVS: T96.1, HR 80, BP 114/50, RR 16, 99% on room air. \nLabs: TropT 0.04, proBNP: 754, Cr 2.3, WBC 5.6, Hgb 10.6\nCultures: urine culture pending. \nMeds: acetaminophen 1g, NS 500mL.\nImaging: CT head: no acute intracranial abnormality. chronic\ninfarcts. \nOn arrival to the floor, pt states that he came to the ED \nbecause\nof his asthma. His daughters are present and state that asthma \nis\nnot, in fact, the reason for his ED presentation. They also\ndescribe anorexia with weight loss. They believe that he looks\nlike he has lost weight, but no clear idea of how much. He\nendorses chills without fevers, which seems to be chronic since\nhis CVA. He has not mentioned chest pain, but has endorsed hand\nand leg cramping. He did have a transient headache which has now\nresolved. \nAt baseline, ___ work full time jobs and have\ntheir own families; pt lives with his wife, who is on HD. ___\ncomes to the house once a week, and pt is followed by RN/BSN \nfrom', ""a6e734ef-1c30-4cb6-ba6d-41227251d4d0\n\nWhen he came home to ___, he apparently thought that he was\nstill in ___, confused his wife for his daughter. On\n___ morning, he fell again. He was confused about the\nconfiguration of the bathroom (no tub in bathroom in PR), so he\ntripped and fell, called his daughter in tears (he often gets\nemotional since his CVA). She booked an appointment for same \nday,\nat which his FSBG>500, HbA1c (point of care, not in OMR) was\n15.0%. He declined to be transferred to the ED. Daughter ___\nwas on vacation from work, and so was able to check on him\nregularly. During these visits, she again established that he is\nnot taking prescribed medications. On the morning of\npresentation, pt's wife called daughter ___, concerned that \npt\nwas increasingly confused. FSBG was >500, and administered\nTresiba 50u at about 8 am. Pt called ___ about 15 minutes\nlater, at which time she again noted confusion and slurred\nspeech, which has intermittently been present since his CVA.\nDecision was made to bring him to the ED. \nOf note, during his last hospitalization ___, he had an\nepisode of dysarthria with confusion and mild expressive and\nreceptive aphasia for which code stroke was called. MRI/MRA \nbrain\nand EEG were unrevealing, with chronic changes and EEG slowing\nonly. He was continued on ASA and atorvastatin.""]","Patient, with history of CVA, presented to ED with claimed asthma, but family denied this, reporting anorexia with weight loss instead. Key findings and actions in ED include:      * **Exam:** No focal neuro deficits.      * **Vital Signs (VS):** T96.1, HR 80, BP 114/50, RR 16, 99% on room air.      * **Labs:** TropT 0.04 (indicating no acute myocardial infarction), proBNP 754 (elevated, suggesting heart failure), Cr 2.3 (elevated, indicating renal impairment), WBC 5.6 (within normal range), Hgb 10.6 (mild anemia). Urine culture pending.      * **Meds Administered in ED:** Acetaminophen 1g, Normal Saline (NS) 500mL.      * **Imaging:** CT head showed no acute intracranial abnormality but chronic infarcts.      * **Symptoms:** Chills without fevers (chronic since CVA), hand and leg cramping, transient headache (now resolved). No chest pain.      * **Pre-ED Context:** Had an episode of confusion, slurred speech, and hyperglycemia (FSBG>500, HbA1c 15.0%) before ED arrival. Was on Tresiba 50u. History of similar neurological episodes, including dysarthria, confusion, and aphasia, during last hospitalization with unrevealing MRI/MRA and EEG, leading to continued ASA and atorvastatin.",custom_multi_hop_query_synthesizer,"Based on the provided instructions and the current question, I'll do my best to provide a relevant response. However, please note that the current question seems to mismatch the provided documents' content. The documents provided (1 through 5) do not mention the patient coming to the ED for asthma with additional symptoms like weight loss, chills, hand and leg cramping, and a history of CVA in the context of questioning the asthma diagnosis. Instead, they detail a patient's visit with symptoms and diagnoses more aligned with heart failure and other conditions. Given this discrepancy, I'll address the question as closely as possible to the provided documents, focusing on the patient's encounter as described.

**Question Breakdown:**
- **Patient's Condition in ED (as per the question, but not directly supported by the documents):** Asthma (disputed), weight loss, chills, hand and leg cramping, history of CVA.
- **Actual Conditions in Documents:** Primarily heart failure symptoms (e.g., dyspnea, chest discomfort on exertion, lower extremity edema) with a history of CVA among other comorbidities.

**Response Based on Provided Documents (since the exact scenario isn't detailed in them):**

1. **Patient/Subject ID:** `13180007` (Consistent across all documents)
2. **Note ID:** `13180007-DS-19` (Consistent across all documents)
3. **Admission ID:** `20774429` (Consistent across all documents)
4. **Chart Time & Store Time:** `N/A` (Consistent across all documents)

**Tests and Meds as per the Documents (not specifically for asthma, weight loss, chills, hand and leg cramping, but for the documented conditions):**

- **Tests:**
  - **EKG:** TWI in lateral leads (Document 1 & 2)
  - **Labs:**
    - **Hgb:** 7.4
    - **Chem:** BUN 39, Cr 2.6
    - **proBNP:** 784
    - **TropT:** 0.03 (Document 1 & 2)
  - **Studies:**
    - **CXR:** Mild pulmonary vascular congestion with small bilateral pleural effusions, left greater than right (Documents 1, 2, & 4)

- **Medications in ED:**
  - **IV Lasix 80mg** (Document 1 & 2, with effectiveness noted in Document 4)

**Note on the Question's Context:**
- The provided documents do not support the scenario of a patient coming to the ED for asthma with the additional symptoms listed (weight loss, chills, hand and leg cramping) and a disputed asthma diagnosis. The primary focus in the documents is on heart failure symptoms (dyspnea, chest discomfort) with a complex medical history including CVA.
- For an accurate response to the question as posed, additional documentation or context specifically addressing the asthma scenario with the mentioned symptoms would be required.","['In the ED:  \nInitial VS: T 98.5, HR 102, BP 178/76, RR 22, SpO2 98% RA \n \nExam:\nGeneral- NAD\nHEENT- PERRL, EOMI, normal oropharynx\nLungs- Non-labored breathing, CTAB\nCV- RRR, systolic murmur, normal S', 'In the ED:  \nInitial VS: T 98.5, HR 102, BP 178/76, RR 22, SpO2 98% RA \n \nExam:\nGeneral- NAD\nHEENT- PERRL, EOMI, normal oropharynx\nLungs- Non-labored breathing, CTAB\nCV- RRR, systolic murmur, normal S', 'DISCHARGE PHYSICAL EXAM\n=======================\nGENERAL: NAD. Mood, affect appropriate.  \nHEENT: Normocephalic atraumatic. Sclera anicteric. EOMI.\nConjunctiva were pink. No pallor or cyanosis of the o', 'Studies notable for:  \n-CXR:  Mild pulmonary vascular congestion with small bilateral\npleural effusions, left greater than right. \n\nVitals on transfer: T 97.3, HR 88, BP 120/54, RR 18, SpO2 98% RA \n\n\n', 'Name:  ___              Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   M\n \nService: MEDICINE\n \nAllergies: \nNo Known Allergies / Adver']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
Wha CK-MB level mean for patient wit chest pain but no ischemia sign?,"[""2b2ce4e1-1e51-4483-8a53-32a58ee918d2\n\nleft pleural effusion. Borderline size of the cardiac silhouette\nwithout pulmonary edema. No pneumonia, no pneumothorax.  The\nlateral radiograph shows mild flattening of the hemidiaphragms,\npotentially as a consequence of functional obstruction.\nHead CT: 1. No evidence of acute intracranial abnormality.\n2. Unchanged appearance of chronic infarcts within the right\nfrontal lobe and left occipital lobe.\n3. Chronic lacunar infarcts within the right basal ganglia.\n4. Redemonstration of few calcifications within the pons,\nfindings which are unchanged in appearance and likely sequela of\nprior ischemic or inflammatory process.\n___ 11:00AM BLOOD cTropnT-0.04*\n___ 09:00PM BLOOD cTropnT-0.02*\n___ 11:00AM BLOOD %HbA1c-14.4* eAG-367*\n___ 11:00AM BLOOD Lipase-73*\n___ 11:00AM BLOOD CK-MB-4 proBNP-754*\nIMAGING:\n___ CXR -\nComparison to ___.  On today's radiograph, a small \npleural\nleft-sided calcification is seen.  There also is a small left \npleural\neffusion.  Borderline size of the cardiac silhouette without"", 'd2113a66-fe4f-4869-b3c0-73646862b32b\n\ngluconate (received 3 doses ___. Upon review of recent \noutpatient visit notes, it appears his volume exam is similar to \nbaseline, and patient was asymptomatic during hospital course. \nHe was diuresed effectively with IV Lasix 80. He was \ntransitioned to PO torsemide 100. His BP was well controlled \nwith regimen as described below.\n# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\nat or lower than levels earlier this year. He has denied chest\npain during admission. He does have risk factors for ischemia \nand\nhas not had stress since ___. However, findings and history \nto\ndate are not suggestive of ischemia and he has an ___. TTE did \nnot show evidence of focal wall motion abnormalities or other \nfindings suggestive of ischemia, so further workup was not \npursued. He was continued on ASA and atorvastatin.\n# ___ on CKD:\nCr elevated to 2.6 on admission from baseline of 1.8-2.2. Given\nevidence of congestion elsewhere, concerns for renal congestion\ncausing renal dysfunction. Cr remained stable and was 2.9 on day \nof discharge. He was continued on home sevelamer.']","Patient have flat CK-MB with mild troponin elevation. CK-MB level specifically mentioned as 4. This, combined with other findings, not suggestive of ischemia. Patient continued on ASA and atorvastatin. Note: CK-MB interpretation in context of patient's Chronic Kidney Disease (CKD) should be considered, though direct implications not detailed in provided context.",custom_multi_hop_query_synthesizer,"Based on the provided instructions, here's the answer to the current question, following the specified format:

**Question:** What CK-MB level means for a patient with chest pain but no ischemia sign?

**Answer Analysis:**

* **Relevant Document(s):** Document 1 and Document 2 (which are identical)
* **Metadata Relevance:** Not directly relevant for the medical question asked, but for context:
	+ **Patient/Subject ID:** 13180007 (consistent across all documents)
	+ **Note ID:** 13180007-DS-19 (consistent across all documents, indicating these are likely duplicate notes or versions)
* **Content Analysis for CK-MB and Ischemia Significance:**
	+ **CK-MB Level Mentioned:** Described as ""flat"" in the context of mild troponin elevation.
	+ **Interpretation in Context of No Ischemia Sign:** The document implies that the combination of mild troponin elevation with a ""flat CK-MB"" is not suggestive of ischemia, especially considering the patient's background of Chronic Kidney Disease (CKD), which can affect troponin levels.

**Answer:**
For the patient (**Patient/Subject ID:** 13180007) with chest pain but no sign of ischemia, the CK-MB level is described as **""flat""**, which in this context, alongside mild troponin elevation and the patient's CKD, does not indicate ischemia. 

**Note:** The term ""flat"" is used qualitatively in the documents to describe the CK-MB level, without providing a specific numerical value. This qualitative description is interpreted in the clinical context to assess the absence of indicative signs for ischemia.","['# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\n', '# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\n', 'In the ED:  \nInitial VS: T 98.5, HR 102, BP 178/76, RR 22, SpO2 98% RA \n \nExam:\nGeneral- NAD\nHEENT- PERRL, EOMI, normal oropharynx\nLungs- Non-labored breathing, CTAB\nCV- RRR, systolic murmur, normal S', 'Studies notable for:  \n-CXR:  Mild pulmonary vascular congestion with small bilateral\npleural effusions, left greater than right. \n\nVitals on transfer: T 97.3, HR 88, BP 120/54, RR 18, SpO2 98% RA \n\n\n', 'ACUTE PROBLEMS\n==============\n# Acute on chronic HFpEF: \nPatient presented with dyspnea and lower extremity edema and\nfound to be volume overloaded on exam. Warm and wet on exam.\nTrigger for HF exacer']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What are the key findings from the patient's Transthoracic Echocardiogram (TTE) regarding ventricular function, valve conditions, and comparisons to prior TTE results, from a medical researcher's analytical perspective?","['6947fbec-1aff-4c0a-8eb5-fe9953adbb08\n\nventricular cavity size with normal free wall motion. The aortic \nsinus diameter is normal for gender with normal ascending aorta \ndiameter for gender. The aortic valve leaflets (3) appear \nstructurally normal. There is no aortic valve stenosis. There is \ntrace aortic regurgitation. The mitral valve leaflets appear \nstructurally normal with no mitral valve prolapse. There is \ntrivial mitral regurgitation. The pulmonic valve leaflets are \nnormal. The tricuspid valve leaflets appear structurally normal. \nThere is physiologic tricuspid regurgitation. The pulmonary \nartery systolic pressure could not be estimated. There is a \ntrivial pericardial effusion.\nIMPRESSION: Mild symmetric left ventricular hypertrophy with \nnormal cavity size and regional/global biventricular systolic \nfunction. No significant mitral regurgitation.\nCompared with the prior TTE ___, the findings are \nsimilar.\nMRI/MRA HEAD AND NECK (___)\nIMPRESSION:\n \n \n1. No hemorrhage or acute infarct.\n2. Chronic infarcts within the subcortical right frontal lobe \nand left\ntemporal and occipital lobes.\n3. Atrophic pons likely a sequela of prior infarcts.', 'db1f4cbf-c584-4ec8-b5c0-1cf04afe2fb4\n\n___ 07:44AM BLOOD CK-MB-7 cTropnT-0.03*\n___ 05:00PM BLOOD CK-MB-7 cTropnT-0.03*\n___ 07:00AM BLOOD CK-MB-6 cTropnT-0.02*\nTFTs:\n___ 09:10AM BLOOD TSH-9.6*\n___ 07:44AM BLOOD T4-6.5 T3-118 Free T4-1.0\nIMAGING:\n========\nCXR (___):\nFINDINGS:  \nThe lung volumes are low-normal.  There is no focal \nconsolidation.  There is mild prominence of the bilateral \npulmonary vessels suggestive of volume \noverload.  The heart is top-normal in size.  There is no large \neffusion or a pneumothorax.  There is no acute osseous \nabnormality, chronic left rib \nfractures are noted. \n  \nIMPRESSION:  \nStable top-normal heart size with mild pulmonary vascular \ncongestion. \nTTE (___):\nThe left atrial volume index is normal. There is no evidence for']","Based on the provided TTE findings, the key observations include:  1. **Mild symmetric left ventricular hypertrophy** with normal cavity size. 2. **Normal regional/global biventricular systolic function**. 3. **Structurally normal valve leaflets** for aortic, mitral, pulmonic, and tricuspid valves. 4. **Trace aortic regurgitation** and **trivial mitral regurgitation** with **physiologic tricuspid regurgitation**. 5. A **trivial pericardial effusion** was noted. 6. **Comparison to prior TTE** shows similar findings, indicating stability in the observed conditions. These findings suggest a relatively stable cardiac condition with some minor abnormalities, but no significant deterioration or new major issues compared to the previous TTE.",custom_multi_hop_query_synthesizer,"**Answering the Current Question with Provided Instructions**

**Note:** Since the question specifically asks about the Transthoracic Echocardiogram (TTE) findings, we'll focus on documents containing relevant TTE information. Based on the provided documents, **Document 3** and **Document 4** contain TTE-related information.

**Key Findings from TTE:**

1. **Ventricular Function:**
	* **Ejection Fraction (EF):** 65% (Document 3)
	* **Diastolic Function:** Diastolic dysfunction (Document 3)
	* **Left Ventricle:** Stiff (Document 4, impression from TTE)
2. **Valve Conditions:**
	* **Aortic Valve:** No stenosis or regurgitation; leaflets mildly thickened (Document 4)
	* **Mitral Valve:** Leaflets mildly thickened, no prolapse, trivial regurgitation (Document 4)
	* **Pulmonic Valve:** Leaflets normal (Document 4)
	* **Tricuspid Valve:** Structurally normal leaflets, physiologic tricuspid regurgitation (Document 4)
3. **Comparisons to Prior TTE Results:**
	* **No direct comparisons provided** in the content of the documents. However, Document 3 mentions that the patient's volume exam is similar to baseline, based on recent outpatient visit notes, but this does not directly relate to TTE findings.

**Metadata Observations (as per instructions):**

* **Patient/Subject ID:** Consistently **13180007** across all documents (Documents 1 through 5).
* **Note ID:** Identical **13180007-DS-19** across all documents (Documents 1 through 5), indicating these notes are part of the same series or visit.
* **Admission ID:** Uniformly **20774429** across all documents (Documents 1 through 5), confirming a single admission period for these observations.
* **Chart Time & Store Time:** Both are **N/A** for all documents (Documents 1 through 5), providing no specific timing for charting or storage beyond the content's implications.","['In the ED:  \nInitial VS: T 98.5, HR 102, BP 178/76, RR 22, SpO2 98% RA \n \nExam:\nGeneral- NAD\nHEENT- PERRL, EOMI, normal oropharynx\nLungs- Non-labored breathing, CTAB\nCV- RRR, systolic murmur, normal S', 'In the ED:  \nInitial VS: T 98.5, HR 102, BP 178/76, RR 22, SpO2 98% RA \n \nExam:\nGeneral- NAD\nHEENT- PERRL, EOMI, normal oropharynx\nLungs- Non-labored breathing, CTAB\nCV- RRR, systolic murmur, normal S', 'ACUTE PROBLEMS\n==============\n# Acute on chronic HFpEF: \nPatient presented with dyspnea and lower extremity edema and\nfound to be volume overloaded on exam. Warm and wet on exam.\nTrigger for HF exacer', 'leaflets (3) are mildly thickened. There is no\naortic valve stenosis. There is no aortic regurgitation. The \nmitral valve leaflets are mildly thickened with\nno mitral valve prolapse. There is trivial ', 'Studies notable for:  \n-CXR:  Mild pulmonary vascular congestion with small bilateral\npleural effusions, left greater than right. \n\nVitals on transfer: T 97.3, HR 88, BP 120/54, RR 18, SpO2 98% RA \n\n\n']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What are the key considerations and current plans for managing the patient's cardiovascular health, particularly regarding the known inducible ischemia in the LCX distribution, in the context of their complex medical history including CKD and recent medication adjustments?","['3854e9c9-f299-4327-94b1-3dc260a4fc6f\n\nLying HR: 68 RR: 20 O2 sat: 98% O2 delivery: 3LNC Dyspnea: 3\nRASS: 0 Pain Score: ___ \n \n  Of note, since ___, he has had known inducible ischemia on\nLCX distribution from stress test. The risks (including dialysis\nafter contrast load) and benefits were discussed with primary\ncardiologist Dr. ___. Coronary angiogram was deferred. \n  He also had a recent admission to the heart failure service\nwith uptitration of blood pressure control agents. Coronary\nangiogram was deferred at that time. ACEi was stopped (prior\nlisinopril 40mg) given worsened CKD vs ___.  Low dose lisinopril\nwas reinitiated at last visit with Dr. ___. \n  Multiple notes in OMR describe issues with ensuring consistent\nsupply of medications. The patient and his family confirm this.\nHowever, they state recently no change in medications, ___ comes\nonce per week.  He describes his diet as healthy but family\nconcerned about salt intake. No h/o arrhythmia, no palpitations. \n On the floor, he reports ongoing mild wheeze, improving\nshortness of breath, no current chest pain. \nREVIEW OF SYSTEMS:  \nPositive per HPI.', '4b3d7a96-6534-434e-8295-b8356c5ca64d\n\nbasal/bolus four times daily regimen. However, this is not a \nsustainable regimen for patient on discharge. Discussed \npossibility of switching to 70/30 mix BID, however currently \npatient cannot be guaranteed to eat regular meal after each \ninsulin injection therefore currently not a tenable plan. In the \nfuture, if patient able to be placed in a day program, \npotentially could switch to this but for now will we continued \nhis prior home regimen (EXCEPT for Jardiance, which was \ndiscontinued due to contraindication with chronic kidney \ndisease) on discharge, with very close ___ follow-up and ___ \nservices to help increase compliance. With regards to his more \nsubacute mental status decompensation, would benefit from \nreferral for outpatient neurocognitive evaluation.\n# Hx of CAD: \n# Hx of ischemic CVA:\nStress test in ___ with area of inducible ischemia in LCx \ndistribution, in setting of multiple risk factors. Has been \nmedically optimized by prescribed medications, but as above it \nseems that pt has been taking these medications. TnT 0.04->0.02 \nin setting of CKD stage III-IV. Continued home aspirin, \natorvastatin, and carvedilol. Note that he was once on \nlisinopril (most recently filled in ___ for 2.5mg dose) \nhowever seems that this has since been discontinued.\n# CKD stage III:']","The patient has known inducible ischemia in the LCX distribution from a previous stress test, alongside multiple risk factors. Management considerations include:         - **Coronary Angiogram Deferral**: Recently deferred due to risks, including dialysis after contrast load, as discussed with Dr. ___.        - **Medication Adjustments**:           - **ACEi (Lisinopril)**: Initially stopped due to worsened CKD, then reinitiated at a low dose.          - **Continued Medications**: Home aspirin, atorvastatin, and carvedilol are continued.          - **Discontinued**: Jardiance, due to contraindication with chronic kidney disease.        - **Future Plans**: Potential switch to a more sustainable insulin regimen (e.g., 70/30 mix BID) if the patient can be placed in a day program, emphasizing close follow-up and compliance services upon discharge.        - **Additional Recommendations**: Outpatient neurocognitive evaluation for subacute mental status decompensation.",custom_multi_hop_query_synthesizer,"Based on the provided documents, here's the response to the current question, following the instructed guidelines:

**Key Considerations and Current Plans for Managing the Patient's Cardiovascular Health:**

1. **Known Inducible Ischemia in the LCX Distribution:** *No direct mention* of inducible ischemia in the LCX distribution is found in the provided documents. However, Document 3 discusses chest pain and mild troponin elevation, suggesting a concern for ischemia, but it does not specify the LCX distribution. Instead, it mentions the patient has risk factors for ischemia and has not had a stress test since an unspecified date. The TTE (Transthoracic Echocardiogram) did not show evidence of focal wall motion abnormalities suggestive of ischemia, leading to no further workup being pursued.

2. **Complex Medical History:**
   - **CKD (Chronic Kidney Disease):** Document 3 notes an elevated Cr (Creatinine) level on admission (2.6) from a baseline of 1.8-2.2, suggesting renal congestion causing renal dysfunction. The patient was continued on home sevelamer.
   - **Recent Medication Adjustments for Cardiovascular Health:**
     - **ASA (Aspirin) and Atorvastatin:** Continued as per Document 3, indicating management of risk factors for ischemia.
     - **Hypertension Management:** Document 4 mentions the patient's hypertension is currently well-controlled with amlodipine 10, Coreg 50 BID, and minoxidil 10 daily.

**Metadata Insights Relevant to the Question:**

- **Patient/Subject ID:** Consistently listed as **13180007** across all documents.
- **Note ID and Admission ID:** Also consistent across all documents as **13180007-DS-19** and **20774429**, respectively, indicating these documents pertain to the same patient encounter.
- **Chart Time and Store Time:** Listed as **N/A** for all documents, providing no additional timing insights relevant to the question.

**Answer to the Question's Implicit Request for IDs and Dates:**

- **Patient/Subject ID:** **13180007** (consistent across documents)
- **Note ID:** **13180007-DS-19** (same across all documents, indicating a single encounter's notes)
- **Admission ID:** **20774429** (consistent, reinforcing a single admission's context)
- **Dates:** Not explicitly requested in the question but are **N/A** in the metadata for Chart Time and Store Time. Admission and Discharge Dates are also not provided in the metadata or content of the documents.","['Studies notable for:  \n-CXR:  Mild pulmonary vascular congestion with small bilateral\npleural effusions, left greater than right. \n\nVitals on transfer: T 97.3, HR 88, BP 120/54, RR 18, SpO2 98% RA \n\n\n', 'Studies notable for:  \n-CXR:  Mild pulmonary vascular congestion with small bilateral\npleural effusions, left greater than right. \n\nVitals on transfer: T 97.3, HR 88, BP 120/54, RR 18, SpO2 98% RA \n\n\n', '# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\n', '# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o', 'Name:  ___              Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   M\n \nService: MEDICINE\n \nAllergies: \nNo Known Allergies / Adver']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
What is the prescribed dosage of hydralazine for a patient with acute on chronic heart failure and hypertension?,"['5d1619ab-197a-416d-b0af-616eff82199c\n\n#*60 Tablet Refills:*0 \n12.  HydrALAZINE 100 mg PO TID \nRX *hydralazine 100 mg 1 tablet(s) by mouth three times a day \nDisp #*90 Tablet Refills:*0 \n13.  Levothyroxine Sodium 100 mcg PO DAILY \nRX *levothyroxine 100 mcg 1 tablet(s) by mouth once a day Disp \n#*30 Tablet Refills:*0 \n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nPRIMARY DIAGNOSIS\n==================\nAcute on chronic heart failure with preserved ejection fraction\nSECONDARY DIAGNOSES\n====================\nAcute kidney injury\nCoronary artery disease\nType 2 Diabetes Mellitus\nHyperkalemia', '71b11357-64d1-43f3-b5b3-9e2b962adaf4\n\n# Volume overload\n# HFpEF, LVEF 55-60% in ___\nVolume overload on exam. Diuresis began while in ICU, net \nnegative 1.8L prior to transfer. Dry weight appears to be \n154-157. s/p Lasix 80mg x 2 so far. 163.4 lb on ___ A-Strict \nI/Os, daily weights. Continued home carvedilol at increased dose \nas below. He was sent home with PO 60 mg Lasix daily and was net \neven in the hospital. \n# HTN\nBlood pressure medications initially held when he was started on \npropofol. Anti-HTN meds started on day of transfer. Persistently \nhypertensive. Increased carvedilol to 50 mg BID and increased \nminoxidil to 5 mg and continued amlodipine 10 mg QD. Of note, he \nhad been on clonidine and hydralazine but these were stopped by \nPCP just prior to admission. He remained mostly normotensive \nalthough goal SBP <130 and should continue to be goal as an \noutpatient. \n# Normocytic Anemia\nBaseline of ___, secondary to CKD and possible AoCD. Required \n1u pRBC on arrival. Hb stable. \nCHRONIC ISSUES:']","According to the provided medical context, the patient was previously on hydralazine but it was stopped by the PCP just prior to admission. However, a past prescription for hydralazine is mentioned in one of the discharge medications lists as: '12. HydrALAZINE 100 mg PO TID' which translates to 'hydralazine 100 mg, 1 tablet by mouth three times a day'. Please note, this might not reflect the current treatment plan as the medication was stopped prior to the described hospital stay.",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

* **Prescribed dosage of hydralazine for a patient with acute on chronic heart failure and hypertension:** 
**None Found**

**Rationale:**

1. **Medication Mentioned:** The question specifically asks about ""hydralazine."" However, upon reviewing the content of all provided documents, there is no mention of ""hydralazine"" as a prescribed medication for this patient.
2. **Heart Failure and Hypertension Management:** While the documents do discuss the patient's conditions of acute on chronic heart failure (Document 3: # Acute on chronic HFpEF) and hypertension (Documents 1 & 2: # Hypertension), the medications listed for managing these conditions do not include hydralazine.
3. **Listed Medications for Heart Failure and Hypertension:**
	* For Heart Failure (HFpEF): The patient was diuresed with IV Lasix 80 and then transitioned to PO torsemide 100 (Document 3 & Document 5: Discharge Medications).
	* For Hypertension: The patient was continued on home medications including amlodipine 10, Coreg (carvedilol) 50 BID, and minoxidil 10 daily (Documents 1 & 2, and also reflected in admission and discharge medications in Documents 4 & 5).

**Metadata IDs (as per instruction, in case of relevance to future questions):**

* **Patient/Subject ID:** 13180007 (consistent across all documents)
* **Note ID:** 13180007-DS-19 (consistent across all documents)
* **Admission ID:** 20774429 (consistent across all documents)
* **Chart Time & Store Time:** N/A (consistent across all documents)","['# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o', '# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o', 'ACUTE PROBLEMS\n==============\n# Acute on chronic HFpEF: \nPatient presented with dyspnea and lower extremity edema and\nfound to be volume overloaded on exam. Warm and wet on exam.\nTrigger for HF exacer', 'CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', 'Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What are the key considerations for a Clinical Care Coordinator managing a patient with Mild Aortic Regurgitation (Mild AR) alongside other cardiac risk factors and extensive intracranial atherosclerosis, in terms of preventing repeated hospital admissions and managing home medications?","['07c9a41e-be29-4f49-810c-9cfabe64e237\n\nInterventions: \n3L LR, Vanc/Cefepime/Flagyl, insulin gtt, Propofol (changed to\nmidazolam for hypotension), fentanyl \nVS Prior to Transfer: temp 96.2, HR 61, BP 109/54, RR 24, O2 sat\n99% Intubation \nROS: Positives as per HPI; otherwise negative.  \n \n \nPast Medical History:\n1. CARDIAC RISK FACTORS  \n- Type 2 Diabetes Mellitus\n- Hypertension  \n- Dyslipidemia  \n- Coronary artery disease\n2. CARDIAC HISTORY  \n- Secondum ASD\n- Mild AR\n3. OTHER PAST MEDICAL HISTORY  \n- Extensive intracranial atherosclerosis, worse in the right\nMCA territory.\n- Cerebrovascular disease, status post CVA in ___\n- Asthma\n- OSteoarthritis', '2fefbd11-fef9-45c9-8e5f-7c57ff45ef50\n\nCase Management, ___, as outpatient. ___ and\n___ both feel that their father needs increased services at\nhome to prevent repeated admissions. They are both providing as\nmuch support as they can, in the setting of having their own \nfull\ntime jobs and families. ___ expresses concern that his home\nmedications will be resumed/uptitrated without the understanding\nthat he is not, in fact, taking them as prescribed; she\nrecognizes that this could result in major adverse events, if \nall\nhome medications were to be resumed at the same time in the\nhospital.\n \nPast Medical History:\n1. CARDIAC RISK FACTORS  \n- Type 2 Diabetes Mellitus\n- Hypertension  \n- Dyslipidemia  \n- Coronary artery disease\n2. CARDIAC HISTORY  \n- Secondum ASD\n- Mild AR\n3. OTHER PAST MEDICAL HISTORY  \n- Extensive intracranial atherosclerosis, worse in the right\nMCA territory.']","Based on the provided context, key considerations for managing such a patient include:  1. **Close Monitoring of Cardiac Condition**: Given the patient's history of Mild AR, Secondary ASD, Type 2 Diabetes Mellitus, Hypertension, Dyslipidemia, and Coronary Artery Disease, careful monitoring of cardiac health is crucial. 2. **Management of Intracranial Atherosclerosis**: The patient's extensive intracranial atherosclerosis, particularly worse in the right MCA territory, and history of CVA, necessitate careful management to prevent further cerebrovascular events. 3. **Preventing Repeated Admissions**: Increasing home services, as suggested by the patient's family, could help in preventing repeated hospital admissions by providing adequate support and monitoring. 4. **Safe Management of Home Medications**: It is critical to understand the patient's adherence to prescribed medications before resuming or uptitrating them post-hospitalization to avoid major adverse events. A tailored approach to medication management, possibly including education on proper medication use, is essential.",custom_multi_hop_query_synthesizer,"**Response**

**Patient Identifier:** 
* **Patient/Subject ID:** 13180007 (consistent across all documents: Document 1, Document 2, Document 3, Document 4, Document 5)
* **Note ID:** 13180007-DS-19 (consistent across all documents)
* **Admission ID:** 20774429 (consistent across all documents)

**Key Considerations for Clinical Care Coordinator:**

Managing a patient with **Mild Aortic Regurgitation (Mild AR)** alongside other cardiac risk factors and **extensive intracranial atherosclerosis** requires a multifaceted approach to prevent repeated hospital admissions and effectively manage home medications. Based on the provided documents, the following are key considerations:

1. **Cardiovascular Risk Management:**
	* **Mild AR, Secundum ASD, Carotid Artery Disease, and Extensive Intracranial Atherosclerosis:** Close monitoring for progression of these conditions. Regular echocardiograms for AR and ASD, and possibly carotid Doppler studies as indicated.
	* **Hypertension Management:** Ensure adherence to prescribed antihypertensive regimen (e.g., amlodipine 10mg, Coreg 50mg BID, minoxidil 10mg daily as per Document 5) to control blood pressure, mitigating risks associated with AR and atherosclerosis.

2. **Medication Management:**
	* **Polypharmacy Review:** Regularly review the patient's extensive medication list (13 medications as listed in Document 4) to minimize potential interactions, especially considering renal function (elevated Cr levels noted in Document 3).
	* **Adherence Support:** Implement strategies to enhance adherence to the complex medication regimen, including potential simplification if possible, and regular follow-ups.

3. **Chronic Condition Management:**
	* **Diabetes Mellitus Type 2 (IDDM) with Poor Control (A1c 14.4 and then 11.4%):** Intensify diabetes management through education, dietary counseling, and potentially adjusting the insulin regimen (currently 70/30 with meals and Lantus at night) to achieve better glycemic control.
	* **Chronic Kidney Disease (CKD):** Monitor renal function closely, adjusting medications as necessary to avoid further renal impairment. Continue sevelamer as prescribed for hyperphosphatemia management in CKD.
	* **Hypothyroidism:** Ensure continued adherence to levothyroxine 100mcg daily, with regular TSH level checks to maintain euthyroid status.

4. **Preventing Repeated Hospital Admissions:**
	* **Regular Outpatient Follow-Ups:** Schedule frequent follow-ups with the patient's healthcare providers to monitor the progression of conditions and adjust treatments as needed.
	* **Patient Education:** Educate the patient and their caregivers on recognizing early signs of decompensation for their various conditions, the importance of medication adherence, and when to seek immediate medical attention.
	* **Multidisciplinary Care Team Involvement:** Engage a team of specialists (cardiology, neurology, nephrology, endocrinology) for comprehensive care and to address any emerging issues promptly.

5. **Additional Recommendations:**
	* **Stress Test:** Consider scheduling a stress test, as mentioned in Document 3, to further evaluate ischemic risk, if not already done.
	* **Nutritional and Lifestyle Counseling:** Provide guidance on heart-healthy diet, exercise (within permissible limits considering osteoarthritis), smoking cessation (if applicable), and stress reduction techniques.","['Studies notable for:  \n-CXR:  Mild pulmonary vascular congestion with small bilateral\npleural effusions, left greater than right. \n\nVitals on transfer: T 97.3, HR 88, BP 120/54, RR 18, SpO2 98% RA \n\n\n', 'Studies notable for:  \n-CXR:  Mild pulmonary vascular congestion with small bilateral\npleural effusions, left greater than right. \n\nVitals on transfer: T 97.3, HR 88, BP 120/54, RR 18, SpO2 98% RA \n\n\n', '# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\n', 'CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', '# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
What are the key findings from the patient's Transthoracic Echocardiogram (TTE) regarding left ventricular function and structure?,"['81401d7e-0074-4c95-b4cf-e031f6b09906\n\nFindings are compatible with moderate pulmonary edema with a \nmoderate left\npleural effusion.  Underlying bibasilar atelectasis and/or \npneumonia in the\nappropriate clinical setting should also be considered.\nCT HEAD WO CON (___)\nIMPRESSION: \n \nArea of low-density left occipital ___ represent subacute \ninfarct, if there are clinical symptoms, consider brain MRI \nwithout contrast. Small chronic lacunar infarct right basal \nganglia. Few calcifications at the pons, nonspecific, may be \nsequela of prior\ninflammatory or ischemic process, cavernoma cannot be excluded.\nTTE (___)\n---------------\nCONCLUSION: The left atrial volume index is mildly increased. \nThere is mild symmetric left ventricular hypertrophy with a \nnormal cavity size. There is normal regional and global left \nventricular systolic function. The visually estimated left \nventricular ejection fraction is 55-60%. There is no resting \nleft ventricular outflow tract gradient. Normal right', 'd2113a66-fe4f-4869-b3c0-73646862b32b\n\ngluconate (received 3 doses ___. Upon review of recent \noutpatient visit notes, it appears his volume exam is similar to \nbaseline, and patient was asymptomatic during hospital course. \nHe was diuresed effectively with IV Lasix 80. He was \ntransitioned to PO torsemide 100. His BP was well controlled \nwith regimen as described below.\n# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\nat or lower than levels earlier this year. He has denied chest\npain during admission. He does have risk factors for ischemia \nand\nhas not had stress since ___. However, findings and history \nto\ndate are not suggestive of ischemia and he has an ___. TTE did \nnot show evidence of focal wall motion abnormalities or other \nfindings suggestive of ischemia, so further workup was not \npursued. He was continued on ASA and atorvastatin.\n# ___ on CKD:\nCr elevated to 2.6 on admission from baseline of 1.8-2.2. Given\nevidence of congestion elsewhere, concerns for renal congestion\ncausing renal dysfunction. Cr remained stable and was 2.9 on day \nof discharge. He was continued on home sevelamer.']","According to the TTE findings, the patient has:               1. **Mildly increased left atrial volume index**.              2. **Mild symmetric left ventricular hypertrophy** with a normal cavity size.              3. **Normal regional and global left ventricular systolic function**.              4. A **visually estimated left ventricular ejection fraction of 55-60%**.              5. **No resting left ventricular outflow tract gradient**.              Additionally, the TTE did not show evidence of focal wall motion abnormalities or other findings suggestive of ischemia.",custom_multi_hop_query_synthesizer,"Based on the provided documents, the key findings from the patient's Transthoracic Echocardiogram (TTE) regarding left ventricular function and structure can be extracted from **Documents 1, 2, and 5**, as these contain relevant echocardiogram conclusions. Since **Documents 1 and 2** are identical in content (though this might be a posting error, as their content is incomplete and identical to each other), we'll consider the unique information from **Documents 1/2** and **Document 5**.

### Left Ventricular Function and Structure Key Findings:

1. **Left Ventricular Systolic Function:**
   - **Normal regional and global left ventricular systolic function** (**Documents 1 & 2**)
   - **Visually estimated left ventricular ejection fraction (LVEF) is 65%** (**Documents 1 & 2**), indicating normal systolic function (normal LVEF range is typically considered 55%).

2. **Left Ventricular Structure:**
   - **Mild symmetric left ventricular hypertrophy with a normal cavity size** (**Documents 1 & 2**), suggesting the heart muscle has thickened, which can be a response to high blood pressure or other heart conditions, but the ventricle's ability to pump is not significantly impaired based on the normal cavity size and LVEF.

3. **Diastolic Function:**
   - **Tissue Doppler suggests an increased left ventricular filling pressure (PCWP greater than 18 mmHg)** (**Documents 1 & 2**)
   - **Echocardiographic evidence for diastolic dysfunction (grade indeterminate)** (**Documents 1 & 2**), indicating potential issues with the heart's ability to relax and fill between beats.

4. **Additional Findings (not exclusively LV but relevant to overall heart function):**
   - **Small pericardial effusion** (**Document 5**)
   - **Stiff left ventricle** (**Document 5**), which aligns with the diastolic dysfunction noted in **Documents 1 & 2**.
   - **No frank tamponade** (**Document 5**), indicating the pericardial effusion is not causing significant compression of the heart.

### Metadata Consistency for Patient ID:
- **Patient/Subject ID: 13180007** is consistent across all documents (**Documents 1 through 5**).
- **Note ID: 13180007-DS-19** and **Admission ID: 20774429** are also consistent across all provided documents, indicating these findings all pertain to the same patient encounter.","['___\nCONCLUSION:\nThe left atrial volume index is normal. The estimated right \natrial pressure is ___ mmHg. There is mild\nsymmetric left ventricular hypertrophy with a normal cavity \nsize. There is norm', '___\nCONCLUSION:\nThe left atrial volume index is normal. The estimated right \natrial pressure is ___ mmHg. There is mild\nsymmetric left ventricular hypertrophy with a normal cavity \nsize. There is norm', 'In the ED:  \nInitial VS: T 98.5, HR 102, BP 178/76, RR 22, SpO2 98% RA \n \nExam:\nGeneral- NAD\nHEENT- PERRL, EOMI, normal oropharynx\nLungs- Non-labored breathing, CTAB\nCV- RRR, systolic murmur, normal S', 'Studies notable for:  \n-CXR:  Mild pulmonary vascular congestion with small bilateral\npleural effusions, left greater than right. \n\nVitals on transfer: T 97.3, HR 88, BP 120/54, RR 18, SpO2 98% RA \n\n\n', 'leaflets (3) are mildly thickened. There is no\naortic valve stenosis. There is no aortic regurgitation. The \nmitral valve leaflets are mildly thickened with\nno mitral valve prolapse. There is trivial ']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What is the prescribed dosage and administration schedule for HydrALAZINE in the provided medical discharge instructions, and what are the primary and secondary diagnoses associated with its prescription?","['058d90f2-3d7b-4d29-bca6-e70e3cb19e4d\n\n4.  HydrALAZINE 100 mg PO TID \nRX *hydralazine 100 mg 1 tablet(s) by mouth three times daily \nDisp #*90 Tablet Refills:*0 \n5.  Glargine 30 Units Breakfast \n6.  Albuterol Inhaler 2 PUFF IH Q4H  \n7.  amLODIPine 10 mg PO DAILY  \n8.  Atorvastatin 80 mg PO QPM  \n9.  CloNIDine 0.2 mg PO BID  \n10.  Gabapentin 400 mg PO TID  \n11.  Levothyroxine Sodium 100 mcg PO DAILY  \n12.  MetFORMIN (Glucophage) 850 mg PO TID  \n13.  Vitamin D ___ UNIT PO WEEKLY  \n14. HELD- Lisinopril 40 mg PO DAILY  This medication was held. \nDo not restart Lisinopril until told to do so by your doctor\n15.Outpatient Lab Work\nChem-7 to be draw ___\nICD 10: I50.3: Diastolic (congestive) heart failure\nFax results to: ___ ATTN: ___\n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___', '5d1619ab-197a-416d-b0af-616eff82199c\n\n#*60 Tablet Refills:*0 \n12.  HydrALAZINE 100 mg PO TID \nRX *hydralazine 100 mg 1 tablet(s) by mouth three times a day \nDisp #*90 Tablet Refills:*0 \n13.  Levothyroxine Sodium 100 mcg PO DAILY \nRX *levothyroxine 100 mcg 1 tablet(s) by mouth once a day Disp \n#*30 Tablet Refills:*0 \n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nPRIMARY DIAGNOSIS\n==================\nAcute on chronic heart failure with preserved ejection fraction\nSECONDARY DIAGNOSES\n====================\nAcute kidney injury\nCoronary artery disease\nType 2 Diabetes Mellitus\nHyperkalemia']","According to the discharge instructions, HydrALAZINE is prescribed as follows: 100 mg PO (by mouth) TID (three times a day). This medication regimen is associated with the following diagnoses: **PRIMARY DIAGNOSIS** - Acute on chronic heart failure with preserved ejection fraction, and **SECONDARY DIAGNOSES** - Acute kidney injury, Coronary artery disease, Type 2 Diabetes Mellitus, and Hyperkalemia. The prescription details are consistent across both provided medical records (Disp #*90 Tablet Refills:*0 in one record and implied in the other with #*60 Tablet Refills:*0 for a different medication, suggesting a similar dispensing approach might be intended for HydrALAZINE despite the specific refill number not being directly mentioned in the second record for HydrALAZINE).",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

* **Prescribed Dosage and Administration Schedule for HydrALAZINE:**
	+ **Dosage:** Not Available
	+ **Administration Schedule:** Not Available
	+ **Reason:** HydrALAZINE is not mentioned in any of the provided documents (Document 1 through Document 5) under the discharge medications or any other section related to prescribed medications.

* **Primary and Secondary Diagnoses Associated with its Prescription:**
	+ **Primary Diagnosis:** Not Applicable (since HydrALAZINE is not prescribed)
	+ **Secondary Diagnoses:** Not Applicable (since HydrALAZINE is not prescribed)

**Additional Observations Based on the Provided Instructions:**

1. **Patient/Subject ID Consistency:**
	* The **Patient/Subject ID** (`13180007`) is consistent across all documents (Document 1 through Document 5).
2. **Note ID and Admission ID Consistency:**
	* Both the **Note ID** (`13180007-DS-19`) and **Admission ID** (`20774429`) are identical across all provided documents.
3. **Primary and Secondary Diagnoses (for context, though not related to HydrALAZINE):**
	* **Primary Diagnosis:** Acute on chronic diastolic heart failure exacerbation (mentioned in Document 1 and Document 2)
	* **Secondary Diagnoses:** 
		- Acute kidney injury
		- Acute on chronic anemia
		- Type 2 diabetes mellitus (all mentioned in Document 1 and Document 2)","['Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', 'DISCHARGE LABS\n==============\n\n___ 06:35AM BLOOD WBC-5.4 RBC-2.92* Hgb-7.6* Hct-24.3* \nMCV-83 MCH-26.0 MCHC-31.3* RDW-15.9* RDWSD-47.8* Plt ___\n___ 06:35AM BLOOD Glucose-164* UreaN-51* Creat-2.9* Na-1', 'Name:  ___              Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   M\n \nService: MEDICINE\n \nAllergies: \nNo Known Allergies / Adver']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What me worry bout wen patient hav small left pleural effusion, borderline cardiac silhouette, and chronic infarcts in brain CT, but no acute intracranial abnormality? Should i look into somethin else wit dis patient?","[""2b2ce4e1-1e51-4483-8a53-32a58ee918d2\n\nleft pleural effusion. Borderline size of the cardiac silhouette\nwithout pulmonary edema. No pneumonia, no pneumothorax.  The\nlateral radiograph shows mild flattening of the hemidiaphragms,\npotentially as a consequence of functional obstruction.\nHead CT: 1. No evidence of acute intracranial abnormality.\n2. Unchanged appearance of chronic infarcts within the right\nfrontal lobe and left occipital lobe.\n3. Chronic lacunar infarcts within the right basal ganglia.\n4. Redemonstration of few calcifications within the pons,\nfindings which are unchanged in appearance and likely sequela of\nprior ischemic or inflammatory process.\n___ 11:00AM BLOOD cTropnT-0.04*\n___ 09:00PM BLOOD cTropnT-0.02*\n___ 11:00AM BLOOD %HbA1c-14.4* eAG-367*\n___ 11:00AM BLOOD Lipase-73*\n___ 11:00AM BLOOD CK-MB-4 proBNP-754*\nIMAGING:\n___ CXR -\nComparison to ___.  On today's radiograph, a small \npleural\nleft-sided calcification is seen.  There also is a small left \npleural\neffusion.  Borderline size of the cardiac silhouette without"", 'a0523bf3-a15e-4abc-bd78-1c98b6c5dc7e\n\nedema.  No\nevidence of displaced fracture.\nCT head ___:\nThere is no evidence of infarction, hemorrhage, edema,or midline \nshift.  There\nis prominence of the ventricles and sulci suggestive of \ninvolutional changes.\n \nThere is no evidence of fracture.  Opacification of the mastoid \nair cells. \nThe visualized portion of the paranasal sinuses, mastoid air \ncells, and middle\near cavities are clear.  The visualized portion of the orbits \nare\nunremarkable.\nCT abd/pelvis ___:\n1. Bilateral lower lobe opacities, concerning for aspiration or \npneumonia.\n2. No acute finding in the abdomen or pelvis.\nCT C spine ___:\nNG tube and endotracheal tube are noted.  Alignment is normal. \nNo fractures\nare identified. There is no evidence of high-grade spinal canal']","Based on provided CT scans and blood work, key concerns for the patient include:      1. **Small left pleural effusion and borderline size of the cardiac silhouette** observed in the chest X-ray (CXR), suggesting potential cardiac or pulmonary issues, but **no pneumonia or pneumothorax**.     2. **Chronic infarcts** within the right frontal lobe, left occipital lobe, and right basal ganglia, as well as **calcifications in the pons**, indicating past ischemic or inflammatory processes, but **no evidence of acute intracranial abnormality** on the Head CT.     3. **Elevated %HbA1c (14.4)** and **eAG (367)**, indicating poorly controlled diabetes.     4. **proBNP of 754**, which may suggest heart failure or other cardiac conditions.     **Recommendation**: Further investigation into the patient's cardiac health (given the borderline cardiac silhouette and proBNP levels) and management of diabetes are warranted. Monitoring for any signs of neurological deterioration, despite the current lack of acute intracranial abnormalities, is also advisable.",custom_multi_hop_query_synthesizer,"Based on the provided instructions, I'll address the question while following the guidelines.

**Question Analysis**

* The question pertains to a patient's condition, specifically mentioning:
	1. Small left pleural effusion
	2. Borderline cardiac silhouette
	3. Chronic infarcts in brain CT
	4. No acute intracranial abnormality
* The question asks what to worry about with these conditions and if something else should be looked into for this patient.

**Metadata Review (as per instructions)**

* **Patient/Subject ID**: 13180007 (consistent across all documents: **Document 1**, **Document 2**, **Document 3**, **Document 4**, and **Document 5**)
* **Note ID**: 13180007-DS-19 (consistent across all documents)
* **Admission ID**: 20774429 (consistent across all documents)
* **Chart Time** and **Store Time**: N/A (consistent across all documents, indicating no specific time is recorded for charting or storing)

**Content Review Relevant to the Question**

* **Small left pleural effusion**: Mentioned in **Document 1**, **Document 2**, and **Document 5** as ""small bilateral pleural effusions, left greater than right"" in the context of CXR findings.
* **Borderline cardiac silhouette**: Not explicitly mentioned in the provided documents. This might be a finding from an external source or not documented in the given content.
* **Chronic infarcts in brain CT**: Not explicitly mentioned in the provided documents, but **Document 1** mentions ""Cerebrovascular disease, status post CVA in ___"" and ""Extensive intracranial atherosclerosis, worse in the right MCA territory"" in the Past Medical History, indicating a history of cerebral vascular issues.
* **No acute intracranial abnormality**: Not explicitly stated in the provided documents, but the absence of any acute cerebral concerns in the documents might imply this, especially given the focus on other symptoms and conditions.

**Response to the Question**

Given the information:
- **Primary Concerns Based on Provided Documents**:
	1. **Management of Heart Failure (HFpEF)**: As indicated in **Document 4**, with a focus on diuresis (e.g., IV Lasix, transition to PO torsemide) and management of volume overload.
	2. **Monitoring of Chronic Conditions**: Including cerebrovascular disease, hypertension, diabetes mellitus type 2, and others listed in **Document 1**.
- **Investigations Suggested by the Question but Not Covered in Documents**:
	1. **Borderline Cardiac Silhouette**: If this is a new finding, further cardiac evaluation (e.g., echocardiogram, as partially provided in **Document 3** but focusing on the silhouette aspect) might be warranted.
	2. **Chronic Infarcts in Brain CT**: While past cerebrovascular events are noted, a recent brain CT report is not provided. Reviewing this could offer insights into the patient's current cerebral vascular health.
	3. **Comprehensive Review for Acute Intracranial Abnormalities**: Although not indicated in the documents, if there were concerns or new symptoms, an acute intracranial evaluation (e.g., CT or MRI) would be standard to rule out new issues.

**Action Items**:
- Review recent cardiac imaging for the borderline cardiac silhouette.
- Obtain and review the brain CT report for chronic infarcts and assess for any need for further cerebral vascular evaluation.
- Continue managing HFpEF and other chronic conditions as per current treatment plans (**Document 4** and other relevant documents not provided).

**IDs for Reference (as per instruction 2)**:
- **Patient/Subject ID**: 13180007
- **Note ID**: 13180007-DS-19
- **Admission ID**: 20774429","['Studies notable for:  \n-CXR:  Mild pulmonary vascular congestion with small bilateral\npleural effusions, left greater than right. \n\nVitals on transfer: T 97.3, HR 88, BP 120/54, RR 18, SpO2 98% RA \n\n\n', 'Studies notable for:  \n-CXR:  Mild pulmonary vascular congestion with small bilateral\npleural effusions, left greater than right. \n\nVitals on transfer: T 97.3, HR 88, BP 120/54, RR 18, SpO2 98% RA \n\n\n', 'leaflets (3) are mildly thickened. There is no\naortic valve stenosis. There is no aortic regurgitation. The \nmitral valve leaflets are mildly thickened with\nno mitral valve prolapse. There is trivial ', 'ACUTE PROBLEMS\n==============\n# Acute on chronic HFpEF: \nPatient presented with dyspnea and lower extremity edema and\nfound to be volume overloaded on exam. Warm and wet on exam.\nTrigger for HF exacer', 'In the ED:  \nInitial VS: T 98.5, HR 102, BP 178/76, RR 22, SpO2 98% RA \n \nExam:\nGeneral- NAD\nHEENT- PERRL, EOMI, normal oropharynx\nLungs- Non-labored breathing, CTAB\nCV- RRR, systolic murmur, normal S']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What medikashuns shud patient wit Type 2 Diabetes Mellitus, heart failure, and acute kidney injury take when goin home from hospital, espeshally for diabetis?","['281ec1ee-1c32-43a3-8667-6c9eaa2f4734\n\nEKG:  SR, NL axis, NIs, TWIs laterally (c/w prior) \nLabs/studies notable for:  proBNP: 1140, Cr 1.9\nPatient was given:  IV Furosemide 10mg\nOn the floor...  \n---------------\nStates that he feels better than he did when he came to the\nhospital. No SOB, CP, or palpitations. Only complaint is the\nburning/itching in his lower extremities. \n \nPast Medical History:\n1. CARDIAC RISK FACTORS  \n- Type 2 Diabetes Mellitus\n- Hypertension  \n- Dyslipidemia  \n- Coronary artery disease\n2. CARDIAC HISTORY  \n- Secondum ASD\n- Mild AR\n3. OTHER PAST MEDICAL HISTORY  \n- Extensive intracranial atherosclerosis, worse in the right\nMCA territory.\n- Cerebrovascular disease, status post CVA in ___\n- Asthma\n- OSteoarthritis', '5d1619ab-197a-416d-b0af-616eff82199c\n\n#*60 Tablet Refills:*0 \n12.  HydrALAZINE 100 mg PO TID \nRX *hydralazine 100 mg 1 tablet(s) by mouth three times a day \nDisp #*90 Tablet Refills:*0 \n13.  Levothyroxine Sodium 100 mcg PO DAILY \nRX *levothyroxine 100 mcg 1 tablet(s) by mouth once a day Disp \n#*30 Tablet Refills:*0 \n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nPRIMARY DIAGNOSIS\n==================\nAcute on chronic heart failure with preserved ejection fraction\nSECONDARY DIAGNOSES\n====================\nAcute kidney injury\nCoronary artery disease\nType 2 Diabetes Mellitus\nHyperkalemia']","Based on provided context, for a patient with Type 2 Diabetes Mellitus discharged home, the specified medications do not directly target diabetes management at home. However, medications listed in the context that the patient was on or discharged with, which might be relevant or need monitoring in the context of their diabetes and other conditions, include:  - **HydrALAZINE 100 mg PO TID** (primarily for hypertension, a cardiac risk factor for diabetes patients) - **Levothyroxine Sodium 100 mcg PO DAILY** (for thyroid conditions, not directly related to diabetes but important for overall metabolic health) - **IV Furosemide 10mg** was administered in the hospital (for acute kidney injury and heart failure, not a home medication in this context but important for managing conditions that impact diabetes care).  **Direct Diabetes Management Medication:** Not specified in the discharge or hospital administration context provided. Typically, a patient with Type 2 Diabetes Mellitus would be on medications such as Metformin, Sulfonylureas, or other classes depending on their specific condition and health status, but these are not mentioned in the given context.",custom_multi_hop_query_synthesizer,"Based on the provided documents, I'll answer your question following the specified instructions.

**Question Breakdown:**
* Patient's condition: Type 2 Diabetes Mellitus, heart failure, and acute kidney injury
* Query: Medications for these conditions, especially for diabetes, upon discharge

**Answer:**

* **Patient/Subject ID:** 13180007 (consistent across all documents: Document 1, Document 2, Document 3, Document 4, and Document 5)
* **Relevant Medications for Conditions:**
	+ **Type 2 Diabetes Mellitus:**
		- **70/30 Insulin**:
			- 30 Units with Breakfast
			- 10 Units with Lunch (as per Document 1 and Document 2)
		- **Victoza (Liraglutide)**: 0.6 mg/0.1 mL (18 mg/3 mL) subcutaneous DAILY (as per Document 1 and Document 2)
	+ **Heart Failure:**
		- **Torsemide**: 100 mg PO DAILY (as per Document 1 and Document 2)
		- **CARVedilol (Coreg)**: 50 mg PO BID (as per Document 1, Document 2, and mentioned in the context of heart failure management in Document 4)
		- **Minoxidil**: 10 mg PO DAILY (as per Document 1 and Document 2, though primarily noted for hypertension in Document 4)
	+ **Acute Kidney Injury:**
		- No specific medication is highlighted solely for acute kidney injury in the provided documents. However, medications like **Torsemide** (for fluid management) and **sevelamer CARBONATE** (for phosphate control, often relevant in renal impairment) are mentioned:
			- **Torsemide**: 100 mg PO DAILY (as per Document 1 and Document 2)
			- **sevelamer CARBONATE**: 800 mg PO TID W/MEALS (as per Document 1 and Document 2)

**Additional Context from Documents:**
- Document 4 provides additional clinical context, including the management of the patient's diabetes with insulin adjustments and the mention of anemia and its treatment.
- Document 3 and Document 5 offer discharge instructions, emphasizing the importance of medication adherence, follow-up, and monitoring of symptoms, but do not specify medications beyond what's listed in Document 1 and Document 2.

**IDs Consistency:**
- **Patient/Subject ID**, **Note ID**, and **Admission ID** are consistent across all documents (13180007, 13180007-DS-19, and 20774429, respectively).","['Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'WHAT HAPPENED WHILE I WAS IN THE HOSPITAL?  \n You were given medications to help get the fluid out. Your \nsymptoms got better and were ready to leave the hospital.  \n\n WHAT DO YOU NEED TO DO WHEN YOU ', '# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o', 'Discharge Condition:\nMental Status: Clear and coherent.\nLevel of Consciousness: Alert and interactive.\nActivity Status: Ambulatory - Independent.\n\n \nDischarge Instructions:\n Dear ___,  \n\n It was a ple']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"Whats the deal with the Asprin perscription for a patient with a history of CAD and CKD stage III, shouldnt they be on somethin els?","['4b3d7a96-6534-434e-8295-b8356c5ca64d\n\nbasal/bolus four times daily regimen. However, this is not a \nsustainable regimen for patient on discharge. Discussed \npossibility of switching to 70/30 mix BID, however currently \npatient cannot be guaranteed to eat regular meal after each \ninsulin injection therefore currently not a tenable plan. In the \nfuture, if patient able to be placed in a day program, \npotentially could switch to this but for now will we continued \nhis prior home regimen (EXCEPT for Jardiance, which was \ndiscontinued due to contraindication with chronic kidney \ndisease) on discharge, with very close ___ follow-up and ___ \nservices to help increase compliance. With regards to his more \nsubacute mental status decompensation, would benefit from \nreferral for outpatient neurocognitive evaluation.\n# Hx of CAD: \n# Hx of ischemic CVA:\nStress test in ___ with area of inducible ischemia in LCx \ndistribution, in setting of multiple risk factors. Has been \nmedically optimized by prescribed medications, but as above it \nseems that pt has been taking these medications. TnT 0.04->0.02 \nin setting of CKD stage III-IV. Continued home aspirin, \natorvastatin, and carvedilol. Note that he was once on \nlisinopril (most recently filled in ___ for 2.5mg dose) \nhowever seems that this has since been discontinued.\n# CKD stage III:', 'cd30826d-ad9e-4a08-8b63-15e1e3bbfe0c\n\nYou were admitted to the hospital because:\n================================\n-You had worsening shortness of breath, with increased leg \nswelling and weight gain.\nDuring your stay:\n============\n-You had too much volume onboard so you were given IV diuretic \nmedications,. You improved significantly.\nAfter your discharge:\n================\n-Please continue taking all medications as prescribed (see \nbelow).\n-Please stop taking Lisinopril and metoprolol.\n-Please continue taking insulin according to the regimen you \nwere following before this admission.\n-New medications:\n  - Aspirin 81mg once daily\n  - Carvedilol 25mg twice daily\n  - Furosemide 40mg twice daily\n  - Hydralazine 100mg three times daily\n-Please attend any upcoming outpatient appointments you have \n(see below).\nWe wish you the very best!']","According to the patient's care plan, **Aspirin** is indeed continued at home, alongside **atorvastatin** and **carvedilol**, despite the patient's history of CAD (with a past stress test showing inducible ischemia in LCx distribution) and CKD stage III. This decision was made as part of medically optimizing the patient, with close follow-up planned. Specifically, the patient is to take **Aspirin 81mg once daily** as prescribed upon discharge, with no indication in the provided context to switch to an alternative due to these conditions.",custom_multi_hop_query_synthesizer,"Based on the provided instructions, I'll address the question to the best of my abilities, incorporating the specified guidelines.

**Question Analysis:**
The question inquires about the appropriateness of an Aspirin (ASA) prescription for a patient with a history of CAD (Coronary Artery Disease) and CKD (Chronic Kidney Disease) stage III, suggesting an alternative might be more suitable.

**Metadata and Content Review:**

1. **Patient/Subject ID:** Consistently listed as **13180007** across all documents (1, 2, 3, 4, 5).
2. **CAD History:** 
   - **Metadata:** No explicit mention of CAD in metadata across all documents.
   - **Content:** 
     - Document 1 & 2: ""No known history of CAD.""
     - **Contradiction with the Question's Premise:** The documents explicitly state ""No known history of CAD,"" which contradicts the question's assumption of a CAD history.
3. **CKD Stage III:**
   - **Metadata:** No explicit mention of CKD stage in metadata across all documents.
   - **Content:** 
     - Document 1 & 2: Mention of CKD without specifying the stage.
     - **Insufficient Information for Stage III Confirmation:** While CKD is mentioned, the stage is not explicitly confirmed as III in the provided documents.
4. **Aspirin (ASA) Prescription:**
   - **Content (Document 1 & 2):** ""He was continued on ASA and atorvastatin.""

**Response to the Question:**

Given the information in the documents:
- The premise of the question regarding a history of CAD is **not supported** by the documents, which state ""No known history of CAD.""
- The CKD stage is not explicitly mentioned as Stage III in the documents, making it **unclear** if the patient has CKD Stage III.
- Despite these points, the patient **is** on Aspirin (ASA) as per Documents 1 and 2, alongside atorvastatin.

**Recommendation Based on Provided Information:**
Without confirmation of CAD and with the lack of specified CKD stage, it's challenging to definitively advise on alternative medications to Aspirin based solely on the provided documents. Clinical guidelines typically recommend Aspirin for primary or secondary prevention in patients with CAD, among other considerations. For a patient without a known CAD history, as stated, and unclear CKD stage, a thorough clinical evaluation considering all aspects of the patient's health would be necessary to determine the most appropriate therapeutic regimen.

**IDs as Per Instruction:**
- **Patient/Subject ID:** 13180007 (Consistent across Documents 1, 2, 3, 4, 5)
- **Note ID:** 13180007-DS-19 (Consistent across Documents 1, 2, 3, 4, 5)
- **Admission ID:** 20774429 (Consistent across Documents 1, 2, 3, 4, 5)","['# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\n', '# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\n', 'Name:  ___              Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   M\n \nService: MEDICINE\n \nAllergies: \nNo Known Allergies / Adver', 'ACUTE PROBLEMS\n==============\n# Acute on chronic HFpEF: \nPatient presented with dyspnea and lower extremity edema and\nfound to be volume overloaded on exam. Warm and wet on exam.\nTrigger for HF exacer', 'Studies notable for:  \n-CXR:  Mild pulmonary vascular congestion with small bilateral\npleural effusions, left greater than right. \n\nVitals on transfer: T 97.3, HR 88, BP 120/54, RR 18, SpO2 98% RA \n\n\n']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
What is the prescribed administration schedule for Albuterol Inhaler upon hospital admission for a patient experiencing shortness of breath?,['8c579626-76a5-4cd0-9f53-1feadb6904be\n\nMedications on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath \n2. amLODIPine 10 mg PO DAILY \n3. Atorvastatin 80 mg PO QPM \n4. CARVedilol 50 mg PO BID \n5. Furosemide 80 mg PO DAILY \n6. 70/30 30 Units Breakfast\n70/30 10 Units Lunch\n7. Levothyroxine Sodium 100 mcg PO DAILY \n8. Victoza 2-Pak (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) \nsubcutaneous DAILY \n9. Minoxidil 10 mg PO DAILY \n10. Polyethylene Glycol 17 g PO DAILY:PRN Constipation - First \nLine \n11. sevelamer CARBONATE 800 mg PO TID W/MEALS \n12. Aspirin 81 mg PO DAILY \n13. Vitamin D 1000 UNIT PO DAILY \n \nDischarge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast'],"According to the preadmission medication list, Albuterol Inhaler is prescribed as 2 puffs, inhaled (IH) every 8 hours as needed (Q8H:PRN) specifically for shortness of breath.",custom_multi_hop_query_synthesizer,"Based on the provided documents, here is the answer to the question:

**Question:** What is the prescribed administration schedule for Albuterol Inhaler upon hospital admission for a patient experiencing shortness of breath?

**Answer:**
* **Medication:** Albuterol Inhaler
* **Prescribed Administration Schedule (upon hospital admission):** 2 PUFF IH Q8H:PRN (as needed) for **shortness of breath**

**Source:**
* **Document(s):** Document 1 and Document 2 (both have identical content regarding medications)
* **Location within Document(s):** CONTENT > Medications on Admission > 1. Albuterol Inhaler...

**Metadata Relevance for this Question:** None, as the question pertains to medication administration schedule, which is found in the document content, not in the metadata. However, for completeness:
* **Patient/Subject ID (across multiple documents):** 13180007 (consistent across Documents 1 through 5)
* **Note ID (across multiple documents):** 13180007-DS-19 (consistent across Documents 1 through 5)
* **Admission ID (across multiple documents):** 20774429 (consistent across Documents 1 through 5)","['CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', 'CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', 'Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', '# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o', 'Name:  ___              Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   M\n \nService: MEDICINE\n \nAllergies: \nNo Known Allergies / Adver']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What adjustments were made to the patient's medication regimen for managing Type 2 Diabetes Mellitus (T2DM) and Hypertension, and what follow-up actions were recommended upon discharge?","['386e4975-89d1-411a-99a3-9d225138df6c\n\n[] Ensure that patient was able to adhere to a diabetic diet\nPCP:\n[] Had elevated SBP in 130s-150s. Increased minoxidil to 5mg and \ncarvedilol to 50 mg BID. Please follow-up on blood pressures. \n[] Follow up on diuretics and volume status. Please get \nfollow-up labs BUN/Cr at follow-up appointment.\nNew meds: 70-30 novolog (30 units in AM, 20 units at dinner)\nStopped meds: none\nChanged meds: Carvedilol 50 mg twice a day, increased minoxidil \n5 mg daily \nACUTE ISSUES: \n=============== \n# HHS\n# T2DM\nPatient has history of poorly-controlled DM w/ A1c ~14. Based on \nlabs, determined to be in HHS likely precipitated by med \nnon-adherence or difficulty understanding multi-step process. No \nclear infection was identified. Of note, he tends to have high \ninsulin requirements. Pt was continued on insulin basal/bolus \nwhile inpatient. There was significant efforts to have him bring \nin home Victoza but he only had a half dose so he was continued \non basal/bolus course and made a plan for close outpatient \nfollow up and home 2 injections (Victoza and pre-mixed insulin).']","Adjustments made to the patient's medication regimen include: increasing minoxidil to 5mg daily and carvedilol to 50mg twice a day (BID) to manage elevated Systolic Blood Pressure (SBP); continuation of basal/bolus insulin due to high insulin requirements and the patient's difficulty with multi-step medication processes. Specifically for T2DM, the patient was started on 70-30 novolog (30 units in the morning, 20 units at dinner). Upon discharge, recommended follow-up actions include: monitoring blood pressures, assessing diuretics and volume status, and obtaining follow-up labs for BUN/Cr at the next appointment. Additionally, plans were made for close outpatient follow-up and administering two injections at home (Victoza and pre-mixed insulin).",custom_multi_hop_query_synthesizer,"**Adjustments to Medication Regimen and Follow-up Actions for T2DM and Hypertension**

### **Medication Regimen Adjustments:**

1. **Type 2 Diabetes Mellitus (T2DM):**
	* **Adjustments Made:** Transitioned from inpatient insulin regimen to home insulin regimen with:
		+ **70/30 Insulin:** 30 Units with breakfast and 10 Units with lunch (Document 1 & 4)
		+ **Additional Context:** Initially given Lantus 30u on the night of admission, then transitioned (Document 4)
	* **Other Relevant Medications:** Victoza (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) subcutaneous DAILY, which is also used in managing T2DM (Document 1 & 2, though adjustments specifically for T2DM management are noted with insulin)

2. **Hypertension:**
	* **Adjustments Made:** None explicitly stated for hypertension management upon discharge. The patient was continued on:
		+ **amLODIPine (Amlodipine) 10 mg PO DAILY**
		+ **CARVedilol (Coreg) 50 mg PO BID**
		+ **Minoxidil 10 mg PO DAILY** (Document 1, 2, & 4)
	* **Additional Context:** Described as ""currently well controlled"" upon exam (Document 4)

### **Follow-up Actions Recommended Upon Discharge:**

1. **General Follow-up Instructions:**
	* **Medication Adherence:** Take all prescribed medications as listed (Document 5)
	* **Weight Monitoring:** Weigh yourself daily; report weight increases >3 pounds in a day or >5 pounds in a week (Document 5)
	* **Follow-up Appointments:** With doctors as listed (though specific doctors and dates are not provided in the documents) (Document 5)
	* **Danger Signs:** Call the doctor if any are noticed (specific signs not listed in the provided documents) (Document 5)

2. **Specific to T2DM and Hypertension:**
	* **T2DM:**
		- No specific follow-up actions beyond general medication adherence and weight monitoring are mentioned in the provided documents.
		- **Implicit:** Follow-up for diabetes management (e.g., checking A1C levels) is a standard practice, though not explicitly stated here.
	* **Hypertension:**
		- No specific follow-up actions are mentioned beyond continuing the current regimen and general follow-up instructions.

### **Metadata IDs (as per instructions):**

* **Patient/Subject ID:** 13180007 (consistent across all documents)
* **Note ID:** 13180007-DS-19 (consistent across all documents)
* **Admission ID:** 20774429 (consistent across all documents)
* **Chart Time & Store Time:** N/A (consistent across all documents)","['Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'TRANSITIONAL ISSUES\n===================\n[ ] At discharge his symptoms associated with volume overload \nhad subsided, but he was still slightly volume up on exam with \n1+ edema to ankles bilaterally an', '# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o', 'WHAT HAPPENED WHILE I WAS IN THE HOSPITAL?  \n You were given medications to help get the fluid out. Your \nsymptoms got better and were ready to leave the hospital.  \n\n WHAT DO YOU NEED TO DO WHEN YOU ']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What are the current management strategies for a patient with Coronary Artery Disease (CAD) presenting with inducible ischemia and a recent Non-ST Elevation Myocardial Infarction (NSTEMI), given the presence of chronic kidney disease (CKD)?","['2574c42a-a6ef-418e-ac90-a21855611d18\n\npulmonary edema. No pneumonia, no pneumothorax.  The lateral \nradiograph shows mild flattening of the hemidiaphragms, \npotentially as a consequence of functional obstruction.\n___ CT HEAD -\n1. No evidence of acute intracranial abnormality.\n2. Unchanged appearance of chronic infarcts within the right \nfrontal lobe and left occipital lobe.\n3. Chronic lacunar infarcts within the right basal ganglia.\n4. Re-demonstration of few calcifications within the pons, \nfindings which are unchanged in appearance and likely sequela of \nprior ischemic or inflammatory process.\nMICRO:\n___ 3:38 pm URINE\n                            **FINAL REPORT ___\n   URINE CULTURE (Final ___:    < 10,000 CFU/mL. \n \nBrief Hospital Course:\nMr. ___ is a ___ ___ speaking male with a \nPMH of prior CVA ___, residual emotional lability, \ndysarthria), HFpEF, uncontrolled DM2, HTN, CAD, CKD, \n?hypothyroidism, asthma, mild cognitive impairment who presented', '5afc91e0-6481-46b3-aa3c-473b2c2e6895\n\n#Community acquired pneumonia\nCough, worsened SOB, hypoxemia (although alternate explanation) \nbut no leukocytosis or fevers; influenza negative. Legionella \nand strep were negative. Patient was given a 5-day course of \nceftriaxone and azithromycin. \n#Hypertension\nGoal <130/80. As patient is on several anti-hypertensives with \nstill an elevated blood pressure, he underwent a secondary \nhypertension workup. His last renal ultrasound in ___ was \nwithin normal limits. He was placed on continuous O2 monitoring \novernight, and patient did not desaturate. His aldosterone to \nrenin ratio was 0.13, indicating no primary hyperaldosteronism. \n24 hour urine metanephrines and catecholamines were within \nnormal limits.\n#CAD w/ inducible ischemia\n#NSTEMI\nTroponin peaked at 0.02, thought to be type 2 due to volume \noverload. Continued aspirin, atorvastatin, carvedilol. The \ndecision was made to hold off on coronary angiogram due to \nkidney function and the suspicion that this was type 2.\n#H/o CVA\nPatient had an episode while in hospital with dysarthria,']","According to the provided context, for a patient with CAD, inducible ischemia, and recent NSTEMI (troponin peaked at 0.02, suspected as type 2 due to volume overload), the management includes:  - Continuation of aspirin, atorvastatin, and carvedilol.  - A decision was made to hold off on the coronary angiogram due to compromised kidney function and the suspicion of a type 2 myocardial infarction.  Additionally, the patients hypertension is being managed with multiple anti-hypertensives, aiming for <130/80, and a secondary hypertension workup was conducted, which included an aldosterone to renin ratio and 24-hour urine metanephrines and catecholamines, all within normal limits.",custom_multi_hop_query_synthesizer,"Based on the provided instructions and documents, I'll address the question to the best of my abilities. However, please note the following:

1. **CAD and NSTEMI Assumption**: The question assumes the patient has Coronary Artery Disease (CAD) with a recent Non-ST Elevation Myocardial Infarction (NSTEMI). The documents, however, do not explicitly confirm a diagnosis of CAD or a recent NSTEMI. Instead, they mention ""No known history of CAD,"" ""chest pain with mild troponin elevation,"" and concerns related to interpreting troponin levels in the context of CKD.

2. **CKD Confirmation**: The documents do confirm the patient has Chronic Kidney Disease (CKD).

Given these points, the question's premise partially aligns with the provided documents. Here's an attempt to answer, focusing on the management strategies for a patient with suspected ischemic symptoms (given the chest pain and mild troponin elevation) and confirmed CKD, as per the documents:

**Answer:**

- **Patient/Subject ID**: 13180007 (Consistent across all documents)
- **Note ID**: 13180007-DS-19 (Consistent across all documents)
- **Admission ID**: 20774429 (Consistent across all documents)

**Management Strategies (Inferred from Documents, Adjusted for Question's Context):**

1. **Medications for Ischemic Symptoms (Assuming Ischemia, Though Not Confirmed):**
   - **ASA (Aspirin)**: Continued as per Document 1 and implied in others for ischemic heart disease prevention, if applicable.
   - **Atorvastatin**: Continued (Document 1) for managing cholesterol, a risk factor for ischemia.

2. **Management of CKD and Related Complications:**
   - **Sevelamer**: Continued at home (Document 1) to manage hyperphosphatemia associated with CKD.
   - **Monitoring of Renal Function**: Implied through the tracking of Cr (Creatinine) levels, which remained stable (Documents 1 and 3).

3. **General Heart Failure and Hypertension Management (Relevant Given Patient's Profile):**
   - **Diuresis for Volume Overload (HFpEF Context)**: IV Lasix (Document 4) and transitioned to PO Torsemide.
   - **Blood Pressure Management**: Amlodipine, Coreg, and Minoxidil (Document 3) for hypertension.
   - **Iron Supplementation for Anemia**: Ferric gluconate (Documents 3 and 4), considering the patient's anemia and CKD.

**Important Note**: The documents do not explicitly outline a management plan for confirmed CAD with NSTEMI in the context of CKD. The above response is an interpretation based on the provided information, focusing on the patient's actual confirmed conditions (CKD, suspected ischemic symptoms, HFpEF, hypertension, etc.) and the treatments mentioned.

**Recommendation for Accurate Management Strategies**:
- Consult the latest clinical guidelines (e.g., ACC/AHA for CAD/NSTEMI, KDIGO for CKD) for comprehensive management strategies tailored to a patient with confirmed CAD, NSTEMI, and CKD.
- Ensure all management decisions are made by a qualified healthcare professional, considering the patient's full medical history, current condition, and the latest evidence-based practices.","['# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\n', '# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\n', '# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o', 'ACUTE PROBLEMS\n==============\n# Acute on chronic HFpEF: \nPatient presented with dyspnea and lower extremity edema and\nfound to be volume overloaded on exam. Warm and wet on exam.\nTrigger for HF exacer', 'Name:  ___              Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   M\n \nService: MEDICINE\n \nAllergies: \nNo Known Allergies / Adver']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What is the prescribed dosage and administration schedule for sevelamer CARBONATE in the provided patient discharge information, and how might it relate to the patient's diagnosed conditions, particularly those affecting kidney function (e.g., CKD)?","['080dba33-29e9-4409-89cb-54a03af0e470\n\n8.  Levothyroxine Sodium 100 mcg PO DAILY  \n9.  Minoxidil 10 mg PO DAILY  \n10.  Polyethylene Glycol 17 g PO DAILY:PRN Constipation - First \nLine  \n11.  sevelamer CARBONATE 800 mg PO TID W/MEALS  \n12.  Torsemide 100 mg PO DAILY  \n13.  Victoza 2-Pak (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) \nsubcutaneous DAILY  \n14.  Vitamin D 1000 UNIT PO DAILY  \n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nPRIMARY DIAGNSOIS:\n==================\nAcute Hypoxemic Respiratory Failure\nAcute on Chronic Diastolic Heart Failure\nHyperglycemia, Type 2 Diabetes \n___ on CKD \nSECONDARY DIAGNOSIS:', '784a4f17-941d-40ee-a5aa-7471e6a5f600\n\n70/30 10 Units Lunch \n3.  Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath  \n4.  amLODIPine 10 mg PO DAILY  \n5.  Aspirin 81 mg PO DAILY  \n6.  Atorvastatin 80 mg PO QPM  \n7.  CARVedilol 50 mg PO BID  \n8.  Levothyroxine Sodium 100 mcg PO DAILY  \n9.  Minoxidil 10 mg PO DAILY  \n10.  Polyethylene Glycol 17 g PO DAILY:PRN Constipation - First \nLine  \n11.  sevelamer CARBONATE 800 mg PO TID W/MEALS  \n12.  Victoza 2-Pak (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) \nsubcutaneous DAILY  \n13.  Vitamin D 1000 UNIT PO DAILY  \n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nPrimary Diagnosis:\n-Acute on chronic diastolic heart failure exacerbation\nSecondary Diagnosis:']","According to the discharge medication lists (nodes: 080dba33-29e9-4409-89cb-54a03af0e470 and 784a4f17-941d-40ee-a5aa-7471e6a5f600), the prescribed dosage for sevelamer CARBONATE is 800 mg, administered orally three times a day (PO TID) with meals. Sevelamer carbonate is often used to treat high phosphate levels in patients with chronic kidney disease (CKD). Given the patient's secondary diagnosis includes '___ on CKD' in one discharge summary and no explicit mention in the other, but both indicating the presence of kidney issues through CKD, the sevelamer carbonate is likely prescribed to manage hyperphosphatemia associated with CKD, thereby supporting the patient's renal health alongside other treatments for diagnosed conditions like Acute on Chronic Diastolic Heart Failure and Type 2 Diabetes.",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

* **Prescribed Dosage and Administration Schedule for Sevelamer CARBONATE:**
	+ Dosage: 800 mg
	+ Administration Schedule: PO (orally) TID (three times a day) W/MEALS (with meals)

**Source:**
* **Document ID:** 13180007-DS-19 (common across all documents, as per metadata)
* **Patient/Subject ID:** 13180007 (consistent across all documents)
* **Specific Document Referenced for Answer:** Document 3 (due to relevance to discharge medications)

**Relation to Diagnosed Conditions, Particularly Those Affecting Kidney Function (e.g., CKD):**

* **Condition:** Chronic Kidney Disease (CKD)
* **Relevance of Sevelamer CARBONATE:**
	+ Sevelamer CARBONATE is a phosphate binder used to treat high phosphate levels in the blood, which is a common complication in patients with CKD. Elevated phosphate levels can lead to secondary hyperparathyroidism, bone disease, and increased risk of cardiovascular events.
	+ The patient's **Admission ID: 20774429** and **Patient/Subject ID: 13180007** are associated with a diagnosis of CKD, as mentioned in Document 3 under ""Discharge Diagnosis"" (Secondary Diagnosis: -acute kidney injury, implying pre-existing CKD) and discussed in Document 4 (# ___ on CKD).
	+ The prescription of Sevelamer CARBONATE 800 mg PO TID W/MEALS suggests an effort to manage the patient's phosphate levels, thereby mitigating some risks associated with CKD and acute kidney injury, as evidenced by the elevated Creatinine (Cr) levels discussed in the documents (e.g., Document 4 and Document 5).","['DISCHARGE LABS\n==============\n\n___ 06:35AM BLOOD WBC-5.4 RBC-2.92* Hgb-7.6* Hct-24.3* \nMCV-83 MCH-26.0 MCHC-31.3* RDW-15.9* RDWSD-47.8* Plt ___\n___ 06:35AM BLOOD Glucose-164* UreaN-51* Creat-2.9* Na-1', 'DISCHARGE LABS\n==============\n\n___ 06:35AM BLOOD WBC-5.4 RBC-2.92* Hgb-7.6* Hct-24.3* \nMCV-83 MCH-26.0 MCHC-31.3* RDW-15.9* RDWSD-47.8* Plt ___\n___ 06:35AM BLOOD Glucose-164* UreaN-51* Creat-2.9* Na-1', 'Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', '# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\n', 'TRANSITIONAL ISSUES\n===================\n[ ] At discharge his symptoms associated with volume overload \nhad subsided, but he was still slightly volume up on exam with \n1+ edema to ankles bilaterally an']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
"What is the significance of continuing ASA (Aspirin) in the patient's treatment plan, given their medical history and recent hospitalization?","[""a6e734ef-1c30-4cb6-ba6d-41227251d4d0\n\nWhen he came home to ___, he apparently thought that he was\nstill in ___, confused his wife for his daughter. On\n___ morning, he fell again. He was confused about the\nconfiguration of the bathroom (no tub in bathroom in PR), so he\ntripped and fell, called his daughter in tears (he often gets\nemotional since his CVA). She booked an appointment for same \nday,\nat which his FSBG>500, HbA1c (point of care, not in OMR) was\n15.0%. He declined to be transferred to the ED. Daughter ___\nwas on vacation from work, and so was able to check on him\nregularly. During these visits, she again established that he is\nnot taking prescribed medications. On the morning of\npresentation, pt's wife called daughter ___, concerned that \npt\nwas increasingly confused. FSBG was >500, and administered\nTresiba 50u at about 8 am. Pt called ___ about 15 minutes\nlater, at which time she again noted confusion and slurred\nspeech, which has intermittently been present since his CVA.\nDecision was made to bring him to the ED. \nOf note, during his last hospitalization ___, he had an\nepisode of dysarthria with confusion and mild expressive and\nreceptive aphasia for which code stroke was called. MRI/MRA \nbrain\nand EEG were unrevealing, with chronic changes and EEG slowing\nonly. He was continued on ASA and atorvastatin."", 'd2113a66-fe4f-4869-b3c0-73646862b32b\n\ngluconate (received 3 doses ___. Upon review of recent \noutpatient visit notes, it appears his volume exam is similar to \nbaseline, and patient was asymptomatic during hospital course. \nHe was diuresed effectively with IV Lasix 80. He was \ntransitioned to PO torsemide 100. His BP was well controlled \nwith regimen as described below.\n# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\nat or lower than levels earlier this year. He has denied chest\npain during admission. He does have risk factors for ischemia \nand\nhas not had stress since ___. However, findings and history \nto\ndate are not suggestive of ischemia and he has an ___. TTE did \nnot show evidence of focal wall motion abnormalities or other \nfindings suggestive of ischemia, so further workup was not \npursued. He was continued on ASA and atorvastatin.\n# ___ on CKD:\nCr elevated to 2.6 on admission from baseline of 1.8-2.2. Given\nevidence of congestion elsewhere, concerns for renal congestion\ncausing renal dysfunction. Cr remained stable and was 2.9 on day \nof discharge. He was continued on home sevelamer.']","The patient was continued on ASA (Aspirin) and atorvastatin, indicating that these medications are crucial for managing the patient's condition. Given the patient's history of CVA (Cerebrovascular Accident) with episodes of dysarthria, confusion, and aphasia, ASA is likely prescribed for its antiplatelet effects to prevent further cerebrovascular events. Additionally, the patient has risk factors for ischemia, although recent findings were not suggestive of ischemia. ASA's continuation suggests its importance in primary or secondary prevention of cardiovascular events, aligning with the patient's overall cardiovascular and cerebrovascular risk management.",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

**Significance of Continuing ASA (Aspirin) in the Patient's Treatment Plan:**

Based on the provided documents, the significance of continuing ASA (Aspirin) in the patient's treatment plan can be inferred from their medical history and recent hospitalization as follows:

1. **History of CVA (Cerebrovascular Accident)**: As noted in **Documents 1, 2, and 3** under ""CHRONIC PROBLEMS"" and in **Document 4** under ""Past Medical History"" (point 4), the patient has a history of CVA. Aspirin is commonly continued or initiated in patients with a history of CVA to reduce the risk of future ischemic events.

2. **Presence of Risk Factors for Ischemia**: Mentioned in **Document 5** under ""# Chest pain:"", despite the recent presentation not being suggestive of ischemia, the patient has risk factors for ischemia. Aspirin's antiplatelet effects help mitigate these risks.

3. **Absence of Contraindications**: There is no mention across the documents of bleeding disorders, active gastrointestinal ulcers, or other contraindications that would necessitate stopping aspirin.

4. **Stable Continuation with Other Medications**: Aspirin (81 mg PO DAILY) is listed consistently across **Documents 1, 2, and 3** as part of the patient's medications on admission, indicating its established role in their treatment plan. **Document 5** explicitly states the patient was ""continued on ASA and atorvastatin,"" reinforcing its ongoing significance.

**Metadata Relevance**:
- **Patient/Subject ID**: Consistently listed as **13180007** across all documents, confirming that the medical history and treatment plan refer to the same individual.
- **Note ID and Admission ID**: The consistent **Note ID (13180007-DS-19)** and **Admission ID (20774429)** across documents indicate that the information about aspirin's continuation is relevant to the same hospital admission.

**Conclusion**:
Continuing ASA (Aspirin) in the patient's treatment plan is significant for preventing future ischemic events, given their history of CVA and presence of risk factors for ischemia, in the absence of contraindications. This approach is consistent across the provided medical documents for the patient with ID **13180007** during admission **20774429**.","['CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', 'CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', '# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o', 'Studies notable for:  \n-CXR:  Mild pulmonary vascular congestion with small bilateral\npleural effusions, left greater than right. \n\nVitals on transfer: T 97.3, HR 88, BP 120/54, RR 18, SpO2 98% RA \n\n\n', '# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\n']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': 'N/A', 'storetime': 'N/A'}]"
